clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the risk of pregnancy prior to starting treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
studies
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
elimination : steady-state and total clearance of distribution , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic , monohydrate Sodium phosphate dibasic , concentrate for solution for injection
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution ; for single use only .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
the powder is provided in Type 3 ml , prefilled glass ( type I ) .
the solvent is supplied in Type of 3 ml , prefilled glass ( type I ) .
this medicinal product is available in pack sizes of 1 , 5 and 10 TRIFOLD per blister .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
unwrap , prior to use , the solvent
- Chemical and administration have been
in this case , immunisation should be first inspected , and to reconstitute how to reconstitute the powder of BIO-SET .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 150 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
one ampoule contains 150 IU of recombinant BIO-SET Protein IX ( 263 ) .
the reconstituted solution contains 150 IU / ml .
Intra-procedural
mg sucrose , rounded mg of sodium phosphate dibasic , 0.45 mg of sodium phosphate monobasic monohydrate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
the powder should be reconstituted immediately before the use of the solvent
to avoid the volume of volumes too high , this can cause up to 3 blister or vials in 1 ml of solvent .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably IU , at 1000 IU , or preferably to exceed 14 days , if necessary .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
there is evidence for bupropion evidence that levels of Avonex treatment are stable for the first 4 Inflammation and reduces it gradually .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is preferable to adjust the dose at the start of 7 or 14 days and in carrying IU / ml .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response cannot be used when an effective response could not be induced , e. g. diverticulitis , autoimmune organs
hepatic impairment : primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is preferable to adjust the dose at the start of 7 or 14 days and in carrying IU / ml .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS B / newborns is equivalent to that that may be achieved with snacks .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
it contains the hypertrophy of the
too high steroids and high epithelium may result in stronger areas in the Member surfaces , which demonstrates .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be informed of the possible risk of pregnancy prior to starting treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
studies
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
blood flow and total clearance of the total body , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic , monohydrate Sodium phosphate dibasic , concentrate for solution for injection
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution ; for single use only .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
the powder is provided in Type 3 ml , prefilled glass ( type I ) .
the solvent is supplied in Type of 3 ml , prefilled glass ( type I ) .
this medicinal product contains 1 and 10 ampoules per day .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
unwrap , prior to use , the solvent
- Chemical and administration have been
in this case , immunisation should be first inspected , and to reconstitute how to reconstitute the powder of BIO-SET .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 75 IU ( 5.5 micrograms ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a vial contains 6 micrograms of 250-350 international units
the reconstituted solution contains 75 IU / ml .
Intra-procedural
mg of sucrose , rounded mg of sodium dihydrogen phosphate dihydrate , 0.45 mg of sodium phosphate , 0.15 mg of polysorbate 20 .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
in the subcutaneous route of administration .
the powder should be reconstituted immediately before the use of the solvent
to avoid the volume of neuromuscular blockade , may have up to 3 vials with powder in 1 ml of solvent .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
for example , the following within 2 weeks
treatment with peptide furoate at doses of 0.10 during the first 7 days .
the dose will be adjusted on the basis of objective response .
post-marketing experience suggests that treatment limiting data are usually initiated for the first 4 Inflammation and decrease respectively .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response could not be induced , for example : in women :
primary Related Events
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS B / newborns is equivalent to that that may be achieved with snacks .
Photo- sensitivity reactions
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in virologically na√Øve patients , the risk of pregnancy is correlated with the number of implantations , Blacks , Hispanics , and intestines .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
clinically significant interaction with medicinal products did not have any clinically relevant inter-ethnic interactions .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , 87.1 is distributed throughout the fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate , Sodium phosphate dibasic heptahydrate , concentrate for solution for injection
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution ; for single use only .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent comes for reconstitution is supplied in a vial of 2 or 3 ml ( type I glass ) with a stopper ( elastomeric rubber ) or in a pre-filled syringe with a stopper .
this medicinal product contains 1 vial , which contains 1 bottle with solvent or carton in packs of 1 , 5 and 10 vials respectively .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
unwrap , prior to use , the solvent
- Chemical and administration have been
in this case , immunisation should be first inspected , and to reconstitute how to reconstitute the powder of BIO-SET .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
w.1 150 IU ( 11 micrograms ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a vial contains 12 micrograms of 250-350 international units ( 263 ) , extracted of recombinant human plasma
the reconstituted solution contains 150 IU / ml .
Intra-procedural
mg of sucrose , rounded mg of sodium dihydrogen phosphate dihydrate , 0.45 mg of sodium phosphate , 0.15 mg of polysorbate 20 .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent of the subcutaneous route .
the powder should be reconstituted immediately before the use of the solvent
to avoid the volume of neuromuscular blockade , may have up to 3 vials with powder in 1 ml of solvent .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
for example , the following within 2 weeks
34 Treatment with AML , at doses of 0.10 during the first 7 days .
the dose will be adjusted on the basis of objective response .
post-marketing experience suggests that treatment limiting data are usually initiated for the first 4 Inflammation and decrease respectively .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response could not be induced , for example : in women :
primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS B / newborns is equivalent to that that may be achieved with snacks .
analgesic sensitivity reactions
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in virologically na√Øve patients , the risk of pregnancy is correlated with the number of implantations , PART and age of the patient .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
clinically significant interaction with medicinal products did not have any clinically relevant inter-ethnic interactions .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , 87.1 is distributed throughout the fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate , Sodium phosphate dibasic heptahydrate , concentrate for solution for injection
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution ; for single use only and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent comes for reconstitution is supplied in a pre-filled syringe of 1 ml ( type I glass ) with a stopper .
this medicinal product contains 1 vial , which contains 1 pre-filled syringe with solvent .
special precautions for disposal
for single use only .
unwrap , prior to use , the solvent
- Chemical and administration have been
in this case , immunisation should be first inspected , and to reconstitute how to reconstitute the powder of BIO-SET .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 IU ( 2.8 micrograms ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a vial contains 3 micrograms of 250-350 international units ( 263 ) , extracted of recombinant human plasma
the reconstituted solution contains 56.25 IU / ml .
Intra-procedural
mg of sucrose , rounded mg of sodium dihydrogen phosphate dihydrate , 0.45 mg of sodium phosphate , 0.15 mg of polysorbate 20 .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
the powder should be reconstituted immediately before the use of the solvent
grip IU ( 2.8 micrograms ) can be added to in 1 ml of solvent and mixed with bleedinga , enrolling 75 ml ( 11 micrograms ) and / or incapacitating plasma .
up to three vials with powder may be drawn in 1 ml of solvent .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
for example , the following within 2 weeks
in the treatment area , 6 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
post-marketing experience suggests that treatment limiting data are usually initiated for the first 4 Inflammation and decrease respectively .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response could not be induced , for example : in women :
primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS B / newborns is equivalent to that that may be achieved with snacks .
NCI-CTC Grade 3-5 Reactions
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in virologically na√Øve patients , the risk of pregnancy is correlated with the number of implantations , Blacks , Hispanics , and intestines .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
clinically significant interaction with medicinal products did not have any clinically relevant inter-ethnic interactions .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
elimination : the steady-state and total volume of distribution , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate , Sodium phosphate dibasic heptahydrate , concentrate for solution for injection
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution ; for single use only .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent comes for reconstitution is supplied in a pre-filled syringe of 1 ml ( type I glass ) with a stopper .
this medicinal product contains 1 vial , which contains 1 pre-filled syringe with solvent .
special precautions for disposal
for single use only .
unwrap , prior to use , the solvent
- Chemical and administration have been
in this case , immunisation should be first inspected , and to reconstitute how to reconstitute the powder of BIO-SET .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 IU / filter ml ( 77 micrograms / R ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
3 BIO-SET bottles contains 87 micrograms of BIO-SET Technology microgram ( 263 ) , extracted of recombinant human predeposit , extracted of 77 IU ( 16.0 ) corresponding to 0.0533 IU .
Intra-procedural
mg sucrose , rounded mg of sodium phosphate dibasic , 0.45 mg of sodium phosphate monobasic monohydrate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
in doubt to the subcutaneous route .
before first use , the powder should be reconstituted with the haematologic solvent .
w.2 w.3 IU / R ml ( 77 micrograms /
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
for example , the following within 2 weeks
in the treatment area , at doses of 0.10 , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
post-marketing experience suggests that treatment limiting data are usually initiated for the first 4 Inflammation and decrease respectively .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response could not be induced , for example : in women :
primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
during the prophylaxis of patients to eliminate , particular attention should be paid to the specific instructions for the use of the fixed package .
w.2 Capsid o. o .
due to the local active substances , the injection site must not be used
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
in the 30-week clinical study comparing the combination of FPV / Vietnam with human isoforms , it had not been conducted .
comparisons with the published data suggests that the rate of MPS B / newborns is equivalent to that that may be achieved with snacks .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
coadministration
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an evaluation of GGT is recommended for patients to evaluate treatment response to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
905-910 is not mixed with other medicinal products .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , 87.1 is distributed throughout the fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or benzyl alcohol alone ( 0.9 ) caused a recent haemorrhage and
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic , monohydrate Sodium phosphate dibasic , concentrate for solution for injection
solvent :
intranasal treatment
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable for 24 days .
special precautions for storage
store below 25 C.
store in the original package .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent vial is supplied in the pre-filled syringe of 2 ml ( type I glass ) with a stopper .
polypropylene syringes with polypropylene needle gauge needles are also included for administration .
the product in the pack , in one vial containing 1 vial , with 1 pre-filled syringe of solvent for reconstitution and 15 pre-filled syringes , 815 subjects .
special precautions for disposal
thirteen IU / filter ml ,
w.2 w.3 IU / R ml ( 77 micrograms /
any unused pre-filled syringe should be used for reconstitution ; reconstitution should be used for reconstitution .
administration of the pen , 815 units of cyclodextrins , are provided in the puncture-proof container .
the other can be used in a pre-filled syringe of 1 ml marked for a subcutaneous injection .
each ml of reconstituted solution contains 600 IU of 0.25mg .
the following table presents the volume to deliver the correct dose to deliver the correct dose :
dose ( IU ) 75 of the dose
volume
injection
the reconstituted vials are for use only by one patient only .
the next injection should be given at the same time after the next day .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
3 multidose vial contains 44 micrograms wine , 2332 international units ( 16.0 ) , extracted of 33 micrograms corresponding to 450 IU .
Intra-procedural
mg sucrose , rounded mg of sodium phosphate dibasic , 0.45 mg of sodium phosphate monobasic monohydrate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
the white powder : white powder .
clear and colourless solutions of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
before first use , the powder should be reconstituted with the haematologic solvent .
thirteen IU / 0.75 ml ( 33 micrograms / 0.75 ml ) must not be reconstituted with other approved medicinal products .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
population There is evidence that indicates that treatment limiting data are usually initiated for the first 4 Inflammation and reduces it gradually .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response cannot be used when an effective response could not be induced , e. g. diverticulitis , autoimmune organs
hepatic impairment : primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
during the prophylaxis of patients to eliminate , particular attention should be paid to the specific instructions for the use of the fixed package .
w.2 Capsid o. o .
due to the local active substances , the injection site must not be used
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
51 suggests that the levels of ovulation / Vietnam is equivalent to that that may be achieved with snacks .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
treatment with other natural medicines , the risk of pregnancy is higher in lamivudine-refractory patients with microalbuminuria .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
905-910 is not mixed with other medicinal products .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
gastrointestinal disorders and gastrointestinal disorders such as chest pain
nausea , vomiting , diarrhoea , abdominal pain and dysaesthesias
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , 87.1 is distributed throughout the fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or benzyl alcohol alone ( 0.9 ) caused a recent haemorrhage and
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic , monohydrate Sodium phosphate dibasic , concentrate for solution for injection
solvent :
intranasal treatment
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable for 24 days .
special precautions for storage
store below 25 C.
store in the original package .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent comes for reconstitution is supplied in a pre-filled syringe of 1 ml ( type I glass ) with a stopper .
polypropylene syringes with polypropylene needle gauge needles are also included for administration .
the product in the pack , in one vial containing 1 vial , with 1 pre-filled syringe of solvent for reconstitution and 6 pre-filled syringes , 815 subjects with committed .
special precautions for disposal
thirteen IU / 0.75 ml ( 33 micrograms / 0.75 ml ) should be reconstituted , before use
thirteen IU / 0.75 ml ( 33 micrograms / 0.75 ml ) must not be reconstituted with other approved medicinal products .
any unused pre-filled syringe should be used for reconstitution ; reconstitution should be used for reconstitution .
administration of the pen , 815 units of cyclodextrins , are provided in the puncture-proof container .
the other can be used in a pre-filled syringe of 1 ml marked for a subcutaneous injection .
each ml of reconstituted solution contains 600 IU of 0.25mg .
the following table presents the volume to deliver the correct dose to deliver the correct dose :
dose ( IU ) 75 of the dose
volume
injection
the reconstituted vials are for use only by one patient only .
the next injection should be given at the same time after the next day .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
3 multidose vial contains 33 micrograms of 250-350 international units ( 263 ) , extracted of recombinant human plasma
Intra-procedural
mg sucrose , rounded mg of sodium phosphate dibasic , 0.45 mg of sodium phosphate monobasic monohydrate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
the white powder : white powder .
ensuring of the reconstituted solution :
the pH of the reconstituted solution is between 6.5 and 7.5 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
before first use , the powder should be reconstituted with the haematologic solvent .
thirteen 400 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) must not be reconstituted with other approved medicinal products .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250-350 IU prior to conception should be administered 24 to 48 hours after the last dose of 0.10 .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection single injection of 5.25 IU should be administered 24 to 48 hours after the last dose of Twinrix furoate to determine direct extravascular suppression .
Patient-time with the seminiferous epithelium ( HPA ) -negative women is now used to interpret the peak and the postprandial secretion of ranitidine .
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
there is evidence for bupropion markers that peak levels are usually maintained for the first 4 Inflammation and reduces it gradually .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a optimum response is obtained , a single injection of 125I-bevacizumab should be administered 24 to 48 hours after the first dose of serial and 4,658 plasma glucose .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
it is recommended that an effective response cannot be used when an effective response could not be induced , e. g. diverticulitis , autoimmune organs
hepatic impairment : primary
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
during the prophylaxis of patients to eliminate , particular attention should be paid to the specific instructions for the use of the fixed package .
w.2 Capsid o. o .
due to the local active substances , the injection site must not be used
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
patients for haematopoietic growth retardation , in which a treatment of thrombolytics or who are going to receive digitalis , may be hypertrophy or absent .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .
HIV-1 variants of IFN growth and maturation investigating a physician experienced in the Ames test results .
clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
HIV-1 suggests that the effects of ovulation / Vietnam is equivalent to that that may be achieved with snacks .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
this includes splenic hypertrophy , a high plasma count of steroids and increased neurotoxicity that may result in oversuppression of the serine protease and result of that , I62V , L63P .
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
sixty , the risk of pregnancy should be aware of the risk in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the possible risk of pregnancy prior to the initiation of treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
an investigational analysis is recommended for patients to evaluate treatment to evaluate response to treatment response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
905-910 is not mixed with other medicinal products .
pregnancy and lactation
use in pregnancy
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
lactation during lactation
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , 87.1 is distributed throughout the fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
no dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to undergo however , however , the cognitive and mitotic development of 494 pups .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or benzyl alcohol alone ( 0.9 ) caused a recent haemorrhage and
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic , monohydrate Sodium phosphate dibasic , concentrate for solution for injection
solvent :
intranasal treatment
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable for 24 days .
special precautions for storage
store below 25 C.
store in the original package .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
nature and contents of container
905-910 is presented and solvent for solution for injection .
the powder is presented in bottles containing 3 ml ( type I glass ) with a stopper ( bromobutyl ) , sealed a seal as aluminium tamper evident .
the solvent comes for reconstitution is supplied in a pre-filled syringe of 1 ml ( type I glass ) with a stopper .
polypropylene syringes with polypropylene needle gauge needles are also included for administration .
the product in the pack , in one vial containing 1 vial , with 1 pre-filled syringe of solvent for reconstitution and 4 pre-filled syringes , 815 subjects .
special precautions for disposal
thirteen IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should be reconstituted , before use
thirteen 400 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) must not be reconstituted with other approved medicinal products .
any unused pre-filled syringe should be used for reconstitution ; reconstitution should be used for reconstitution .
administration of the pen , 815 units of cyclodextrins , are provided in the puncture-proof container .
the other can be used in a pre-filled syringe of 1 ml marked for a subcutaneous injection .
the following table presents the volume to deliver the correct dose to deliver the correct dose :
dose ( IU ) 75 of the
volume
inject
the reconstituted vials are for use only by one patient only .
the next injection should be given at the same time after the next day .
the reconstituted solution should not be administered if particles or if it is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
thirteen IU / 0.5 ml ( 22 micrograms / 0.5 ml ) solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
a cartridge delivers 300 IU ( equal to 22 micrograms ) in 0.5 ml .
mg of sucrose , 455.0 mg disodium phosphate dihydrate , disodium phosphate dihydrate , sodium chloride , 0.05 mg Macrogolglycerol Ricinoleate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
the recommended dosage regimen provides in the elderly with urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250 microgram or 460 IU of wine should be administered 24 to 48 hours following the last dose of bevacizumab .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection a single injection of 250 microgram or reperfusion to 0.03 IU of wine is administered 24 to 48 hours following the last annual dose of bevacizumab to determine direct cognitive and direct cognitive variations .
Lansoprazol with a net gland or procaine build-up ( moxifloxacin ) antagonist is now a
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
there is evidence for bupropion decrease indicates that treatment seroprotection rates are usually maintained for the first 4 Inflammation and reduces it gradually .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a para-hydroxy-sulphate to the optimum response is obtained , a single injection of 250 microgram or 460 IU immunoglobulin should be administered 24 to 48 hours following the first dose of bevacizumab and 4,658 5 to 48 hours afterwards .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
adverse Reactions
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
particular attention will be paid to the specific instructions for using the pre-filled pen .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
RESIST patients will be aware of the restoration of intra-abdominal growth , such as antilymphocytic infertility , or dehydrated or cardiogenic involvement .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .

clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS with azithromycin / newborns was equivalent to that of the IOP-lowering effects .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
it contains the hypertrophy of the
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be informed of the risk of pregnancy prior to starting treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
a definitive analysis is recommended for 4 to 6 months after initiation of treatment , as measured by the patient &apos;s response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
pregnancy and lactation
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
treatment in men
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , immunisation is distributed into cellular fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
the dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of Epoetin alfa , steady state is achieved in 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to donate the development of cognitive and mitotic development , however , cognitive and mitotic foetal development .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
63kg shell Ethanol Sodium phosphate monobasic monohydrate , Sodium hydroxide Medium All√© , concentrate for solution for injections
Incompatibilities
not applicable .
Shelf life
once opened , the product may be kept at a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of up to 3 months , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
store in the original package in order to protect from light .
for storage conditions of the storage Instructions for use , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge of 3 ml ( type I glass ) with plunger ( Teflon-faced rubber ) and aluminium overseal and
pack of 1 pre-filled pen and 5 needles to use with the pen for administration .
special precautions for disposal
the solution should not be administered if particles or if it is cloudy .
any unused solution should be discarded at the same time every day .

discard any needles used immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
3.18 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
a cartridge delivers 450 IU ( equal to 33 micrograms ) in 0.375 ml .
mg of sucrose , 0 mg of sodium phosphate disodium phosphate dihydrate , 455.0 mg of phosphate , 455.0 mg Macrogolglycerol Ricinoleate , 108 mg Macrogolglycerol Ricinoleate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
the recommended dose to speed up the elderly with the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250 microgram or 460 IU of wine should be administered 24 to 48 hours following the last dose of bevacizumab .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection a single injection of 250 microgram or reperfusion to 0.03 IU of wine is administered 24 to 48 hours following the last annual dose of bevacizumab to determine direct cognitive and direct cognitive variations .
Lansoprazol with a net gland or procaine build-up ( moxifloxacin ) antagonist is now a
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
based on similarities indicates that treatment limiting than in general deposition and reduces it gradually by periodic ANC .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a para-hydroxy-sulphate to the optimum response is obtained , a single injection of 250 microgram or 460 IU immunoglobulin should be administered 24 to 48 hours following the first dose of bevacizumab and 4,658 5 to 48 hours afterwards .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
adverse Reactions
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
particular attention will be paid to the specific instructions for using the pre-filled pen .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
RESIST patients will be aware of the restoration of intra-abdominal growth , such as antilymphocytic infertility , or dehydrated or cardiogenic involvement .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .

clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS with azithromycin / newborns was equivalent to that of the IOP-lowering effects .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
it contains the hypertrophy of the
the following symptoms may be observed : abdominal pain : abdominal pain , bumps , gingival hypoaesthesia , weight consistently , weight decreased , dyspnoea , and diarrhoea .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the risk of pregnancy prior to starting treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
a definitive analysis is recommended for 4 to 6 months after initiation of treatment , as measured by the patient &apos;s response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
pregnancy and lactation
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
treatment in men
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , immunisation is distributed into cellular fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
the dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of Epoetin alfa , steady state is achieved in 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to donate the development of cognitive and mitotic development , however , cognitive and mitotic foetal development .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
63kg shell Ethanol Sodium phosphate monobasic monohydrate , Sodium hydroxide Medium All√© , concentrate for solution for injections
Incompatibilities
not applicable .
Shelf life
2 years .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of up to 3 months , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
store in the original package in order to protect from light .
for storage conditions of the storage Instructions for use , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge of 3 ml ( type I glass ) with plunger ( Teflon-faced rubber ) and aluminium overseal and
pack of 1 pre-filled pen and 7 needles using the pre-filled pen for administration .
special precautions for disposal
the solution should not be administered if particles or if it is cloudy .
any unused solution should be discarded at the same time every day .

discard any needles used immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 IU / 1.5 ml solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
a cartridge sealed in 100 ml ( equal to 66 micrograms ) in 1.5 ml .
mg of sucrose , 455.0 mg of phosphate disodium phosphate dihydrate , covering mg of sodium phosphate , 0.15 mg of phenylalanine , 108 mg Macrogolglycerol day-1 .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
thirteen ( including osteomyelitis ) .
enrollment , in combination with an anti-clotting preparation ( glucan ) is recommended to support the pre- development in post-menopausal women and included in functioning .
clinical studies were
thirteen percent is indicated to inhibit osteoclast activity in men with pseudoexfoliative contagiosum , invasive or iatrogenic immunoglobulin should be combined with the serine human Health .
posology and method of administration
cardio-vascular disorders should be explained by the supervision of a physician experienced in the treatment of reproductive problems .
thirteen percent .
the recommended doses for determining the plasma supply to the urinary vacuolisation .
the clinical significance of ice that daily doses , therapeutic and treatment monitoring should not be monitored for the first patient experienced urinary preparations .
however , when these doses were used in a clinical study comparing with bleedinga , stupor , and -interferon were more effective than the urinary donor of the total dose required and duration of treatment , to reach haemodynamic conditions .
the dose of doses of equivalent to 2,900 or resistant immunoglobulin was demonstrated .
at lower doses of recommended , see section below .
patients ( including anophthalmia ) :
the goal of treatment with irinotecan is develop a single demyelinating form of adjacent Bleeding from time to launch it .
thirteen percent can be prescribed .
in patients who were started on the first 7 days of the cycle .
treatment should be individualised for individual patients , determined by theoretical height , determined by the restoring dose of echocardiography and / or intracellular secretion .
standard AT therapy with 75 to 150 IU of dementia per day and is increased to preferably
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
a patient had no adequate response after 4 weeks of treatment , this cycle should be terminated and the patient hospitalised with a higher starting dose than before the cycle .
when a optimum response is obtained , a single injection of 250 microgram or 460 IU of wine should be administered 24 to 48 hours following the last dose of bevacizumab .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see section 4.4 ) .
treatment should continue until the following formula of at the elected cycle .
patients with neonatal-onset reactivity undergoing ovarian growth assessments prior to conception in Member State :
the treatment scheme is to be able to reconsider the administration of 150 to 225 IU of beer per day , starting the front or right dose of the cycle .
in general , embryo-foetal development is achieved on an average of visit days ( 5 to 20 days ) .
injection a single injection of 250 microgram or reperfusion to 0.03 IU of wine is administered 24 to 48 hours following the last annual dose of bevacizumab to determine direct cognitive and direct cognitive variations .
Lansoprazol with a net gland or procaine build-up ( moxifloxacin ) antagonist is now a
if a treatment is declared , immunisation will be administered approximately 2 weeks after initiation of previous therapy .
for example , the most common after the two weeks of treatment with faecal excretion , 150 to 225 IU of beer during the first 7 days .
the dose will be adjusted on the basis of objective response .
population There is evidence that indicates that treatment limiting data are usually initiated for the first 4 Inflammation and reduces it gradually .
patients in view of the severe deficiency and included :
thirteen percent should be administered as a single daily injection , with the same sampling .
these patients have routinely and with low compliance , the treatment may be started at any time of the cycle .
treatment should be individualised for individual patients , based on the individual patient &apos; s height and cellular secretion .
treatment with 75 IU of 250-350 alfa per day , 75 to 150 IU of 5.9 .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
it can be appropriate for a Rotation Cycle up to 5 weeks .
when a para-hydroxy-sulphate to the optimum response is obtained , a single injection of 250 microgram or 460 IU immunoglobulin should be administered 24 to 48 hours following the first dose of bevacizumab and 4,658 5 to 48 hours afterwards .
the patient is calculated to have an increase in the day of the day on the same day as well as the day .
CONCLUSIONS may be given .
a phase I list may be considered , in addition to antitumour activity ( glucan / 1214 ) following ovulation .
if a sudden response is obtained , therapy should be discontinued and will not be given .
treatment should continue until the following cycle of the reactive cycle .
men with co-morbidities :
thirteen percent should be administered at 150 IU / week 3 times per week , in combination with basiliximab , for 4 months .
in addition , after this patient has not responded to established treatment , this patient may not be resumed ; the clinical experience can be continued until the patient is switched to treatment .
Contraindications
adverse Reactions
special warnings and precautions for use
Sixty-four percent is an antimicrotubule substance that can cause adverse reactions to severe adverse reactions , and should only be used by specialists experienced in the management of sterility .
intermittent taxane therapy to the glucocorticoid of the warts should and health care professionals , as well as the use of adequate contraceptive precautions .
in women , use well tolerated and effective centres requires periodic monitoring of the distal ovarian response by Histology
in response to the administration of 14C-entecavir may vary in individual patients , some patients may show a low response .
depending on the rate of treatment ( men and females ) , the effective dose should be used .
the prevalence of ice should only be performed by patients who have finished , guilty , and find it .
particular attention will be paid to the specific instructions for using the pre-filled pen .
the first route of fungi should be given under close medical supervision .
patients with a family design should be monitored closely during therapy with irinotecan .
stopping it of or stopping treatment .
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
treatment in women :
prior to initiating therapy , the immunoglobulins should be based on tests and other medicinal products to be considered .
Polyglutamated examinations any particular in the symptoms and evidence of mitochondrial failure , maturation , and cognitive tumours and embryofoetal tumours should be used .
RESIST patients will be aware of the restoration of intra-abdominal growth , such as antilymphocytic infertility , or dehydrated or cardiogenic involvement .
risk of such events should be collected when the recommended treatment regimen were judged with the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored .

clinical studies have demonstrated that haematopoietic chemistry increased in case of administration with chromogenic alfa .
if an increase in the dose is required , it is best to adjust the dose at the start of 7 or 14 days .
no formal clinical trials comparing the combination of FPV / Vietnam with psychotic contributions ( 16.1 ) was conducted .
comparisons with the published data suggests that the rate of MPS with azithromycin / newborns was equivalent to that of the IOP-lowering effects .
ovarian embolism
Patient-time is a different condition of glucuronyl hypertrophy .
this may include Stevens-Johnson syndrome .
it contains the hypertrophy of the
hypertension of high fat and increased fatty acids that may result in stronger areas in the Member surfaces , which demonstrates .
clinical judgement , Hypothyroidism , myositis , ileus , sinus toxicity , petechiae , cerebral effusion , cerebral effusion , and thrombotic events .
very rarely , severe exacerbations may be accompanied by pulmonary complications such as pulmonary embolism , ischaemic attack or myocardial infarction .
excessive ovarian response to treatment with irinotecan causes severe degradation of the cases where AML is administered to interpret the ovulation .
therefore , caution should be kept in case of sickle cell SYRINGE , benzodiazepines , unblock the administration of 5.25 and 104 to patients not demonstrating a high perceived risk for at least 4 days .
Re-priming can progress ( 24 hours at several days ) to a possible symptom of potentially serious , patients should be followed during at least two weeks after high-dose administration .
to reduce the risk of vasoconstriction or pregnancy , precise examinations and blood chemistry levels are recommended .
keep in patients who are already taking the risk of vasoconstriction and a medicinal product for an increase in fasting plasma levels &gt; 900 pg / ml ( 4.0 / l ) and longer
yields , the risk of venous thromboembolism is an increased risk of vasoconstriction &gt; 0.5x109 / ml ( Saltz 103.7 / L ) and 20 - 10 mm or more diameter of 12 mm .
if the OBR is &gt; 40-70 / ml ( Saltz 5.20 / l ) and / or there is a total of 40 -
patients should be aware of the risk of thromboembolism and medicinal products will be locked if the recommended treatment regimen were changed to the recommended dose of 5.25 , at the recommended treatment regimen and if treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in immunocompromised patients , the sheath pleuromutilins prior to leukaemia , prior to leukaemia , may reduce the risk of developing a hole .
however , can be more severe in pregnancy and then longer for pregnancy .
the most frequent undesirable effects occur after cessation of concomitant therapy and has reached a maximum of 3 days following cessation of therapy .
Patient-time is usually replaced on the onset of healed .
in the case of severe diaries , treatment with anti- genotypes and specific treatment should be started .
the incidence of this events is higher in patients with polycystic ovary disease .
pregnancy
vaccinated women , especially in insulin-dependent stimulating agents , a important risk of skeletal complications and constipating complications .
there are a small chance of pregnancy in previously-treated patients with AIDS-KS .
the majority of these tested findings are annual .
to minimize the risk of pregnancy , close monitoring of cardiac response is recommended .
in patients with CLCR re-occurrence of breath , the risk of pregnancy is mainly related to the number of implantations , Blacks , and the patient of the patient .
patients should be aware of the risk of pregnancy prior to starting treatment .
gynaecomastia
a
pregnancy
women with a pre-existing history of autoimmune disease are at pregnancy , however , pregnancy has been obtained with respect to pregnancy or in the past .
2 Isolated cases of pregnancy after extubation is 2 to 1.5 in the general population .
8 5.3 Preclinical effects
there have been reports of tumours or the recurrent tumours , benign and malignant tumours reported in women who received infertility .
there is no information on the baseline patient on the risk of developing these tumours .
aggression
the malformations of possible birth defects may be slightly higher following spontaneous spontaneous administration .
this is thought to be related to solar characteristics ( e. g. age , haematotoxicity ) and a different rate of multiple IOP-lowering agents .
fatal outcome
in women with risk factors for the development of thromboembolic events , such as patient history or family history of parathyroid aggregation may increase the risk of development of .
foetal growth restriction in women should be monitored for the administration of 14C-entecavir in these women .
however , it should be noted that pregnancy results in an increased risk of thromboembolic events .
treatment in men :
high cholesterol levels have occurred in patients with end-stage renal disease .
such patients do not justify treatment with lepirudin / epidural treatment .
a definitive analysis is recommended for 4 to 6 months after initiation of treatment , as measured by the patient &apos;s response .
interaction with other medicinal products and other forms of interaction
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
pregnancy and lactation
it is not known for pregnancy .
no teratogenic risk was observed , following leukapheresis of the clinical use of bleomycin .
there is insufficient clinical data to support the safety effects of L-dopa .
however , no undesirable effects have been reported .
no teratogenic effects were observed in animal studies .
thirteen percent is not indicated during breast-feeding .
in breast-feeding , secretion secretion may limit the likely of ovarian molecules .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in women
very rare ( &lt; 1 / 10,000 )
7 Mild allergic reactions ( e. g. erythema erythema multiforme , rash , facial oedema , urticaria , angioneurotic discomfort ) .
there have also been reports of serious allergic reactions , including anaphylactic reaction , including anaphylactic reaction .
general disorders and administration site conditions
very Common ( 1 / 10,000 to &lt; 1 / 10 )
rare
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
causes of asthma
gastrointestinal disorders
common ( 1 / 100 to &lt; 1 / 10 )
nausea and infestations
reproductive system and breast disorders :
very Common ( 1 / 10 )
1.48
common ( 1 / 100 to &lt; 1 / 10 )
30.4 ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
mitochondrial
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
treatment in men
adverse Drug Reaction Rash / Erythema
common ( 1 / 100 to &lt; 1 / 10 )
due to
reproductive system and breast disorders :
common ( 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Telithromycin Antifungals
general disorders and administration site conditions
very Common ( 1 / 10 )
common at the site of injection ( pain , redness , haematoma , pain and / or local irritation at the injection site )
common ( 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the potential for overdose with delusions is not known , but the possibility of Sweet &apos;s syndrome cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
30.4 is composed of 628 IOP-lowering cells ( ELC ) -receptors produced by eukaryotic cells ( 16.1 ) .
in women , the most notable important effect of administration of 14C-entecavir were the development of 6-monthly vasoconstrictors .
in clinical trials , patients with severe deficiency of the severe deficiency were randomly assigned to the average plasma concentration of LH IU / l ( as per 1000 IU / l ) .
however , it should be taken into consideration by patients on a hole in the dose recommendations .
in men with deficiency , 87.1 administered with basiliximab blockade for 4 months no evidence of etiology .
pharmacokinetic properties
following intravenous administration , immunisation is distributed into cellular fluids with a total of approximately 2 hours and eliminated with a terminal half-life of approximately 24 hours .
the steady-state volume of distribution and total clearance of body clearance , respectively , were 10 l / h .
the dose titration is excreted in the urine .
after subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of Epoetin alfa , steady state is achieved in 3 to 4 days with a approximately 3 .
in women who are unable to endogenous tubular secretion is unable to donate the development of cognitive and mitotic development , however , cognitive and mitotic foetal development .
preclinical safety data
the nonclinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , other than those mentioned in this SPC .
fertility was reported in rats exposed to doses of 125I-bevacizumab ( &gt; 40 IU / kg / day ) for prolonged periods , indicating that there was evidence of reduced fertility .
pyridoxine at high doses ( &gt; 5 IU / kg / day ) , remodeling alfa decreases the number of foetal pups at two-yearly intervals , and results in a constant percentage of the three dose seen with 3.75 of the urine .
however , since these data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
63kg shell Ethanol Sodium phosphate monobasic monohydrate , Sodium hydroxide Medium All√© , concentrate for solution for injections
Incompatibilities
not applicable .
Shelf life
2 years .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of up to 3 months , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
store in the original package in order to protect from light .
for storage conditions of the storage Instructions for use , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge of 3 ml ( type I glass ) with plunger ( Teflon-faced rubber ) and aluminium overseal and
pack of 1 pre-filled pen and 14 needles to use with the pen for administration .
special precautions for disposal
the solution should not be administered if particles or if it is cloudy .
any unused solution should be discarded at the same time every day .

discard any needles used immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
last renewal :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
upper Limit of implantations
C / Dr. Testi ( Madrid ) Spain
name and address of the manufacturer responsible for batch release
Merck Sharp Dohme S. p . A.
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to restricted medical prescription ( See Annex I :
summary of Product Characteristics , section 4.2 ) .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
statement OF ACTIVE SUBSTANCE ( S )
a ampoule powder contains : calcitonin alfa 75 IU :
list OF EXCIPIENTS
other ingredients : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , citric acid , sodium hydroxide .
one ampoule solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 unit powder for solution for injection .
1 ampoule solvent .
5 ampoules of powder for solution for injection .
5 ampoules of solvent .
blister pack .
solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 ampoule solvent .
5 ampoules of solvent .
solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
thirteen 75 IU powder for solution for injection Histamine alfa Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / Trimethoprim .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE ( S )
a ampoule powder contains : calcitonin alfa 150 IU .
list OF EXCIPIENTS
other ingredients : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , citric acid , sodium hydroxide .
one ampoule solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 unit powder for solution for injection .
1 ampoule solvent .
blister pack .
solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 ampoule solvent .
solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 150 IU powder for solution for injection Histamine alfa Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / Trimethoprim .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
statement OF ACTIVE SUBSTANCE ( S )
a vial with powder contains 6 micrograms of 250-350 international units , extracted of Low less than 75 IU .
list OF EXCIPIENTS
also contains : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , heptahydrate , polysorbate 20 , concentrated sodium hydroxide .
one vial with solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 vial with solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
statement OF ACTIVE SUBSTANCE ( S )
a vial with powder contains 6 micrograms of 250-350 international units , extracted of Low less than 75 IU .
list OF EXCIPIENTS
also contains : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , heptahydrate , polysorbate 20 , concentrated sodium hydroxide .
one pre-filled syringe with solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
5 vials of powder for solution for injection .
5 pre-filled syringes with solvent .
vials of powder for solution for injection .
pre-filled syringes with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
5 pre-filled syringes with solvent .
pre-filled syringes with solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL FOR 75 IU ( 5.5
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 75 IU ( 5.5 g ) Powder for solution for injection Nonacog alfa
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE ( S )
a powder vial contains 12 micrograms of 250-350 microgram , extracted of 11 micrograms and 73.9 hours .
list OF EXCIPIENTS
also contains : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , heptahydrate , polysorbate 20 , concentrated sodium hydroxide .
one pre-filled syringe with solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg 150mcg
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE ( S )
one vial with powder contains 3 micrograms of 250-350 international units , extracted of 2.8 micrograms and 73.9 micrograms .
list OF EXCIPIENTS
also contains : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , heptahydrate , polysorbate 20 , concentrated sodium hydroxide .
one pre-filled syringe with solvent contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL ( MF
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg 67.25kg
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains : calcitonin alfa 1750 IU / 2 ml .
single vial per vial :
list OF EXCIPIENTS
other ingredients : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , citric acid , sodium hydroxide .
one pre-filled syringe with solvent contains :
2 ml water for injections and benzyl alcohol ( 0.9 ) .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
pre-filled syringes , 815 Units of cyclodextrins .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
single use injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the solvent pre-filled syringe should only be used for reconstitution .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
store below 25 C.
store in the original package in order to protect from light .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
pre-filled syringes , 815 Units of cyclodextrins .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL FOR UNIT
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg LOWERING MEDICINAL PRODUCTS
method OF ADMINISTRATION
read the package leaflet before use .
IRY DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 87 g ) / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
2 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
each vial of powder contains : calcitonin alfa 600 IU / ml .
single vial per vial :
list OF EXCIPIENTS
other ingredients : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , citric acid , sodium hydroxide .
one pre-filled syringe with solvent contains :
1 ml of water for injections and benzyl alcohol ( 0.9 ) .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
6 Pre-filled syringes , 815 with units of cyclodextrins .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
single use injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the solvent pre-filled syringe should only be used for reconstitution .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
store below 25 C.
store in the original package in order to protect from light .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
6 Pre-filled syringes , 815 with units of cyclodextrins .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Assay
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL FOR UNIT
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 450 IU / 0.75 ml powder for solution for injection Nonacog alfa
method OF ADMINISTRATION
read the package leaflet before use .
IRY DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections , benzyl alcohol ( 0.9 ) Propylene glycol adapters with needles IU / 0.75 ml
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains : calcitonin alfa 450 IU / 0.75 ml .
single vial per vial :
list OF EXCIPIENTS
other ingredients : sucrose , sodium phosphate monobasic , sodium phosphate dibasic , citric acid , sodium hydroxide .
one pre-filled syringe with solvent contains :
ml water for injections and benzyl alcohol ( 0.9 ) .
4 pre-filled syringes , 815 with units of cyclodextrins .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
single use injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the solvent pre-filled syringe should only be used for reconstitution .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
store below 25 C.
store in the original package in order to protect from light .
after reconstitution to store below 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
4 pre-filled syringes , 815 with units of cyclodextrins .
lot Potency
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL FOR 300 IU / 0.50
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 300 IU / 0.50 ml powder for solution for injection Nonacog alfa
method OF ADMINISTRATION
read the package leaflet before use .
IRY DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water :
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
ml / pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
one cartridge delivers 300 IU
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
w.1 188 , sucrose , sodium chloride , di- and monobasic monohydrate , sodium hydroxide , hydrochloric acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge in the pre-filled pen and 5 needles for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intramuscular use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
at 18 months , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
5 needles .
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
30.4 / 0.5 ml
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
30.4 300 IU / 0.5 ml
a vial will be covered to allow the patient to run feeding .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 300 IU / 0.5 ml solution for injection in a pre-filled pen Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
EXP { MM / YYYY } after first use :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 0.5 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
one cartridge delivers International IU
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
w.1 188 , sucrose , sodium chloride , di- and monobasic monohydrate , sodium hydroxide , hydrochloric acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge in the pre-filled pen and 7 injection needles .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intramuscular use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
during a period of the shelf life , the product may be kept below 25 C for a maximum of 3 months , without being refrigerated again , if not used after 3 months .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
7 pre-filled pens
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Danmark
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
AUC0- 450 IU / 0.75 ml
a vial will be covered to allow the patient to run feeding .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg use IU / 0.75 ml ( 33 micrograms / 0.75 ml )
method OF ADMINISTRATION
read the package leaflet before use .
EXP { MM / YYYY } after first use :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 0.75 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
one cartridge
3.18 plasma , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
w.1 188 , sucrose , sodium chloride , di- and monobasic monohydrate , sodium hydroxide , hydrochloric acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge for the pre-filled pen , and 14 needles .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intramuscular use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
3 The shelf-life of the product may be kept below 25 C for up to 3 months , and must not be stored below 25 C for up to 3 months .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Europe Limited 56 Forest Gate Wellington Road
MARKETING AUTHORISATION NUMBER ( S )
cartridge .
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
30.4 / 1.5 ml
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 IU / 1.5 ml
a vial will be covered to allow the patient to run feeding .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark IU / 1.5 ml solution for injection in a pre-filled pen Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
EXP { MM / YYYY } after first use :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 1.5 ml
other
package LEAFLET
package LEAFLET :
information FOR THE USER
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by wearing up to 75 IU in 7 or preferably 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 IU or 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing no dosage adjustments or target doses at the target times .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 out of the needle
- a glass ball containing 240
- a ampoule solvent of solvent
- a MAOI for
open the solvent ball ( liquid colourless ) :
based on the tip of the solvent tip , you will find a small site needle : just in the Part A was designed to break easily .
tap the mark of the 24-week needle to learn in the liquid circuit which may find in the tip tip .
gently firmly push the on the above transformations of the neck , and 4,658 by 0.13 to 0.30 .
carefully wipe on the surface set on the surface of it .
draw the solvent :
with the syringe in one hand , recovered the needle out of the solvent you will have further , and draw all the solvent all the solvent .
tap gently tap the syringe to clean the surface area .
follow the injection solution :

draw the resulting powder into the syringe .
( if your doctor has told you more easily , abrasions , slowly and / or relieve liquid ) in new rest from the liquid , injected up to the prescribed solution .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after the powder , draw within the syringe as well as the 1.0 ml solution below and 4,658 in the immunosurveillance circuit .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum blisters of 3 ampoules / vials may be drawn into the contents of a solvent of solvent .
push down on the plunger until the air bubbles rise .
inject the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly into a skin
insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection immediately and select soluble closed with an appropriate container .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the letters after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is
in CHO cell line , perform species ) .
disodium edetate
- The solvent is water for injections .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
there are no 1 , 5 and 10 TRIFOLD powder respectively .
the quantity of the powder contains 75 IU and ampoule of the solvent for reconstitution contains 1 ml of water for injections .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme .
Merck Sharp Infection
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by wearing up to 75 IU in 7 or preferably 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if a excessive response is obtained , therapy should be discontinued and building up .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 IU or 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing no dosage adjustments or target doses at the target times .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 out of the needle
- a glass ball containing 240
- a ampoule solvent of solvent
- a MAOI for
open the solvent ball ( liquid colourless ) :
based on the tip of the solvent tip , you will find a small site needle : just in the Part A was designed to break easily .
tap the mark of the 24-week needle to learn in the liquid circuit which may find in the tip tip .
gently firmly push the on the above transformations of the neck , and 4,658 by 0.13 to 0.30 .
carefully wipe on the surface set on the surface of it .
draw the solvent :
with the syringe in one hand , recovered the needle out of the solvent you will have further , and draw all the solvent all the solvent .
tap gently tap the syringe to clean the surface area .
follow the injection solution :

draw the resulting powder into the syringe .
( if your doctor has told you more easily , abrasions , slowly and / or relieve liquid ) in new rest from the liquid , injected up to the prescribed solution .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after the powder , draw within the syringe as well as the 1.0 ml solution below and 4,658 in the immunosurveillance circuit .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum blisters of 3 ampoules / vials may be drawn into the contents of a solvent of solvent .
push down on the plunger until the air bubbles rise .
inject the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly into a skin
insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection immediately and select soluble closed with an appropriate container .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the letters after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is
in RBCs is produced by eukaryotic cells ( cycloolefinic completing scan ) .
disodium edetate
- The solvent is water for injections .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
the following pack sizes may be marketed .
the quantity of the powder contains 150 IU and letter from the solvent of solvent for reconstitution .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Infection
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU and 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
- a pre-filled syringe ,
- a needle for reconstitution and a final needle for subcutaneous injection
remove the plastic cap from the solvent vial .
grip the needle out of the syringe and draw air into the syringe by pulling the air plunger into the syringe by pulling about 1 ml .
and , gently push the needle into the vial .
tap gently tap the syringe surface so far not to touch the needle .
follow the injection solution :
remove the needle cover from the vial with polypropylene child-resistant closure , take the syringe and inject the solvent into the powder vial from the powder .
eighteen your daily syringe , without shaking .
once the powder is dissolved ( this usually occur ) , check that the resulting solution is clear and doesn &apos;t contain particles .
invert the vial with your body and slowly go back into the syringe .
( if your doctor has told you more alert , 34.7 solution in a new vial , injected up the solution into a new vial , injected up to the prescribed solution ) .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after mixing the powder , draw into the syringe as the 1.0 below the solution below and 4,658 in the powder vial from the powder .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum of 3 vials may be drawn into 1 ml of solvent .
remove the needle used for reconstitution and will be washed out by the needle to rotate injection .
dispose of air bubbles : if you are test air bubbles in the syringe pointing upwards , then the intramuscular needle pointing upwards .
push down on the plunger until the air bubbles rise .
- Examine the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection needle immediately , vials and syringes empty and syringes made into an appropriate container for this purpose .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , but Stevens-Johnson syndrome with increased volume of malignancy may result in a possible accumulation of the fluid in the abdomen or muscle vessels as well as possible complications of the tumour .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
Sixty-four allergic reactions associated with blistering have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
in CHO cell line , perform species ) .

- The solvent is water for injections .
195 b
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
there is supplied in pack sizes of 56 x 1 vial with solvent .
the powder comes 75 .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
France Astellas Pharma International s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
63kg 75 IU powder and solvent for solution for injection Nonacog alfa
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU and 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
- a vial containing the solvent vial
- a pre-filled syringe contains the solvent
- two moles of alcohol
- a MAOI for
remove the protective protective cap from bending and pre-filled syringe of solvent .
J Keeping the needle for reconstitution on the pre-filled syringe and inject all the solvent into the powder vial from the vial .
eighteen your daily syringe , without shaking .
once the powder is dissolved ( this usually occur ) , check that the resulting solution is clear and doesn &apos;t contain particles .
invert the vial with your body and slowly go back into the syringe .
( if your doctor has told you more alert , 34.7 solution in a new vial , injected up the solution into a new vial , injected up to the prescribed solution ) .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after mixing the powder , draw into the syringe as the 1.0 below the solution below and 4,658 in the powder vial from the powder .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum of 3 vials may be drawn into 1 ml of solvent .
remove the needle used for reconstitution and will be washed out by the needle to rotate injection .
dispose of air bubbles : if you are test air bubbles in the syringe pointing upwards , then the intramuscular needle pointing upwards .
push down on the plunger until the air bubbles rise .
note immediately :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection needle immediately , vials and syringes empty and syringes made into an appropriate container for this purpose .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , but Stevens-Johnson syndrome with increased volume of malignancy may result in a possible accumulation of the fluid in the abdomen or muscle vessels as well as possible complications of the tumour .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
erythrodysaesthesia syndrome
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
in CHO cell line , perform species ) .

- The solvent is water for injections .
what TO looks like and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
there is supplied in packs containing 1 , 5 and 10 vials with powder will be sufficient .
not all pack sizes may be marketed .
the powder comes 75 .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme .
France Astellas Pharma International s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU and 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a variable length of the 7 or 14 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
- a vial containing the solvent vial
- a pre-filled syringe contains the solvent
- two moles of alcohol
- a MAOI for
remove the protective protective cap from bending and pre-filled syringe of solvent .
J Keeping the needle for reconstitution on the pre-filled syringe and inject all the solvent into the powder vial from the vial .
eighteen your daily syringe , without shaking .
once the powder is dissolved ( this usually occur ) , check that the resulting solution is clear and doesn &apos;t contain particles .
invert the vial with your body and slowly go back into the syringe .
( if your doctor has told you more alert , 34.7 solution in a new vial , injected up the solution into a new vial , injected up to the prescribed solution ) .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after mixing the powder , draw into the syringe as the 1.0 below the solution below and 4,658 in the powder vial from the powder .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum of 3 vials may be drawn into 1 ml of solvent .
remove the needle used for reconstitution and will be washed out by the needle to rotate injection .
dispose of air bubbles : if you are test air bubbles in the syringe pointing upwards , then the intramuscular needle pointing upwards .
push down on the plunger until the air bubbles rise .
1st immediately :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection needle immediately , vials and syringes empty and syringes made into an appropriate container for this purpose .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , but Stevens-Johnson syndrome with increased volume of malignancy may result in a possible accumulation of the fluid in the abdomen or muscle vessels as well as possible complications of the tumour .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
289 ( nettle allergic reactions ) Systemic allergic reactions have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
in CHO cell line , perform species ) .

- The solvent is water for injections .
greyish Not known and contains
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
there is supplied in pack sizes of 56 x 1 vial with solvent .
the powder vial contains 150 IU of nonacog alfa and the pre-filled syringe of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme .
France Astellas Pharma International s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
haematemesis Ileus
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four percent must not be mixed in the same syringe with other medicinal products except
studies have shown that these two medicinal products may be mixed and injected at all end of the two weeks .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
the usual dose is 75 to 150 IU of dams each day .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be given as a maximum dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up to 300 IU .
treatment should be continued with
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU and 150 IU per square metre .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
for single use only .
before you inject yourself , read the the following instructions :
wash your hands .
it is important that your hands and skull are also available as possible .
- two moles of alcohol
- a needle for reconstitution and a final needle for subcutaneous injection
follow the injection solution :
remove the protective protective cap from bending and pre-filled syringe of solvent .
J Keeping the needle for reconstitution on the pre-filled syringe and inject all the solvent into the powder vial from the vial .
eighteen your daily syringe , without shaking .
once the powder is dissolved ( this usually occur ) , check that the resulting solution is clear and doesn &apos;t contain particles .
invert the vial with your body and slowly go back into the syringe .
( if your doctor has told you more alert , 34.7 solution in a new vial , injected up the solution into a new vial , injected up to the prescribed solution ) .
if your doctor has told you to take Reconstituted CANCIDAS , you may administer the two medicines within the same injection rather than separately .
in this case , after the powder , draw within the syringe as well as the 1.0 ml solution below and unlock the powder for the powder will be drawn .
immediately after administration of the powder , draw into the syringe .
because , check that the solution does not contain particles and do not inject it if it is not clear .
a maximum of 3 vials may be drawn into 1 ml of solvent .
remove the needle used for reconstitution and will be washed out by the needle to rotate injection .
dispose of air bubbles : if you are test air bubbles in the syringe pointing upwards , then the intramuscular needle pointing upwards .
push down on the plunger until the air bubbles rise .
222 immediately the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the injection needle immediately , vials and syringes empty and syringes made into an appropriate container for this purpose .
UNUSED solution should be discarded .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
Impetiginous allergic reactions Systemic allergic reactions have occurred , causing the skin , redness , rash , swelling , rash , as well as respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle after EXP .
that expiry date refers to the last day of that month .
use immediately after reconstitution .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is
in CHO cell line , perform species ) .

- The solvent is water for injections .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
there is supplied in pack sizes of 56 x 1 vial with solvent .
the powder vial contains 35.7 IU of 250-350 alfa and the pre-filled syringe of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme .
France Astellas Pharma International s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
thirteen Calculation of several injections .
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
dead allergic reactions have been reported rarely .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
w.1 IU / filter ml ( 77 micrograms /
w.1 IU / R ml ( 77 micrograms / R ml ) must not be mixed with other approved medicinal products in the same bottle or the same syringe .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a dose of 75 to 150 IU .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
w.2 Capsid ovarian imaging ( UVR ) -negative patients undergoing haemodynamic contraceptives prior to launch or other suggestion of mitochondrial infiltrates .
this is to be made up .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU ( range 0.25 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 0.25 ml )
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
in the doubt of the enclosed yourself , please read the following instructions carefully :
the reconstituted vials are for use only by one patient only .
90 If you have enough medicines to make up for a few days .
the next injection should be given at the same time after the next day .
your doctor has prescribed a dose of 5.25 IU .
you must be given either for the administration of two pre-filled syringes , dantrolene with units of cyclodextrins , supplied in the carton .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
remember a clean , well-lit , motion .
see the picture .
follow the injection solution :
you should have a pre-filled syringe of 2 ml .
remove the protective protective cap from bending and pre-filled syringe of solvent .
take your pre-filled syringe with solvent and inject all the solvent ( 2 ml ) the solvent vial from the powder vial .
take off the syringe used for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
you can still take the full daily dose .
take the syringe to remove the administration of the prescribed dose .
gently swirl the vial with solvent .
push the syringe in the vial , invert the vial by pressing air into the vial and draw the correct dose of the 2 for the administration .
dispose of air :
if you see air bubbles in the syringe hold the syringe .
push down on the plunger until the air bubbles rise .
inject the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the syringes immediately in an appropriate container .
for the injections with the reconstituted solution containers , repeat steps 4 to 7 .
the reconstituted solution is for use with other medicinal products by any other patients .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
as can result in local alcohol , as possible , the same injection site must not be used .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , precise medical advice should be sought .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
store below 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle label or carton after EXP .
that expiry date refers to the last day of that month .
once the medicine is opened ( mixed ) , the store below 25 C.
do not freeze .
store in the original package and use in an interval of 28 days .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
46.6
disodium edetate
- The solvent contains water for injections and benzyl alcohol to 0.9 .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
inadvertent , there is a powder vial with a pre-filled syringe , with a pre-filled syringe of solvent and 15 pre-filled syringes , 815 units .
the vial of lyophilised powder contains 35.7 IU of 250-350 international ml and the pre-filled syringe contains 2 ml of solvent .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Infection
√çsland H√∂rgat√∫n ehf .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
thirteen Calculation of several injections .
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
dead allergic events have been reported rarely .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four IU / 0.75 ml ( 33 micrograms / 0.75 ml ) must not be mixed with other medicinal products in the same injection .
unwrap International IU / 0.75 ml ( 33 micrograms / 0.75 ml ) must not be mixed with other approved medicinal products in the same bottle or the same syringe .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a dose of 75 to 150 IU .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
the usual dose is 78 to 300 IU .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU ( range 0.25 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 0.25 ml )
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
before you inject yourself , read the the following instructions :
the reconstituted vials are for use only by one patient only .
if
the next injection should be given at the same time after the next day .
your doctor has prescribed a dose of 5.25 IU .
you must be use any of the 6 syringes for administration , dantrolene with units of cyclodextrins , supplied in the carton .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
remember a clean , well-lit , firm motion : the 1 vial of solvent , 1 ml of solvent , the vial pointing upwards , and syringe for administration .
see the picture .
follow the injection solution :
you should a pre-filled syringe of 1 ml .
remove the protective protective cap from bending and pre-filled syringe of solvent .
take your pre-filled syringe with solvent and inject all the solvent ( 1 ml ) the solvent vial from the powder vial .
take off the syringe used for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
you can still take the full daily dose .
take the syringe to remove the administration of the prescribed dose .
gently swirl the vial with solvent .
push the syringe in the vial , invert the vial by pressing air into the vial and draw the correct dose of the 2 for the administration .
dispose of air :
if you see air bubbles in the syringe hold the syringe .
push down on the plunger until the air bubbles rise .
inject the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the syringes immediately in an appropriate container .
for the injections with the reconstituted solution containers , repeat steps 4 to 7 .
the reconstituted solution is for use with other medicinal products by any other patients .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
as can result in local alcohol , as possible , the same injection site must not be used .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , precise medical advice should be sought .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
store below 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle label or carton after EXP .
that expiry date refers to the last day of that month .
once the medicine is opened ( mixed ) , the store below 25 C.
do not freeze .
store in the original package and use in an interval of 28 days .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
46.6
disodium edetate
- The solvent contains water for injections and benzyl alcohol to 0.9 .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
inadvertent , there is a powder vial with a pre-filled syringe , with a pre-filled syringe of solvent and 6 pre-filled syringes for administration .
the vial of lyophilised powder contains 600 IU and the pre-filled syringe contains 1 ml of solvent .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme Ges. m. b . H.
13-10-2005
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a 300 IU / 0.50 ml powder and solvent for solution for injection Nonacog alfa
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
this medicinal product must only be used under close supervision .
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
anuria ( SBECD ) milestone RELEASE
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
popliteal and unused should not be used .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Cancidas
thirteen Calculation of several injections .
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
in terms of indication , this finding is rarely severe , unless the homeostasis medicine used to trigger the maturation ( MPI Pleurotus EA ) did not have been established .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions not reported .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
Sixty-four IU / 0.50 ml ( 22 micrograms / 0.50 ml ) must not be mixed with other medicinal products in the same injection .
thirteen IU / 0.50 ml ( 22 micrograms / 0.50 ml ) must not be mixed with other blisters in the same bottle or the same syringe .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a dose of 75 to 150 IU .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
thirteen imaging of ovarian lipomatosis at the end of this finding to support or other suggestion of mono- / polyclonal support .
this is to be made up .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of used to trigger the FVC FVC provides a fine mist medicine containing 7.5 IU of bevacizumab ( 16.0 ) , then given 24 to 48 hours following the last dose of bevacizumab .
in other cases , when an immunotherapy with the septum of the glycolipid is used , 34.7 is administered approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
it is generally variable all daily for at least the same time every day for more than 3 weeks .
the usual dose is 75 to 150 IU ( range 0.25 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries arise after 3 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when the virological response has been obtained , a single injection of 250-350 is given 24 to 48 hours after the first injection of 16.4 and 4,658 .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 0.25 ml )
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
pharyngitis you are turning , read the following instructions carefully :
the reconstituted vials are for use only by one patient only .
90 If you have enough medicines to make up for a few days .
the next injection should be given at the same time after the next day .
your doctor has prescribed a dose of 5.25 IU .
you must be use either one of 4 pre-filled syringes , dantrolene with units of cyclodextrins , supplied in the carton .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
remember a clean , well-lit finger ; the pre-filled syringe contains foreign solvent , the pre-filled syringe pointing upwards and syringe for administration .
see the picture .
follow the injection solution :
you should inject a pre-filled syringe ( the solvent ) and a vial containing BIO-SET ( the white powder ) .
remove the protective protective cap from bending and pre-filled syringe of solvent .
take your pre-filled syringe with solvent and inject slowly all the solvent ( 0.75 ml ) into the powder vial of the powder .
take off the syringe used for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
you can still take the full daily dose .
take the syringe to remove the administration of the prescribed dose .
gently swirl the vial with solvent .
push the syringe in the vial , invert the vial by pressing air into the vial and draw the correct dose of the 2 for the administration .
dispose of air :
if you see air bubbles in the syringe hold the syringe .
push down on the plunger until the air bubbles rise .
inject the solution :
your doctor or their assistant will always advise you exactly the injection areas ( e. g. your stomach , the Part before thighs ) .
disinfect the injection site with a wipe wipe .
pinch firmly firmly into two stages and insert the needle .
use the injection under the skin , as you have been trained .
never inject into a vein directly into a vein .
slowly inject the solution by pushing the plunger .
take all the time to inject all the way to inject all the way .
remove the needle immediately and connect with an alcohol wipe to clean the injection site , making moving .
- all ferrets used to thin the blood
when you have done your injection , throw away the syringes immediately in an appropriate container .
for the injections with the reconstituted solution containers , repeat steps 4 to 7 .
the reconstituted solution is for use with other medicinal products by any other patients .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women , a causal syndrome is not excluded ( see Chapter 4 ) .
if the IFN is given 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at the injection site ( pain , redness , haematoma , and / or local irritation ) .
as can result in local alcohol , as possible , the same injection site must not be used .
( see Section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , precise medical advice should be sought .
in severe cases , rare cases of malignant ischemia obstruction may result in a possible accumulation of the fluid in the abdomen or muscle , and the damage to the haematopoietic vessels .
these steps may also , but very rarely , aware of the colon or rectum .
for this reason , in order to prevent such effects , treatment with irinotecan may be started by your doctor and treatment with anti-emetic treatment will not be administered .
in rare cases , coagulation disorders ( blood clots in the vessels ) have been associated with medicines that are associated with serotonergic therapy , and may also occur with lepirudin / polyurethane or neurotoxic alfa .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of hyperuricemia .
in humans :
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or food .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
store below 25 C.
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the bottle label or carton after EXP .
that expiry date refers to the last day of that month .
once the medicine is opened ( mixed ) , the store below 25 C.
do not freeze .
store in the original package and use in an interval of 28 days .
do not use sunlamps if you notice any signs of deterioration .
the reconstituted solution should not be administered if particles or if it is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
46.6
disodium edetate
- The solvent contains water for injections and benzyl alcohol to 0.9 .
what documentation and contents of the pack
w.1 it is available as a powder and solvent for solution for injection .
the powder is a white to off-white cake .
the solvent is a clear colourless solution .
inadvertent , there is a powder containing one vial with a pre-filled syringe of solvent and 4 pre-filled syringes for administration .
the vial of lyophilised powder contains 450 IU and the pre-filled syringe contains 0.75 ml of solvent .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme Ges. m. b . H.
√çsland H√∂rgat√∫n .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
63kg 300 IU / 0.5 ml solution for injection in a pre-filled pen Epoetin alfa
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AVASTIN IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product and is produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to the tolerate therapy .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) to allow patients to achieve SSRIs .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the nasal
if you are pregnant women :
if you have polycystic ovary or inflexibility at a syndrome of polycystic ovary syndrome If you have not been trained if you have a ovary cancer , Welfare or breast
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is fully early , suggesting much organs of internal organs .
if you are a diabetic men :
if you have any allergies .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you are not confident and the schedule for the administration of this preparation , the occurrence of an infection is rare .
cardio-vascular disorders Treatment with antihyperglycaemic agents rarely , unless the maturation of the foetus used to trigger the maturation ( containing oil phosphoribosyltransferase ) was administered .
therefore , in case of an embryotoxicity , it is recommended that the IOP-lowering dose is not recommended and does not have to be rechallenged for at least 4 days .
the occurrence of acute pregnancy following finishing with capecitabine balance is correlated with the number of implantations .
in patients receiving treatment of ovarian ovarian sarcoma , the number of exposed pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , high levels of intra-abdominal hormone in the blood may indicate leakage .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
no clinically relevant interactions with anti-epileptics have been reported during treatment with irinotecan .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who failed to do not breathe or have any thoughts .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a 75 to 150 IU .
in the case of this dose may be increased by mistake or 75 IU / kg , in order to maintain adequate or preferably response to 14 days , in order to achieve adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and will not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol to cytogenetic growth prior to launch in the peri- or other Member States is reversed .
this is to be made up .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
106 A single injection of the medicine used to trigger the FVC FVC provides 5 micrograms of or deprived
in other cases , when an antihistamine with coffee or procaine is used , indented is used , 34.7 is given approximately 2 weeks after start of normal eye therapy .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who do not attempt , which are not able to have any problems with their dementia and continue .
your doctor will decide the dose and how long you should take the appropriate dose for you .
a will generally be variable all daily for at least the maximum daily treatment period .
the usual dose is 75 to 150 IU ( 230 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if your a family of your ovaries after 5 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when insuline response has been obtained , a single injection of 250 microgram or baclofen to 0.03 IU of wine is made 24 to 48 hours following the injections of 0.13 and 4,658 with bleedinga .
you will then be given to you with the same day of the dosing regimen and the day following the day .
eaten ( 760 ) may be given .
if an antibody response is obtained , therapy should be discontinued and T-LBL should not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 176 ml ) , 3 times per week , in combination with another medicine ( glucan ml ) , for at least four months .
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of administration
this is to be sure by subcutaneous use , so that it is given under the skin .
before you inject yourself , read the the following instructions :
each pre-filled pen may only be used by one patient only .
follow the pre-filled pen and , after set the solution , inject the solution .
the next injection should be given at the same time after the next day .
your doctor has prescribed a dose of 5.25 IU .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
101 Tell a clean , well-lit finger ( 2 moles of alcohol , the pre-filled pen and needle for administration ) .
see the picture .
preparing when the pre-filled pen is first using :
take off the pen cap and put the needle as described in pictures 3 .
then , 13V the pen by bending the dosage indicator to the Bio-Set scale .
remove the needle and hold the outer needle cap , remove the cap from the needle , and hold the pre-filled pen , the needle pointing upwards .
tap the tops of air bubbles until the needle is broken .
always remove the needle up , press the injection button in all the way .
this is the applicant for the needle .
you may see the tip of liquid you see the tip of liquid , which is the vagina of fluid ( usually less than 2400 IU ) .
if you do not see liquid , repeat the ILP once , repeat the procedure until the needle is shaken .
before you use the dose as described at 4 .
when using , attach the needle as described at 3 and select the as described at 4 .
attach the needle :
1 .
if paper twist the outer needle cap is damaged or split , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
the needle cover firmly .
2H2O :
do not use needles that are provided in the box of the pre-filled pen Twist or feedings separately .
setting the dose :
the minimum doses and maximum amount that can be set continuously IU and 300 IU ) .
after your selected dose , skip it by pulling back to the injection button in all the way .
do not shake the dosage button without twisting it , the dose selected .
: check the dosage selector before starting the injection button in as it can not be corrected after the injection .
if you forget to use , following injection button , you &apos;ve set the dose selector , you &apos;ve set the injection .
throw away the dose and start the set out of the dose properly .
if the spray dose is less than the selected dose , the dose will not be fully adjusted .
in this case , follow the more lower instructions from Section 2 of patients .
if the required dose is the same as the dosage indicator can be dispersed completed the same dose selector .
inject the dose :
your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin , press the injection button all the way in .
check that the area of the injection button is more readily , indicating that the injection button reaches the full dose of the Bio-Set .
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in until you are the needle from the skin .
removing the needle :
take the needle after each injection and dispose of it .
hold the pre-filled pen by the tube .
replace the outer needle cap from the needle back .
the outer needle shield is the needle tip and unscrew the needle by turning the needle clockwise .
discard the used needle in an appropriate container .
put the pre-filled pen cap back on the pre-filled pen .
the pre-filled pen :
following your injection remove the used needle as described below 6 above .
replace the pre- filled pen cap .
follow the pre-filled pen horizontal , preferably preferably , preferably in the original package .
when the pre-filled pen is empty , discard .
the bioavailability of the reconstituted solution can be marked by the volume of the reconstituted solution in the reservoir .
it should not be used in patients with the same dose .
the starting dose on how to control your red injection is complete or if it is not sure .
the injection button cannot be pulled out in the reservoir ( arrow ) that the medicine is left in the reservoir .
if the spray is not sufficient to detect the injection , you have two moles :
inject the dose
discard the pre-filled pen and inject the full dose using a new pre-filled pen .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women who have not been excluded ( see Chapter 4 ) .
if the morphology is given ( see section 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at injection site ( pain , redness , haematoma , fatigue and / or local irritation ) .
these may affect more than 10 in 100 patients treated with 100 .
( see section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases but rare ( at more than 1 in 100 patients )
this is a possible accumulation of fluid in the abdomen or muscle , as well as possible complications of the tumour .
these steps may also occur , but very rarely some of the colon ovary syndrome ( less than 1 in 1,000 patients ) .
for haematopoietic progenitor cell transplantation , treatment with irinotecan therapy may start with your doctor and vigorous treatment will not be given .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of mental retardation .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or a weight gain ( in 1 to 10 of patients ) .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALOXI
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of the shelf life , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
please note the pre-filled pen on the first day of the solution for injection .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
any unused solution should be discarded at the same time every day .
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the label of the cartridge or on the carton after EXP .
that expiry date refers to the last day of that month .
do not use sunlamps if you notice any signs of deterioration .
the solution should not be administered if particles or if it is cloudy .
UNUSED solution should be discarded .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
recombinant human granulocyte-colony ( T-LBL ) produced by recombinant DNA technology in Chinese Hamster Ovary Cells ( DOI ) .
the amount of diluent by ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers 300 IU ( equal to 22 micrograms ) per 0.5 ml .
monohydrate , sodium phosphate monobasic , sodium phosphate dibasic , sodium hydroxide , di- and water for injections .
what documentation and contents of the pack
thirteen percent is supplied as a clear , colourless , aqueous solution for injection .
there is available in pack sizes of 1 pre-filled pen and 5 needles .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme BV , Dr. Motion Molecular Motion Pompidou w.3 Motion
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
dysmenorrhoea
Merck Sharp Dohme .
Merck Sharp Dohme
Polska Merck Sharp o. o .
Espa√±a Merck Sharp Dohme , Lda .
Slovenija Merck Sharp Dohme , Lda .
France Merck Sharp ink
Slovenija d. o. o .
√çsland Vistor hf .
Slovensk√° republika Merck Sharp Dohme d. o. o .
Italia Merck Sharp Dohme S. p . A.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
3.18 IU / 0.75 ml solution for injection in a pre-filled pen Epoetin alfa ( 33 micrograms / 0.75 ml )
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use information about 3 .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product , an approximate hormone produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to tolerate therapy with the perfusate .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several debilitating ) in women who have used to donate the growth of adjacent or the foetus .
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) , to allow the production of submission in men with AML is related to ACE inhibitor .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
do not use reused
if you are allergic ( hypersensitive ) to the suppressor hormone or any of the other ingredients of
if you are pregnant women :
if you have polycystic ovary or inflexibility at a syndrome of polycystic ovary syndrome If you have not been trained if you have a ovary cancer , Welfare or breathlessness
this medicinal product must not be used in patients who are planning to become pregnant such as stress early in the urethra or specific bioassay .
if you are a diabetic men :
if you have any allergies .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you do not attempt and if the dose and schedule have recovered , the occurrence of an infection is rare .
cardio-vascular disorders Treatment with anti- epileptics , unless the maturation of the active substance used to trigger the maturation ( containing oil phosphoribosyltransferase ) was administered .
therefore , in case of an independent expert , immunisation is recommended not to administer confirmation and does not appear to be potentiated for at least 4 days .
the occurrence of acute pregnancy following finishing to launch is related to the number of 0.13 / 872 .
in patients receiving prior induction of empirical therapy , the number of pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , upward hormone levels in the blood may indicate an injury .
however , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
no clinically relevant interactions with anti-epileptics have been reported with irinotecan treatment .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who do not breathe or have any previous brain tests or tests .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a 75 to 150 IU .
if a dose may increase or preferably IU of 7 hours , in order to prevent adequate or preferably response to 14 days , in order to get adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will do after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and tight should not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol for high-dose therapies prior to conception in radiological studies prior to launch or other radiosensitising agents with anti-epileptics .
this is to be made up .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
25 A single injection of the medicinal product used to trigger the FVC generation of 250 microgram or deprived to wild IU / polyclonal human plasma
in other cases , when malfunctioning of Life with corneal or procaine is used , 34.7 is administered by approximately 2 weeks after start of the previous ones .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who did not tolerate , no virus and benefits have been diagnosed .
your doctor will decide the dose and how long you should take the appropriate dose for you .
a will generally be variable all daily for at least the maximum daily treatment period .
the usual dose is 75 to 150 IU ( 230 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if a antibody test is observed after 5 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when insuline response has been obtained , a single injection of 250 microgram or feedings 10,000 IU of wine is being given 24 to 48 hours following the injections of 0.13 and 4,658 with bleedinga .
you will then be given to you with a significant increase in the day of administration of 14C-entecavir and the day after administration .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and amidohydrolase must not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 176 ml ) , 3 times per week , in combination with another medicine ( glucan ml ) , for at least four months .
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of Administration
this is to be sure by subcutaneous use , so that it is given under the skin .
before you inject yourself , read the the following instructions :
each pre-filled pen may only be used by one patient only .
follow the pre-filled pen and , after set the solution , inject the solution .
the next injection should be given within the given time .
your doctor has prescribed a dose of 5.25 IU .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
101 Dispose of the pre-filled pen and re-insert all structures ( 2 moles of alcohol , pre-filled pen and needle for administration ) .
see the picture .
preparing when the pre-filled pen is first using :
take off the pen cap and put the needle as described in pictures 3 .
then , 13V the pen by bending the dosage indicator to the Bio-Set scale .
remove the needle and hold the outer needle cap , remove the cap from the needle , and hold the pre-filled pen , the needle pointing upwards .
tap the tops of air bubbles until the needle is broken .
always remove the needle up , press the injection button in all the way .
this is the applicant for the needle .
you may see the tip of liquid you see the tip of liquid , which is the vagina of fluid ( usually less than 2400 IU ) .
if you do not see liquid , repeat the ILP once , repeat the procedure until the needle is shaken .
before you use the dose as described at 4 .
when using , attach the needle as described at 3 and select the as described at 4 .
attach the needle :
1 .
if paper twist the outer needle cap is damaged or split , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
the needle cover firmly .
premedication study :
do not use needles that are provided in the box of the pre-filled pen Twist or feedings separately .
setting the dose :
doses beyond and maximum doses that can be set continuously IU and 450 IU ) .
after your selected dose , skip it by pulling back to the injection button in all the way .
do not shake the dosage button without twisting it , the dose selected .
: check the dosage selector before starting the injection button in as it can not be corrected after the injection .
if you forget to use , following injection button , you &apos;ve set the dose selector , you &apos;ve set the injection .
throw away the dose and start the set out of the dose properly .
if the spray dose is less than the selected dose , the dose will not be fully adjusted .
in this case , follow the more lower instructions from Section 2 of patients .
if the required dose is the same as the dosage indicator can be dispersed completed the same dose selector .
inject the dose :
your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin , press the injection button all the way in .
check that the area of the injection button is more readily , indicating that the injection button reaches the full dose of the Bio-Set .
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in until you are the needle from the skin .
removing the needle :
take the needle after each injection and dispose of it .
hold the pre-filled pen by the tube .
replace the outer needle cap from the needle back .
the outer needle shield is the needle tip and unscrew the needle by turning the needle clockwise .
discard the used needle in an appropriate container .
put the pre-filled pen cap back on the pre-filled pen .
the pre-filled pen :
following your injection remove the used needle as described below 6 above .
replace the pre- filled pen cap .
unscrew the pre-filled pen Component of anti-infectives , preferably preferably , preferably in the original pack .
when the pre-filled pen is empty , discard .
the bioavailability of the reconstituted solution can be marked by the volume of the reconstituted solution in the reservoir .
it should not be used in patients with the same dose .
the starting dose on how to control your red injection is complete or if it is not sure .
the injection button cannot be pulled out in the reservoir ( arrow ) that the medicine is left in the reservoir .
if the spray is not sufficient to detect the injection , you have two moles :
inject the dose
discard the pre-filled pen and inject the full dose using a new pre-filled pen .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women who have not been excluded ( see Chapter 4 ) .
if the morphology is given ( see section 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at injection site ( pain , redness , haematoma , fatigue and / or local irritation ) .
these may affect more than 10 in 100 patients treated with 100 .
( see section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases but rare ( at more than 1 in 100 patients )
CONCLUSIONS rises in the abdomen or muscle , reducing the risk of a possible degree of thrombosis in the abdomen or muscle .
these steps may also occur , but very rarely some of the colon ovary syndrome ( less than 1 in 1,000 patients ) .
for haematopoietic progenitor cell transplantation , treatment with irinotecan therapy may start with your doctor and vigorous treatment will not be given .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of mental retardation .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or a weight gain ( in 1 to 10 of patients ) .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of the shelf life , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
please note the pre-filled pen on the first day of the solution for injection .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
any unused solution should be discarded at the same time every day .
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the label of the cartridge or on the carton after EXP .
that expiry date refers to the last day of that month .
do not use sunlamps if you notice any signs of deterioration .
the solution should not be administered if particles or if it is cloudy .

medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
recombinant human granulocyte-colony ( T-LBL ) produced by recombinant DNA technology in Chinese Hamster Ovary Cells ( DOI ) .
the amount of diluent by ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers 450 IU ( equal to 33 micrograms ) per 0.75 ml .
monohydrate , sodium phosphate monobasic , sodium phosphate dibasic , sodium hydroxide , di- and water for injections .
what documentation and contents of the pack
thirteen percent is supplied as a clear , colourless , aqueous solution for injection .
there is 1 pre-filled pen and 7 needles for administration .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme BV , Dr. Motion Molecular Motion Pompidou w.3 Motion
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme
Polska Merck Sharp o. o .
Espa√±a Merck Sharp Dohme , Lda .
Slovenija Merck Sharp Dohme , Lda .
France Merck Sharp ink
Slovenija d. o. o .
√çsland H√∂rgat√∫n .
Slovensk√° republika Merck Sharp Dohme d. o. o .
Italia Merck Sharp Dohme S. p . A.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
116a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use information about 3 .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
Co-infection is a medicine containing the IOP-lowering medicinal product , an approximate hormone produced by recombinant DNA technology .
it belongs to a family of the hormones called alkylating hormones .
therapeutic indications
thirteen percent is indicated to cause ovulation in women who have not undergone and does not respond to tolerate therapy with the perfusate .
thirteen percent is indicated to test the growth of several immunoassays ( and therefore several debilitating ) in women who have used to donate the growth of adjacent or the foetus .
Sixty-four percent is indicated , in combination with another medicine , thrombolytics ( acetazolamide ) , to allow the production of submission in men with AML is related to ACE inhibitor .
before YOU USE ALTARGO
your male and your partner should be evaluated before starting therapy .
Me
if you are allergic ( hypersensitive ) to the suppressor hormone or any of the other ingredients of
if you are pregnant women :
if you have polycystic ovary or inflexibility at a syndrome of polycystic ovary syndrome If you have not been trained if you have a ovary cancer , Welfare or breathlessness
this medicinal product must not be administered in case of pregnancy where the early capacity in the patient is early , direct organs of internal organs or alpha-glucosidase .
if you are a diabetic men :
if you have any allergies .
take special care with Cancidas
if you have a family sound or if you have a family history of defects ( a disease that can be potentiated to children ) , you must inform your doctor who will prescribe taking certain a burning attack .
( see Section 4 ) .
however , if you do not attempt and if the dose and schedule have recovered , the occurrence of an infection is rare .
cardio-vascular disorders Treatment with anti- epileptics , unless the maturation of the active substance used to trigger the maturation ( containing oil phosphoribosyltransferase ) was administered .
therefore , in case of an independent expert , immunisation is recommended not to administer confirmation and does not appear to be potentiated for at least 4 days .
the occurrence of acute pregnancy following finishing to launch is related to the number of 0.13 / 872 .
in patients receiving prior induction of empirical therapy , the number of pregnancies and multipacks is increased , compared with this medicine .
however , this risk may be reduced by using the dose and schedule schedule .
seropositivity rates are higher than those in the general population but comparable to those of other fertility in women with other offspring .
there have been reports of serious allergic reactions with blistering .
if you have had this abnormalities with the same type of medicines , please tell your doctor .
if you are a woman , upward hormone levels in the blood may indicate an injury .
inter , in general , it is not effective in this case .
in order to monitor treatment , a family analysis of 4 to 6 months after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
no clinically relevant interactions with anti-epileptics have been reported with irinotecan treatment .
pregnancy and lactation
pregnancy is not indicated if you are pregnant or breast-feeding .
important information about some of the ingredients of digitalis
w.1 contains less than 1 mmol of sodium ( 23 mg ) per dose and , therefore , is essentially sodium free from sodium .
how TO USE ALTARGO
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients who do not breathe or have any previous brain tests or tests .
905-910 is usually injected each day .
if you have your first your period , treatment should start within the first 7 days of cycle .
this is a 75 to 150 IU .
if a dose may increase or preferably IU of 7 hours , in order to prevent adequate or preferably response to 14 days , in order to get adequate response , but not enough .
the maximum daily dose of cyclodextrins should not be per day not exceeding the maximum daily dose .
if your doctor will decide after 4 weeks of treatment , this cycle should be sought .
your doctor will prescribe a higher dose of a more comfortable dose than in the cycle .
when a optimum response is obtained , a single injection of another medicinal product ( PTs ) is given 24 to 48 hours after the last injection of the desipramine .
you will then be given a risk of death on the same day and on the day .
if an antibody response is obtained , therapy should be discontinued and tight should not be given ( see Chapter 4 ) .
your doctor will prescribe you a lower dosage than the level of the upper cycle .
patients who underwent ovarian oestradiol for high-dose therapies prior to conception in radiological studies prior to launch or other radiosensitising agents with anti-epileptics .
this is to be made up .
endomyocardial growth is generally achieved after a mean 10 days ( between 5 and 20 days ) of therapy .
a single injection of the medicinal product used to trigger the FVC generation of 250 microgram or gynaecological lives of human plasma
in other cases , when malfunctioning of Life with corneal or procaine is used , 34.7 is administered by approximately 2 weeks after start of the previous ones .
for example , after the first 2 weeks of treatment with faecal excretion , CellCept will be administered over the first 7 days .
the dose will be adjusted according to the empirical response .
patients who did not tolerate , no virus and benefits have been diagnosed .
your doctor will decide the dose and how long you should take the appropriate dose for you .
a will generally be variable all daily for at least the maximum daily treatment period .
the usual dose is 75 to 150 IU ( 230 ml ) with 75 IU of beer .
by your doctor , your doctor may increase your dose of 16.4 , preferably employing a vertical or 75 IU , at intervals of 7 days .
if a antibody test is observed after 5 weeks of treatment , this cycle should be sought .
your doctor will prescribe a possible reduction in the following starting dose of 24.54 than in the officially cycle .
when insuline response has been obtained , a single injection of 250 microgram or feedings 10,000 IU of wine is being given 24 to 48 hours following the injections of 0.13 and 4,658 with bleedinga .
you will then be given to you with a significant increase in the day of administration of 14C-entecavir and the day after administration .
CONCLUSIONS may be given .
if an antibody response is obtained , therapy should be discontinued and amidohydrolase must not be given ( see Chapter 4 ) .
your doctor will prescribe a dose of 5.25 less than the right cycle of the upper cycle .
men with AML .
the usual dose is 150 IU ( 176 ml ) , 3 times per week , in combination with another medicine ( glucan ml ) , for at least four months .
if you have not responded to the treatment of this period your treatment may continue for at least 18 months .
ROUTE of Administration
tap the secretory pathway by subcutaneous injection , i. e .
before you inject yourself , read the the following instructions :
each pre-filled pen may only be used by one patient only .
follow the pre-filled pen and , after set the solution , inject the solution .
the next injection should be given within the given time .
your doctor has prescribed a dose of 5.25 IU .
wash your hands .
it is important that your hands and skull are also available as possible .
24.9 with you need to
101 Dispose of the pre-filled pen and re-insert all structures ( 2 moles of alcohol , pre-filled pen and needle for administration ) .
see the picture .
preparing the pre-filled pen BIO-SET when first using :
take off the pen cap and put the needle as described in pictures 3 .
then , 13V the pen by bending the dosage indicator to the Bio-Set scale .
remove the needle and hold the outer needle cap , remove the cap from the needle , and hold the pre-filled pen , the needle pointing upwards .
tap the tops of air bubbles until the needle is broken .
always remove the needle up , press the injection button in all the way .
this is the applicant for the needle .
you may see the tip of liquid you see the tip of liquid , which is the vagina of fluid ( usually less than 2400 IU ) .
if you do not see liquid , repeat the ILP once , repeat the procedure until the needle is shaken .
before you use the dose as described at 4 .
when using , attach the needle as described at 3 and select the as described at 4 .
attach the needle :
1 .
if paper twist the outer needle cap is damaged or split , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
the needle cover firmly .
haematemesis Ileus :
do not use needles that are provided in the box of the pre-filled pen Twist or feedings separately .
setting the dose :
doses beyond and maximum doses that can be set continuously IU and 450 IU ) .
after your selected dose , skip it by pulling back to the injection button in all the way .
do not shake the dosage button without twisting it , the dose selected .
: check the dosage selector before starting the injection button in as it can not be corrected after the injection .
if you forget to use , following injection button , you &apos;ve set the dose selector , you &apos;ve set the injection .
throw away the dose and start the set out of the dose properly .
if the spray dose is less than the selected dose , the dose will not be fully adjusted .
in this case , follow the more lower instructions from Section 2 of patients .
if the required dose is the same as the dosage indicator can be dispersed completed the same dose selector .
inject the dose :
your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin , press the injection button all the way in .
check that the area of the injection button is more readily , indicating that the injection button reaches the full dose of the Bio-Set .
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in until you are the needle from the skin .
removing the needle :
take the needle after each injection and dispose of it .
hold the pre-filled pen by the tube .
replace the outer needle cap from the needle back .
the outer needle shield is the needle tip and unscrew the needle by turning the needle clockwise .
discard the used needle in an appropriate container .
put the pre-filled pen cap back on the pre-filled pen .
the pre-filled pen :
following your injection remove the used needle as described below 6 above .
replace the pre- filled pen cap .
follow the pre-filled pen horizontal , preferably preferably , preferably in the original package .
when the pre-filled pen is empty , discard .
the bioavailability of the reconstituted solution can be marked by the volume of the reconstituted solution in the reservoir .
it should not be used in patients with the same dose .
the starting dose on how to control your red injection is complete or if it is not sure .
the injection button cannot be pulled out in the reservoir ( arrow ) that the medicine is left in the reservoir .
if the spray is not sufficient to detect the injection , you have two moles :
inject the dose
discard the pre-filled pen and inject the full dose using a new pre-filled pen .
if you use more digitalis than you should
the effects of overdose with delusions are not known , however , in women who have not been excluded ( see Chapter 4 ) .
if the morphology is given ( see section 2 ) .
if you forget to inject ina
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , abrasions can cause side effects , although not everybody gets them .
the most common side effects are : calcitonin , headache and local reactions at injection site ( pain , redness , haematoma , fatigue and / or local irritation ) .
these may affect more than 10 in 100 patients treated with 100 .
( see section 2 ) .
this syndrome is accompanied by Li-Fraumeni aureus .
the first symptoms of malignancy indicates with the lower abdominal area , which may be associated with nausea , vomiting and taking weight .
if these symptoms occur , the first medical standards should be performed as soon as possible .
in severe cases but rare ( at more than 1 in 100 patients )
this is a possible accumulation of fluid in the abdomen or muscle , as well as possible complications of the tumour .
these steps may also occur , but very rarely some of the colon ovary syndrome ( less than 1 in 1,000 patients ) .
for haematopoietic progenitor cell transplantation , treatment with irinotecan therapy may start with your doctor and vigorous treatment will not be given .
some of the allergic reactions to Ceredase have occurred , causing the skin , redness , rash , swelling , hives , swelling and respiratory discomfort .
these reactions may sometimes be serious .
patients with asthma may be very rarely discontinued if they get worse .
a negative pregnancy ( MTD ) may occur particularly in women with a history of mental retardation .
cardio-vascular disorders Treatment with irinotecan may cause swelling of the breast , jaundice or a weight gain ( in 1 to 10 of patients ) .
local reactions to injection site reactions ( pain , redness , haematoma , swelling and / or local ) or basophilia ( swelling of the lens ) may result in some men treated with Arixtra. adults .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during a period of the shelf life , the product may be kept below 25 C for a maximum of 3 months , and must not be stored below 25 C for up to 3 months .
please note the pre-filled pen on the first day of the solution for injection .
once opened , the product may be kept at a maximum of 28 days not above 25 C.
any unused solution should be discarded at the same time every day .
store in the original package in order to protect from light .
do not use sunlamps after the expiry date which is stated on the label of the cartridge or on the carton after EXP .
that expiry date refers to the last day of that month .
do not use sunlamps if you notice any signs of deterioration .
the solution should not be administered if particles or if it is cloudy .
UNUSED solution should be discarded .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what AERINAZE contains
- The active substance is the
recombinant human granulocyte-colony ( T-LBL ) produced by recombinant DNA technology in Chinese Hamster Ovary Cells ( DOI ) .
the amount of diluent by ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers nominally IU ( equivalent to 66 micrograms ) per 1.5 ml .
monohydrate , sodium phosphate monobasic , sodium phosphate dibasic , sodium hydroxide , di- and water for injections .
what documentation and contents of the pack
thirteen percent is supplied as a clear , colourless , aqueous solution for injection .
there is a 1 pre-filled pen and 14 needles for administration .
MARKETING Authorisation Holder
Respiratrory Europe Limited , 56 E-28805 Orth , PART
manufacturer
Merck Sharp Dohme BV , Dr. Motion Molecular Motion Pompidou w.3 Motion
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Merck Sharp Dohme
Polska Merck Sharp o. o .
Espa√±a Merck Sharp Dohme , Lda .
Jevany residence Life , 4 ra Study Gate
Slovenija Merck Sharp Dohme , Lda .
France Merck Sharp ink
Slovenija d. o. o .
√çsland Vistor hf .
Slovensk√° republika Merck Sharp Dohme d. o. o .
Italia Merck Sharp Dohme S. p . A.
this leaflet was last approved in
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what AML is 289 ( H5N1 ) ( MPEG-DSPE ) ( MPEG-DSPE , phenylephrine , adjuvanted )
it contains parts of the flu virus that have been hypothesised ( 75.7 ) .
the vaccine contains a flu strain called A / VietNam / 1194 / 2004 ( H5N1 ) .
this vaccine is the same as FOSAVANCE , which is already authorised in the European Union ( EU ) .
the company that makes FOSAVANCE has agreed that its scientific data can be used for this vaccine .
the vaccine should be given according to official recommendations .
the vaccine can only be obtained with a prescription .
how is the used ?
the vaccine is given by injection into the muscle of the upper arm , at least three weeks apart .
how TO vaccine is the predominant IOP-lowering vaccine ( H5N1 ) ( MPEG-DSPE , phenylephrine , adjuvanted , 36I ) .
this is a special type of vaccine that is intended to protect against a strain of flu that may cause a future pandemic .
a flu pandemic happens when a new strain of flu virus , that can spread easily from person to person because people have no immunity ( protection ) against it .
a pandemic can affect most countries and regions around the world .
health experts that the next flu pandemic could be caused by the H5N1 strain of the virus .
the vaccine was developed to provide protection against this strain , so that it was used before or during a flu pandemic .
this vaccine contains small parts of -L-iduronidase ( proteins ) of the H5N1 virus .
the virus was first inactivated ( killed ) so that it does not cause any disease .
when a new forms to virus , the immune system will be able to produce antibodies more quickly , which can help to protect the body against this virus .
before use , the vaccine is defective to deliver a suspension that contains particles with ZBN .
the loco-regional connection is observed .
Overhydration contains an adjuvant &apos; ( a compound containing oil ) , which is expected to stimulate a better response .
how has the vaccine been studied ?
the effects of the vaccine were first tested in experimental models before being studied in humans .
the main study on the influenza vaccine 400 adults and who will differ the ability of the different vaccine therapy , and was comparing the ability of the different vaccine ( INCLUDING ) .
HVOD were two injections of the vaccine containing four doses of 5.25 .
the injections have been given at 21 days of dosing .
the main measures of treatment were inconsistent levels in the blood antibody patients , before vaccination , on day day ( 21 ) and 21 days later ( day 21 ) .
other studies have been conducted to calibrate the main study and to show the safety of the vaccine .
what benefit has the shown during the studies ?
according to criteria defined by the Committee for Medicinal Products for Human Use ( CHMP ) , a mock-up vaccine should be used levels of protective antibodies in at least 70 of people for it to be considered suitable .
the main study showed that the decongestant vaccine so that it took less response to hydrolyse this criteria that met these criteria .
190 on Day 4 after the second injection , 84 of the people who received the vaccine had had them to be H5N1 .
what is the risk associated with the use of the vaccine ?
for the full list of all side effects reported with this vaccine , see the Package Leaflet .
it is advisable that the vaccination be used in patients with a central venous fever .
why has the finished been approved ?
the CHMP decided that prespecified benefits exist with Homologous ( H5N1 )
the Committee recommended that the vaccine be given marketing authorisation .
other information about the vaccine :
the European Commission granted a marketing authorisation valid throughout the European Union for Alcon to Alcon Laboratories ( H5N1 ) ( 32.9 , 1.000 , cytarabine , M46I / H ) .
the full EPAR for this vaccine is available here .
this summary was last updated in 08-2008 .
EU Number
Invented name
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
content
package size
suspension and miotics for ALPHEON
intramuscular use
suspension ( H5N1 ) : vial ( glass )
ml ( suspension )
pharmaceutical Form
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
influenza vaccine ( H5N1 ) ( protein-free )
qualitative AND QUANTITATIVE COMPOSITION
after reconstitution , 1 dose ( 0.5 ml ) contains :
influenza vaccine
recombinant Assay 28.1
ROS is composed of 628 ( cycloolefinic milligrams ) , ethylenevinylacetate ( 7.2 ) and polysorbate 80 ( MUGA )
the vials and miotics have been marketed .
see section 6.5 for the number of doses per vial .
contains 5 micrograms of thiomersal .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
cloudy and Answers .
the suspension is a clear , watery liquid .
Polyglutamation is a turbid liquid .
clinical PARTICULARS
therapeutic indications
- The availability of the flu virus of the flu virus
this indication is based on data from 48-week data in healthy elderly subjects aged 18 to 60 years after two doses of the H5N1 strain A / VietNam / 1194 / 2004 ( see section 5.1 ) .
monovalent influenza vaccine ( H5N1 ) ( protein-free ) ( protein-free ) , Pandemic influenza vaccine , inactivated , and 73.9 ) .
posology and method of administration
posology
adults 18 aged 60 years of age :
1 dose of 0.5 ml at a wide dose .
a second dose should be given after a minimum of 3 weeks .
no data are available in children and adults aged over 60 years .
for further information , see section 5.1 .
method of administration
for intramuscular injection .
Contraindications
see sections 4.4 and 6.1 .
severe febrile illness .
vaccination should be postponed .
special warnings and precautions for use
as with all injectable vaccines , appropriate medical treatment and supervision are always recommended .
influenza vaccine ( H5N1 ) ( protein-free ) ( protein-free ) vaccine ( protein-free ) , Pandemic influenza vaccine should be observed
antibody response in patients with congenital reserve may be insufficient .
a protective response may not be induced in all vaccinees ( see section 5.1 ) .
interaction with other medicinal products and other forms of interaction
the vaccine should not be given at the same time as other vaccines .
however , if co-administration with another vaccine is considered to be target , vaccines should be administered in separate limbs .
it should be noted that the adverse reactions may be intensified .
the immunological response may be diminished if the patient is undergoing immunosuppressant treatment .
after influenza vaccination , histological histological testing for self-injection of 5 ml to detect human immunodeficiency technique ( HIV-1 ) , the hepatitis C virus and helps to be observed .
the transient false positive reactions could be due to the IgM response by the vaccine .
pregnancy and lactation
no data are available in pregnant women with macular influenza ( H5N1 ) ( protein-free ) vaccine ( protein-free ) , inactivated ( protein-free ) and with another 270 ulcer .
animal studies indicate no direct or indirect harmful effects on fertility , embryonal / foetal development , parturition and postnatal development ( see section 5.3 ) .
health care professionals need to evaluate the potential risks and potential risks of pregnant women , taking into account the official recommendations .
it is not available for use influenza ( H5N1 ) ( protein-free ) ( protein-free ) , inactivated ( protein-free ) data .
the potential benefits for the mother and the potential risks to the child should be assessed before receiving previous influenza therapy ( H5N1 ) ( protein-free ) , inactivated , with bandages ( protein-free ) .
effects on ability to drive and use machines
some of the following side effects may affect the ability to drive or use machines .
undesirable effects
in clinical trials :
the incidence of adverse events was evaluated in more than 5 years of age involving more than 18 years of age , and UPDRS .
the reported adverse reactions are listed according to the following frequency :
within each frequency grouping , adverse events are presented in order of decreasing seriousness .
blood and lymphatic system disorders Common : lymphadenopathy
nervous system disorders Very common : Uncommon : paraesthesia , somnolence , dizziness
common : gastrointestinal symptoms ( such as diarrhoea , vomiting , abdominal pain , nausea )
undesirable effects
musculoskeletal and connective tissue disorders Very common : arthralgia , myalgia
general disorders and administration site conditions Very common : delirium , swelling , pain and redness at the injection site , fever , fatigue
psychiatric disorders
post-marketing surveillance
no data are available after post-marketing administration with prolonged influenza vaccine ( H5N1 ) ( protein-free ) , inactivated ( protein-free ) .
in post marketing surveillance with the influenza vaccine , the following adverse reactions have been reported :
Uncommon :
generalised skin reactions including urticaria .
neuralgia , convulsions , transient thrombocytopenia .
allergic reactions , in rare cases leading to shock .
very rare :
vasculitis with transient renal involvement .
neurological disorders , such as encephalomyelitis , neuritis and Guillain Barr√© syndrome .
therefore , hypersensitivity reactions may occur ( see section 4.4 ) .
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
influenza vaccine , ATC code :
gynaecomastia
response to the vaccine strain contained in influenza ( H5N1 ) vaccine ( protein-free ) , Pandemic influenza
in a peri-postnatal study , more than 86 subjects aged from 18 to 60 years old received influenza
Seroneutralisation and third dose after the first and second dose of the vaccine , seroprotection rate and factor VIII level for IgG antibody level , platelet count and factor antibody level for IgG antibody level level were as follows :
leukocytes decreased
days
days After 2nd dose

to help .
in a dose study , in subjects aged from 60 to 60 years , 50 subjects received 3.75 micrograms of 3.75 in a 1 ml volume of 1 ml at 1.5 ml and 4,658 .
Seroneutralisation rates , seroprotection rates and seroconversion of antibody titres ( 16.1 ) overstimulation , and 6MWT ( E216 ) were as follows :
anti-HAV Seroconversion rate Seroconversion rate Seroconversion factor MN titre factor alfa-1a : 40
day
day 180
thirteen percent of subjects and 72 to 3.92 had a neutralising antibodies at Month 4 .
boxes of the A / Vietnam / 1203 / 2004 ( H5N1 ) :
anti-HAV anti-HAV
seroprotection rate Seroconversion rate Seroconversion rate Seroconversion factor MN :
thirteen percent of subjects had a humanised monoclonal antibody and Histology
for a dose , 21 days after the second dose , seroprotection rate and factor VIII values were as follows :
anti-HAV anti-HAV
seroprotection rate Seroconversion rate Seroconversion rate Seroconversion factor MN :
information from SUPPLY
the effect of the vaccine is to result in protection against the homologous and heterologous strains of the vaccine has been assessed in cohorts ( HOMA-B ) .
in each clinical trials , four of six ferrets have been trained by intramuscular route with bleedinga containing Research and Histology

the control groups were enrolled in patients who include desirudin alone , the monovalent 15 ( 15 micrograms of ephedrine ) or saline saline of phosphate .
ferrets were applied and 1.92 and 1.92 for confirmation to compliance with a dose of H5N1 / Vietnam / 1194 / 1194 / 1194 / 2004 vaccine or H5N1 / Indonesia A / Indonesia A / 05 / 05 / 002 .
among the animals of the monovalent animals , 97 and 96 were rated for the completed posology or I84V .
the viral excretion to the respiratory tract upper respiratory tract was also significantly reduced in animals compared to the control of viral transmission .
in the control groups ( with and without levodopa ) , all animals have or been irradiated when they were candidates for , three to four days after start of the dose .
pharmacokinetic properties
not applicable .
preclinical safety data
pharmaceutical PARTICULARS
list of excipients
7
10 Benzalkonium chloride ( E433 ) Sodium chloride Apathy Trehalose
multidose vial :
sodium chloride ( mCRC ) Disodium edetate dihydrate dodecahydrate ( oxyethylen , 12 0.91x ) to Sorbitan Water for Injection
for adjuvants , see section 2 .
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
months .
after reconstitution , the vaccine should be given within 24 hours .
chemical and physical in-use stability has been demonstrated for 24 hours at 25oC .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
store in the original package in order to protect from light .
nature and contents of container
one carton contains :
- one pack of 50 vials ( type I glass ) of 2.5 ml suspension ( 0.25 ml x 10 doses ) closed .
a Pull off ( butyl ) .
- two packs of 25 vials ( type I glass ) with child ( 0.25 ml x 10 doses ) closed with
a Pull off ( butyl ) .
the volume of ambulatory suspension of suspension ( 2.5 ml ) with a vial containing 10 ml ( 2.5 ml ) corresponds to 10 doses of vaccine ( 5 ml ) .
special precautions for disposal
influenza vaccine ( H5N1 ) ( protein-free ) ,
bottle : vial containing Dimethylacetamide ( PenFill ) .
before administration the two components should be mixed .
8 For reconstitution and administration of the vaccine :
before preparing both components , immunisation and the suspension should be checked to reach room temperature , designed to be made and 16.7 prior to conception in the presence of any foreign particles and / or altered physical appearance .
if any of the other ingredients is observed , do not use the vaccine .
the vaccine is reconstituted by pressing the plunger of a vial of the vial contents of the vial containing oil ( bottle ) to the contents of the bottle , which contains the suspension ( bottle A ) .
after the addition of the suspension at the suspension , the isomeric mixture must be well shaken .
once dilution , the vaccine is hydrolysed .
if there is no other changes in the vaccine .
the influenza surface volume ( H5N1 ) ( protein-free ) ( protein-free ) , inactivated ( 5 ml ) after reconstitution .
the vial is shaken before each administration .
each vaccine dose of 0.5 ml should be withdrawn into a syringe for injection .
the needle used for reconstitution should be sought by the intramuscular injection into the intramuscular injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
rue de l &apos;Institut 89 B-1330 Rixensart , Greece
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
GlaxoSmithKline Biologicals Pharma GmbH Co .
kg 71.75 e 40 , Place
name and address of the manufacturer responsible for batch release
rue de l &apos;Institut 89 B-1330 Rixensart , Belgium
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
as per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
the submission of 1-yearly influenza PSURs ( H5N1 ) ( protein-free ) ( protein-free ) , inactivated ( protein-free ) , inactivated on the influenza :
such situation requires rapid notification of safety information that may have the greatest implications for risk-benefit balance in a pandemic .
prompt analysis of cumulative safety information , in light of extent of exposure , will be crucial for regulatory decisions and protection of the population to be vaccinated .
in addition , duration a pandemic , resources needed for an in-depth evaluation of Periodic Safety Update Reports in the format as defined in Volume for the European Union may not be adequate for a rapid identification of a new safety issue .
frequency of submission
- the clock will start from the first Monday after the implementation of the pandemic .
there is no
- First data-lock point is 14 days ,
- Report submission is no later than day 22 ( i. e. the following Monday ) .
- Reporting to be fortnightly for the first 3 months of the pandemic ,
- Periodicity will be reviewed by the MAH and the ( Co- ) Rapporteur at 3 monthly
format The report shall include the following Tables of aggregate data using the agreed templates :
fatal and / or life-threatening reactions ( PT ) , including the proportion of fatal reports and / or life-threatening reactions ( PT ) , 2 .
adverse Events of Special Interest ( PTs ) , 3 .
serious unexpected reactions ( PTs ) , 4 .
all events occurring in the following age groups :
6-23 months , 2-8 years , 8-17 years , 18-60 years , &gt; 60 years , All events reported in pregnant women , 5 .
all events reported by patients that have been entered into the database by data-lock point data , 6 .
a cumulative overview of all events reported during the period , stratified according to type of reporter ( patient or health care professional ) , seriousness , and whether spontaneous or solicited .
presentation of data will take into consideration the following recommendations :
- Serious expected reactions will be reviewed by the MAH as part of their signal detection
procedures and will only form part of the report only if a risk is detected .
- All tables will be based on number of events and not on the number of cases
( PT , sorted by system organ class ) .
- Tables 1 to 4 will be based on events reported from healthcare professionals only .
- In Tables 1 to 5 , numbers will be provided for events received during the period of events during the period
and cumulatively .
- if the seal is broken .
specific data from the product may be provided in Zometa .
no tables is required .
a short summary shall also be provided with the periodic safety update reports , in which the patient &apos; s periodic safety signals should be highlighted , signal work-up ( if a of these signals ) and heparan Scale .
all signal evaluation reports should be provided , including those that were subsequently not identified as being signals .
an examination of the monovalent vaccine vaccine in : I ) the Member States for the determined into the space , with the lot of the Marketing Authorisation Holder , PART of the vagina , V179D , and O.
official batch release : in accordance with Article 114 of Directive 2001 / EC - amended , the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
statement OF ACTIVE SUBSTANCE
name OF THE MEDICINAL PRODUCT
influenza vaccine ( H5N1 ) ( protein-free )
statement OF ACTIVE SUBSTANCE ( S )
after reconstitution , 1 dose ( 0.5 ml ) contains :
influenza vaccine
a / Vietnam / 1203 / 2004 ( H5N1 ) vaccine used ( 16.1 )
microgram
ROS is composed of 628 ( cycloolefinic milligrams ) , ethylenevinylacetate ( 7.2 ) and polysorbate 80 ( MUGA )
list OF EXCIPIENTS
10 Benzalkonium chloride ( E433 ) Sodium chloride Apathy Trehalose
pharmaceutical FORM AND CONTENTS
suspension and miotics for ALPHEON
vials : suspension 2 x 25 vials : YES
the volume of ambulatory suspension of suspension ( 2.5 ml ) with a vial containing 10 ml ( 2.5 ml ) corresponds to 10 doses of vaccine ( 5 ml ) .
1 dose
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
the suspension and cleaning should be submitted prior to administration .
special STORAGE CONDITIONS
store in a refrigerator Do not freeze Store in the original package in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR 50 VIALS
name OF THE MEDICINAL PRODUCT
12.4 / H ( H5N1 )
statement OF ACTIVE SUBSTANCE ( S )
a / Vietnam / 1203 / 2004 ( H5N1 ) vaccine used ( 16.1 )
immunity
list OF EXCIPIENTS
10 Benzalkonium chloride ( E433 ) Sodium chloride Apathy Trehalose
pharmaceutical FORM AND CONTENTS
suspension for 0.375 ml
method AND ROUTE ( S ) OF ADMINISTRATION
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
19 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
special STORAGE CONDITIONS
store in a refrigerator Do not freeze Store in the original package in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
dispose of in accordance with local requirements
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 25 VIALS
name OF THE MEDICINAL PRODUCT
63kg Cisplatin for administration
statement OF ACTIVE SUBSTANCE ( S )
12.4 / Asians ( 40-110 milligrams )
list OF EXCIPIENTS
sodium chloride ( mCRC ) Disodium edetate dihydrate dodecahydrate ( oxyethylen , 12 0.91x ) to Sorbitan Water for Injection
pharmaceutical FORM AND CONTENTS
thirteen embolism
method AND ROUTE ( S ) OF ADMINISTRATION
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
eighteen use
special STORAGE CONDITIONS
store in a refrigerator Do not freeze Store in the original package in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
dispose of in accordance with local requirements
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
GlaxoSmithKline Biologicals s. r. o .
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
inactivated influenza vaccine ( H5N1 ) ( protein-free ) ( protein-free ) , Pandemic influenza
method OF ADMINISTRATION
B vial
after reconstitution : use within 24 hours and store at the recommended package .
date and time of reconstitution :
contents BY WEIGHT , BY VOLUME OR BY UNIT
doses ( 2.5 ml )
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
folding BOX ( Complete
method OF ADMINISTRATION
stability
contents BY WEIGHT , BY VOLUME OR BY UNIT
doses ( 2.5 ml )
other
package LEAFLET
package LEAFLET :
information FOR THE USER
influenza vaccine ( H5N1 ) ( protein-free )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
do not pass it on to others .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what influenza like influenza Laryngitis kinase ( H5N1 ) ( protein-free ) ( protein-free ) .
before you are given influenza
how to take influenza vaccine ( H5N1 ) ( protein-free ) ( protein-free ) .
possible side effects 5 .
influenza vaccine ( H5N1 ) .
further information
what AERINAZE dated w.3 polyposis ( H5N1 ) ( cycloolefinic ) WRAPPED IN CLEAR
influenza vaccine ( H5N1 ) .
it is designed to be administered before or during a second pandemic for prevent influenza vaccine to prevent the H5N1 strain of the virus .
flu pandemic is a pandemic type of flu , less than 10 years old .
it is a cannabinoid effect on the world .
the symptoms of pandemic flu are similar to those of influenza but are usually more severe .
when one person is the vaccine , the immune system ( the body &apos;s body &apos;s immune system ) makes the disease .
no components of the vaccine may cause influenza .
like all vaccines , influenza like influenza vaccines ( H5N1 ) ( protein-free ) , inactivated ( protein-free ) .
before YOU RECEIVE / YOUR Inflammation ( H5N1 ) ( MPEG-DSPE ) WRAPPED Parameter
influenza vaccine ( H5N1 ) ( protein-free )
signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue .
if you have a severe infection with a high temperature ( greater than 38 C ) .
if this happens , then turn your vaccination will be postponed until you feel better .
your doctor will inform you if you have
take special care with Abseamed ( H5N1 ) ( protein-free ) ( protein-free ) , inactivated ( protein-free )
see 6 Further information about some of the immune system disorders , as your vaccine may change the blood tests to see if you sample by certain virus .
during the first several weeks after an course with flu virus ( H5N1 ) ( protein-free ) , Pandemic drug results , in the clinical study results may be ct .
Uncommon :
using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
there are no data on the monovalent influenza vaccine ( H5N1 ) ( protein-free ) .
influenza
however , if this cannot be avoided , the other vaccine should be administered in the other arm .
possible side effects may be more severe .
pregnancy and breast-feeding There is no experience in pregnant women or lactation .
your doctor should therefore assess the benefit and potential risks of administering this vaccine if you are pregnant or breast-feeding .
if you are pregnant or could be pregnant , tell your doctor or pharmacist if you are planning to become pregnant , and follow physical advice .
driving and using machines Tell your doctor if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet .

this medicinal product contains less than 1 mmol ( 23 mg ) sodium per dose , and less than 1 mmol ( 39 mg ) per dose , i. e. essentially sodium-free and without free
AUC0- ( BMI ) ANTI-INFECTIVES Antiretrovirals w.3 Motion ( 40-110 ) WRAPPED Parameter
treatment will be 2 doses of influenza hepatitis ( H5N1 ) ( protein-free ) , inactivated ( protein-free ) .
the second dose should be given after one interval of at least three weeks .
the doctor or nurse will give influenza influenza vaccine ( H5N1 ) .
the vaccine must not be injected into a vein or under the skin .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , influenza like lives ( H5N1 ) ( protein-free ) , inactivated ( protein-free ) film , inactivated , and not everyone gets them .
very common side effects ( which can occur in more than 1 in 10 doses of vaccine ) : pain Fever , redness , swelling or induration at the injection site Fever , joint joint pain
common
if conditions are
usually , resolve without treatment with 1 or 2 days .
in other unwanted effects that occurred in the days or weeks after vaccination with influenza vaccines have been reported :
general disorders and administration site conditions
very rare ( which can occur in up to 1 in 10,000 patients ) : narrowing or blood vessels of the blood vessels , or of blood vessels , causing pain , weakness and paralysis which can also be all responding to the body .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE dated w.3 polyposis ( H5N1 ) ( cycloolefinic ) WRAPPED IN Motion
keep out of the reach and sight of children .
prior to reconstitution :
do not use the suspension and dirt after the expiry date which is stated on the carton .
the expiry date refers to the last day of that month .
store in a refrigerator ( 2 C 8 C ) .
store in the original package in order to protect from light .
do not freeze .
after reconstitution of the vaccine :
after reconstitution use the vaccine in 24 hours and store at 25 C.
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
y ( H5N1 )
- active Inflammations :
after reconstitution , a 0.5 ml dose of 0.5 micrograms of randomisation for the following influenza vaccine include
the vial contains an adjuvant &apos; ( Shuttle ) .
in the component of this component , Welfare ( NEVER ) and propyl hydroxybenzoate ( BuCy4 ) .
Nonsteroidal are used to improve the immune response of the body &apos;s immune response .
- Other ingredients :
what influenza like influenza like illness ( H5N1 ) (
a puncture-proof container ( H5N1 ) ( protein-free ) , Pandemic influenza vaccine , inactivated , with hyperthermia
- One pack of 50 vials of 2.5 ml suspension
- Two packs of 25 ml
the suspension is a slightly clear liquid to slightly opalescent .
Polyglutamation is a turbid liquid .
before administration the two components should be mixed .
the reconstituted vaccine is milky .
MARKETING Authorisation Holder and Manufacturer
rue de l &apos;Institut 89 B-1330 Rixensart , Belgium
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
kg
Espa√±a GlaxoSmithKline , S.A.
this leaflet was last approved in
influenza vaccine ( H5N1 ) ( protein-free ) ,
bottle : vial containing nominally ( E951 ) Bottle containing the vial ( E572 ) Bottle containing glibenclamide ( E572 ) .
before administration the two components should be mixed .
instructions for reconstitution and administration of the vaccine :
before mix both the ingredients , IFN and the suspension should be dispersed to reach room temperature , replaced and O.
if any of the other cases is observed , do not use the vaccine .
the vaccine is reconstituted by pressing the plunger of a vial of the vial contents of the vial containing oil ( bottle ) to the contents of the bottle , which contains the suspension ( bottle A ) .
after the addition of the suspension at the suspension , the isomeric mixture must be well shaken .
once dilution , the vaccine is hydrolysed .
if there is no other changes in the vaccine .
the influenza vaccine ( H5N1 ) ( protein-free ) ( protein-free ) .
the vial is shaken before each administration .
each vaccine dose of 0.5 ml should be withdrawn into a syringe for injection .
the needle used for reconstitution should be sought by the intramuscular injection into the intramuscular injection .
any unused product or waste material should be disposed of in accordance with local requirements .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is AML ?
thirteen esk√° is a vaccine , available in bottles and pre-filled syringes , in pre-filled syringes and pre-filled syringes .
it contains certain parts of hepatitis B virus as the active ingredient .
thirteen percent is available in two ( 10 and 40 micrograms / ml ) .
what is increasing used for ?
10V is used to provide hepatitis B virus against hepatitis B viruses , such as on official recommendations .
the medicine can only be obtained with a prescription .
how is ANSWERS used ?
one vaccination course should include at least three four-week apart .
the recommended dose in children up to 15 years of age is 0.5 ml of the lower concentration ( 10 micrograms / ml ) to each injection .
for adults and adolescents aged 16 years and over , 1 ml of the lower concentration is administered to each injection .
the most common ( 40 micrograms / ml ) is used in patients who are , or who are taking dialysis ( a blood clearance technique ) .
thirteen percent is usually given by injection into a muscle of the thigh in infants and young children , adolescents and young children .
the schedule of the injections depends on age of the patient , on the immune system response , the immune response to the vaccination and the likelihood of virus to the hepatitis B virus .
see the Summary of Product Characteristics ( also part of the EPAR ) for the full list of administration .
how does INJECT work ?
revascularization is a vaccine .
vaccines work by teaching &apos;the immune system ( the body &apos;s natural defences ) how to defend itself against a disease .
thirteen percent of small amounts of the hepatitis B surface antigen ( proteins ) of the hepatitis B virus .
when one person is the vaccine , the immune system recognises the surface antigens as foreign &apos;and makes antibodies against them .
immune system disorders will then be increased by the body to stop the immune system
reproduction is authorised provided the source is acknowledged .
this helps to protect against hepatitis B infection .
this means that they accumulate on the source of the pack to form a better response .
10V has been developed specifically from a vaccine already used in the European Union , to remove this compound .
high dose prednisolone from diaries such as medicines and food may lead to its accumulation in the organs .
this accumulation might be performed and is a concern of concern .
how has Ammonaps been studied ?
as the active substance in Reference was already authorised in the European Union , LV-1011 no formal studies .
the company supplied information on the comparison of other vaccines with and without revascularisation , including studies of the active substance in a the same active substance as recommended .
what benefit has AML shown during the studies ?
the results of the studies showed that CXCR4-virus emerged in compliance with compliance of antibodies to the hepatitis B virus against the hepatitis B vaccine as compared to those receiving thiomersal vaccines .
of these vaccines breaks on the same active substance other than planned .
what is the risk associated with foreskin- ?
the most common side effects with delusions ( seen in between 1 and 10 patients in 100 ) are injection site reactions , including pain , erythema ( redness ) and induration ( T-LBL ) .
for the full list of all side effects reported with delusions , see the Package Leaflet .
eighteen it should not be used in people who may be hypersensitive ( allergic ) to the active substance or to any of the other ingredients .
it should also not be used in people who have a high fever .
as with all vaccines , if you are going to have discussed this with SSRI , there is a risk of precipitation ( rectum ) in infants .
respiratory pressure should be monitored for three days after vaccination .
why has AML been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) concluded that the level of acquired vaccines does not significantly alter their effectiveness by the hepatitis B virus , but reducing them .
it has been recommended that Celvapan be given marketing authorisation .
other information about :
the European Commission granted a marketing authorisation valid throughout the European Union for MSD to Alcon Laboratories on 27 April 2001 .
the marketing authorisation was renewed on 27 April 2006 .
the full EPAR for self-administration can be found here .
this summary was last updated in 02-2008 .
EU Number
Invented name
strength
intranasal form
ROUTE of Administration
PACKAGING
content ( concentration )
package size
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10000 / ml )
1 vial
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
1 pre-filled syringe without needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
pre-filled syringes without needles
suspension for injection
intramuscular use
vial ( glass )
1 vial
suspension for injection
intramuscular use
vial ( glass )
vials
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe without needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
pre-filled syringes without needles
suspension for injection
intramuscular use
vial ( glass )
1 vial
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10000 g / ml )
vials
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10000 g / ml )
1 vial 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
pre-filled syringes without needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
pre-filled syringes without needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
1 pre-filled syringe with 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
pre-filled syringes with 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
1 pre-filled syringe with 2 needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10000 g / ml )
syringes with 2 needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe with 1 injection needle
oral use Oral use
suspension for injection
intramuscular use
pre-filled syringe ( glass )
pre-filled syringes with 1 injection needle
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe with 2 needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
syringes with 2 needles
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
qualitative AND QUANTITATIVE COMPOSITION
one dose ( 0.5 ml ) contains :
micrograms produced as NRTI ( 0.25
on a recombinant printing ink Shellac ( strain ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection Clear .
clinical PARTICULARS
therapeutic indications
consideration are provided on the basis of official recommendations .
it can be expected that the vaccination with homologous features has also been shown to develop hepatitis B virus since hepatitis B virus ( may have the anti-HBV agent ) cannot be discarded .
posology and method of administration
dosage and adolescents ( rats ) :
1 g ( 5 g ) in each injection should be used .
primary outcome :
the usual vaccination course should include at least three injections .
two vaccination regimens may be recommended :
2 , 6 .
0 , 1 , 2 .
2 It is recommended that the vaccine be administered concomitantly .
infants receiving short duration ( 0 , 1 month ) should be receive a dose of 12 months for to achieve high titre antibodies .
remember :
J05AX09
the need for a booster dose in neutropaenic patients who undergoing primary vaccination have not been established .
however , homologous vaccination of current vaccination are currently recommendation for a booster dose recommendation and they should be re-evaluated .
immunosuppressed patients ( such as ALT , haematuria )
further patients have
carcinogenesis
when subjects were diagnosed after primary vaccination , 34.7 of them developed a antibody response after both a previous dose and 76 after the administration of a further additional doses .
however , due to insufficient safety data
Patient-time should be considered for subjects at high risk for causative effects after the potential benefit and general risks of undesirable effects and general potential for undesirable effects .
recommendations :
recommendations for HIV-infected mothers of hepatitis B virus carriers
- At the high dose , hepatitis B virus ( within 24 hours ) .
it could be a consequence
an increase in the levels of hepatitis B infection at the same time as the injection site .
-
local vaccination .
recommendations for high exposure or gynaecological hepatitis B ( e. g. stenoses , hydroureter ) :
- administration of radioactive hepatitis B infection as soon as possible after
- The first dose of vaccine should be given in the seven days following the first dose .
it may be given at the same time as the immunoglobulins injection site , but in an injection site .
- Bleeding surgery is also recommended , with subsequent injections of the vaccine , if
for the description of the patient in a vertical and long-term supervision of the patient .
- Some people or not breathe , the injections
appropriate vaccination should be made as appropriate .
the
3 Method of administration This vaccine should be injected under the skin .
in neonates and infants , injection should have complete in the peri- of the thigh .
in children and adolescents , the injection should be preferably within the deltoid muscle .
do not administer intravascularly .
exceptionally , in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe family
special warnings and precautions for use
because the long risk of hepatitis B infection is possible , the virus may not be predicted at the time of vaccination .
in such cases , it may not cause infection of the hepatitis B virus .
the vaccine will not prevent infection caused by hepatitis A virus , hepatitis E or other known agents known to infect the liver .
as with all vaccines , appropriate medical treatment should always be used immediately , as rare reactions after the administration of the vaccine .
this vaccine may contain traces of phenylalanine , which is used in the vaccination of the vaccine .
therefore , hypersensitivity reactions may occur .
due to the limited benefit of vaccination in these infants , the administration should not be discontinued or quantitative .
interaction with other medicinal products and other forms of interaction
this vaccine may be given :
- with hepatitis B carriers , required to use a separate injection site .
- to derive a certain primary illness or can be used in patients who have received to
choose a separate vaccine against hepatitis B vaccine .
- with other vaccines using the maximum injection sites and injection syringes administered together with the injection sites
the concomitant administration of the monovalent liposomal vaccine ( sBCCs ) with a hepatitis B vaccine using a hepatitis B vaccine , 1 month and 0 , 1 month was not adequately studied .
pregnancy and lactation
not applicable .
effects on ability to drive and use machines
not applicable
undesirable effects
the following adverse reactions have been reported after widespread use of the vaccine .
as with other vaccines against hepatitis B vaccines , in some cases , the causal relationship with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) thrombocytopenia , lymphadenopathy
immune system disorders Very rare ( &lt; 1 / 10,000 ) , central nervous system excitation .
vascular disorders Very rare ( &lt; 1 / 10,000 ) pruritus .
gastrointestinal disorders :
gastrointestinal disorders very rare ( &lt; 1 / 10,000 )
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) of alopecia , alopecia , hives , itching , hives , erythema .
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 )
very rare ( &lt; 1 / 10,000 ) Fluid disorder , fever , malaise , symptoms .
psychotic disorder 10
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics for ATC code :
this vaccine leads to a gene surface antigen against the hepatitis B surface virus ( RTA ) .
in two clinical studies in newborn infants using different vaccination regimens and with various numbers of antibodies , the proportion of patients who had developed protective levels of antibodies were 12.2 and 212 with the mean geometric gap and 6MWT respectively .

as with other vaccines hepatitis B vaccines , the way it will not be known to date .
treatment with a booster dose of booster is not defined , as the booster dose of 12 months with a booster dose of 1 , 2 .

studies have shown that the relationship between chronic hepatitis B virus and arterial cancer and of the liver cancer population are resulting by infection of the hepatitis B virus .
hepatitis B vaccine has been used as the first vaccine as it prevents the formation of tumour cancer .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Histidine Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
ml suspension for injection in a vial ( Type I glass ) .
40 ml suspension for injection in a vial ( Type I glass ) and a syringe for injection in a vial .
pack of 1 .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
once the vial has been tried , the vaccine should be used rapidly and the vial should be withdrawn .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
27 / 05 / 2001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe .
qualitative AND QUANTITATIVE COMPOSITION
one dose ( 0.5 ml ) contains :
micrograms produced as NRTI ( 0.25
on a recombinant printing ink Shellac ( strain ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
cloudy , the suspension for injection in a pre-filled syringe
clinical PARTICULARS
therapeutic indications
the primary groups to be determined based on official recommendations .
it can be expected that the vaccination with homologous features has also been shown to develop hepatitis B virus since hepatitis B virus ( may have the anti-HBV agent ) cannot be discarded .
posology and method of administration
dosage and adolescents ( rats ) :
1 g ( 5 g ) in each injection should be used .
primary outcome :
the usual vaccination course should include at least three injections .
two vaccination regimens may be recommended :
2 , 6 .
0 , 1 , 2 .
9 It is recommended that the vaccine is administered concomitantly .
infants receiving short duration ( 0 , 1 month ) should be receive a dose of 12 months for to achieve high titre antibodies .
remember :
J05AX09
the need for a booster dose in neutropaenic patients who undergoing primary vaccination have not been established .
however , homologous vaccination of current vaccination are currently recommendation for a booster dose recommendation and they should be re-evaluated .
immunosuppressed patients ( such as ALT , haematuria )
further patients have
carcinogenesis
when subjects were diagnosed after primary vaccination , 34.7 of them developed a antibody response after both a previous dose and 76 after the administration of a further additional doses .
however , due to insufficient safety data
Patient-time should be considered for subjects at high risk for causative effects after the potential benefit and general risks of undesirable effects and general potential for undesirable effects .
recommendations :
recommendations for HIV-infected mothers of hepatitis B virus carriers
- At the high dose , hepatitis B virus ( within 24 hours ) .
it could be a consequence
an increase in the levels of hepatitis B infection at the same time as the injection site .
-
local vaccination .
recommendations for high exposure or gynaecological hepatitis B ( e. g. stenoses , hydroureter ) :
- administration of radioactive hepatitis B infection as soon as possible after
- The first dose of vaccine should be given in the seven days following the first dose .
it may be given at the same time as the immunoglobulins injection site , but in an injection site .
- Bleeding surgery is also recommended , with subsequent injections of the vaccine , if
for the description of the patient in a vertical and long-term supervision of the patient .
- Some people or not breathe , the injections
appropriate vaccination should be made as appropriate .
the
method of administration This vaccine should be injected under the skin .
in neonates and infants , injection should have complete in the peri- of the thigh .
in children and adolescents , the injection should be preferably within the deltoid muscle .
do not administer intravascularly .
exceptionally , in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe family
special warnings and precautions for use
because the long risk of hepatitis B infection is possible , the virus may not be predicted at the time of vaccination .
in such cases , it may not cause infection of the hepatitis B virus .
the vaccine will not prevent infection caused by hepatitis A virus , hepatitis E or other known agents known to infect the liver .
as with all vaccines , appropriate medical treatment should always be used immediately , as rare reactions after the administration of the vaccine .
this vaccine may contain traces of phenylalanine , which is used in the vaccination of the vaccine .
therefore , hypersensitivity reactions may occur .
due to the limited benefit of vaccination in these infants , the administration should not be discontinued or quantitative .
interaction with other medicinal products and other forms of interaction
this vaccine may be given :
- with hepatitis B carriers , required to use a separate injection site .
- to derive a certain primary illness or can be used in patients who have received to
choose a separate vaccine against hepatitis B vaccine .
- with other vaccines using the maximum injection sites and injection syringes administered together with the injection sites
the concomitant administration of the monovalent liposomal vaccine ( sBCCs ) with a hepatitis B vaccine using a hepatitis B vaccine , 1 month and 0 , 1 month was not adequately studied .
pregnancy and lactation
not applicable .
not applicable .
undesirable effects
the following adverse reactions have been reported after widespread use of the vaccine .
as with other vaccines against hepatitis B vaccines , in some cases , the causal relationship with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) thrombocytopenia , lymphadenopathy
immune system disorders Very rare ( &lt; 1 / 10,000 ) , central nervous system excitation .
vascular disorders Very rare ( &lt; 1 / 10,000 ) pruritus .
gastrointestinal disorders :
gastrointestinal disorders very rare ( &lt; 1 / 10,000 )
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) of alopecia , alopecia , hives , itching , hives , erythema .
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 )
very rare ( &lt; 1 / 10,000 ) Fluid disorder , fever , malaise , symptoms .
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics for ATC code :
this vaccine leads to a gene surface antigen against the hepatitis B surface virus ( RTA ) .
in two clinical studies in newborn infants using different vaccination regimens and with various numbers of antibodies , the proportion of patients who had developed protective levels of antibodies were 12.2 and 212 with the mean geometric gap and 6MWT respectively .

as with other vaccines hepatitis B vaccines , the way it will not be known to date .
treatment with a booster dose of booster is not defined , as the booster dose of 12 months with a booster dose of 1 , 2 .

studies have shown that the relationship between chronic hepatitis B virus and arterial cancer and of the liver cancer population are resulting by infection of the hepatitis B virus .
hepatitis B vaccine has been used as the first vaccine as it prevents the formation of tumour cancer .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Histidine Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
ml suspension for injection in a pre-filled syringe .
pack size of 1 , 10 , 20 , 50 .
ml suspension for injection in a pre-filled syringe ( Type I glass ) with 1 injection needle , with screw cap ( chlorobutyl rubber ) .
pack of 1 , 10 .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
keep the syringe down and set it until it locks back to the syringe .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Sanofi SYNTHELABO LIMITED Influenza 8 , rue de Henares France
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
27 / 05 / 2001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
10 micrograms / ml suspension for injection Hepatitis B ( rDNA )
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
micrograms produced as NRTI ( 0.50 - 9.2 )
on a recombinant printing ink Shellac ( strain ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection Clear .
clinical PARTICULARS
therapeutic indications
the primary groups to be determined based on official recommendations .
it can be expected that the vaccination with homologous features has also been shown to develop hepatitis B virus since hepatitis B virus ( may have the anti-HBV agent ) cannot be discarded .
posology and method of administration
adults and adolescents ( from age of 16 years of age ) :
1 ml ( 10 g ) in each injection should be used .
primary outcome :
the usual vaccination course should include at least three injections .
two vaccination regimens may be recommended :
2 , 6 .
0 , 1 , 2 .
the vaccine is recommended , the vaccine is recommended .
people receiving your short term schedule ( 0 , 1 month ) should receive a dose of 12 months for to achieve high titre antibodies .
remember :
J05AX09
the need for a booster dose in neutropaenic patients who undergoing primary vaccination have not been established .
however , homologous vaccination of current vaccination are currently recommendation for a booster dose recommendation and they should be re-evaluated .
haemophiliac patients ( e. g. peritoneal dialysis dialysis , transplant patients )
further patients have
carcinogenesis
when subjects were diagnosed after primary vaccination , 34.7 of them developed a antibody response after both a previous dose and 76 after the administration of a further additional doses .
however , due to insufficient safety data
Patient-time should be considered for subjects at high risk for causative effects after the potential benefit and general risks of undesirable effects and general potential for undesirable effects .
guidelines for epilepsy and haematotoxic Related to hepatitis B ( e. g. stenoses , hydroureter ) :
- administration of radioactive hepatitis B infection as soon as possible after
) .
- The first dose of vaccine should be given in the seven days following the first dose .
it may be given at the same time as the immunoglobulins injection site , but in an injection site .
- Bleeding surgery is also recommended , with subsequent injections of the vaccine , if
however , the patient &apos;s ability to achieve protection and long-term use .
- Some people or not breathe , the injections
appropriate vaccination should be made as appropriate .
the
method of administration This vaccine should be injected under the skin .
do not administer intravascularly .
exceptionally , in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
- Hypersensitivity to the active substance or to any of the excipients
- severe family
special warnings and precautions for use
because the long risk of hepatitis B infection is possible , the virus may not be predicted at the time of vaccination .
in such cases , it may not cause infection of the hepatitis B virus .
some factors may reduce the immune response to hepatitis B infection .
these factors include age , diminished , CYP2C9 , CYP2C19 , route of administration and some late-onset conditions .
2 TIMI control should be considered in patients with a risk of not exceeding the good Periodic Safety Update Report ( PSUR ) .
further doses may need to be used in people who have failed or not .
the vaccine will not prevent infection caused by hepatitis A virus , hepatitis E or other known agents known to infect the liver .
as with all vaccines , appropriate medical treatment should always be used immediately , as rare reactions after the administration of the vaccine .
this vaccine may contain traces of phenylalanine , which is used in the vaccination of the vaccine .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
this vaccine may be given :
these are with hepatitis B infection , injected a separate injection site .
- to derive a certain primary illness or can be used in patients who have received to
choose a separate vaccine against hepatitis B vaccine .
- with other vaccines using the maximum injection sites and injection syringes administered together with the injection sites
pregnancy and lactation
for the surface of hepatitis B virus ( PTs ) there are no data on the use of alli in pregnant women .
however , as for all vaccines sympathomimetic medicines , it should not be expected to be taken for adverse reactions .
this is not recommended whether the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine when breast-feeding has not been studied ; no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , abnormal side effects or rare side effects which may impair the ability to drive or use machines .
undesirable effects
the following adverse reactions have been reported after widespread use of the vaccine .
as with other vaccines against hepatitis B , in some cases , the causal relationship with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) thrombocytopenia , lymphadenopathy
immune system disorders Very rare ( &lt; 1 / 10,000 ) , central nervous system excitation .
vascular disorders Very rare ( &lt; 1 / 10,000 ) pruritus .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) related to bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 )
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) of alopecia , alopecia , hives , itching , hives , erythema .
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 )
very rare ( &lt; 1 / 10,000 ) Fluid disorder , fever , malaise , symptoms .
common ( &lt; 1 / 10,000 ) Acute liver enzymes
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics for ATC code :
this vaccine leads to a gene surface antigen against the hepatitis B surface virus ( RTA ) .
in two clinical studies in rats and adults , 80.1 of Caucasian subjects developed protective levels of antibodies , with the geometric means of mono- / l of Streptomyces IU / l .
as with other vaccines hepatitis B vaccines , the way it will not be known to date .
treatment with a booster dose of booster is not defined , as the booster dose of 12 months with a booster dose of 1 , 2 .
high liver cancer by cell lung cancer is a serious complication of the hepatitis B infection virus with the hepatitis B virus .
studies have shown that the relationship between chronic hepatitis B virus and arterial cancer and of the liver cancer population are resulting by infection of the hepatitis B virus .
hepatitis B vaccine has been used as the first vaccine as it prevents the formation of tumour cancer .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Histidine Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a vial ( Type I glass ) .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
27 / 05 / 2001 Date of last renewal :
name OF THE MEDICINAL PRODUCT
AUC0- 10 micrograms / ml suspension for injection in a pre-filled syringe .
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
micrograms produced as NRTI ( 0.50 - 9.2 )
on a recombinant printing ink Shellac ( strain ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
cloudy , the suspension for injection in a pre-filled syringe
clinical PARTICULARS
therapeutic indications
the primary groups to be determined based on official recommendations .
it can be expected that the vaccination with homologous features has also been shown to develop hepatitis B virus since hepatitis B virus ( may have the anti-HBV agent ) cannot be discarded .
posology and method of administration
adults and adolescents ( from age of 16 years of age ) :
1 ml ( 10 g ) in each injection should be used .
primary outcome :
the usual vaccination course should include at least three injections .
two vaccination regimens may be recommended :
2 , 6 .
0 , 1 , 2 .
the vaccine is recommended to administer the vaccine once a day .
people receiving your short term schedule ( 0 , 1 month ) should receive a dose of 12 months for to achieve high titre antibodies .
remember :
J05AX09
the need for a booster dose in neutropaenic patients who undergoing primary vaccination have not been established .
however , homologous vaccination of current vaccination are currently recommendation for a booster dose recommendation and they should be re-evaluated .
haemophiliac patients ( e. g. peritoneal dialysis dialysis , transplant patients )
further patients have
carcinogenesis
when subjects were diagnosed after primary vaccination , 34.7 of them developed a antibody response after both a previous dose and 76 after the administration of a further additional doses .
however , due to insufficient safety data
Patient-time should be considered for subjects at high risk for causative effects after the potential benefit and general risks of undesirable effects and general potential for undesirable effects .
guidelines for epilepsy and haematotoxic Related to hepatitis B ( e. g. stenoses , hydroureter ) :
- administration of radioactive hepatitis B infection as soon as possible after
) .
- The first dose of vaccine should be given in the seven days following the first dose .
it may be given at the same time as the immunoglobulins injection site , but in an injection site .
- Bleeding surgery is also recommended , with subsequent injections of the vaccine , if
however , the patient &apos;s ability to achieve protection and long-term use .
- educational people or not are currently available , the injections should be additional
take special care with Atripla .
the
method of administration This vaccine should be injected under the skin .
in adults and adolescents , the injection should be preferably within the deltoid muscle .
do not administer intravascularly .
exceptionally , in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe family
special warnings and precautions for use
because the long risk of hepatitis B infection is possible , the virus may not be predicted at the time of vaccination .
in such cases , it may not cause infection of the hepatitis B virus .
some factors may reduce the immune response to hepatitis B infection .
these factors include age , diminished , CYP2C9 , CYP2C19 , route of administration and some late-onset conditions .
2 TIMI control should be considered in patients with a risk of not exceeding the good Periodic Safety Update Report ( PSUR ) .
further doses may need to be used in people who have failed or not .
the vaccine will not prevent infection caused by hepatitis A virus , hepatitis E or other known agents known to infect the liver .
as with all vaccines , appropriate medical treatment should always be used immediately , as rare reactions after the administration of the vaccine .
this vaccine may contain traces of phenylalanine , which is used in the vaccination of the vaccine .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
this vaccine may be given :
these are with hepatitis B infection , injected a separate injection site .
- to derive a certain primary illness or can be used in patients who have received to
choose a separate vaccine against hepatitis B vaccine .
- with other vaccines using the maximum injection sites and injection syringes administered together with the injection sites
pregnancy and lactation
for the surface of hepatitis B virus ( PTs ) there are no data on the use of alli in pregnant women .
however , as for all vaccines sympathomimetic medicines , it should not be expected to be taken for adverse reactions .
this is not recommended whether the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine when breast-feeding has not been studied ; no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , abnormal side effects or rare side effects which may impair the ability to drive or use machines .
undesirable effects
the following adverse reactions have been reported after widespread use of the vaccine .
as with other vaccines against hepatitis B vaccines , in some cases , the causal relationship with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) thrombocytopenia , lymphadenopathy
immune system disorders Very rare ( &lt; 1 / 10,000 ) , central nervous system excitation .
vascular disorders Very rare ( &lt; 1 / 10,000 ) pruritus .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) related to bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 )
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) of alopecia , alopecia , hives , itching , hives , erythema .
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 )
very rare ( &lt; 1 / 10,000 ) Fluid disorder , fever , malaise , symptoms .
common ( &lt; 1 / 10,000 ) Acute liver enzymes
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics for ATC code :
this vaccine leads to a gene surface antigen against the hepatitis B surface virus ( RTA ) .
in two clinical studies in rats and adults , 80.1 of Caucasian subjects developed protective levels of antibodies , with the geometric means of mono- / l of Streptomyces IU / l .
as with other vaccines hepatitis B vaccines , the way it will not be known to date .
treatment with a booster dose of booster is not defined , as the booster dose of 12 months with a booster dose of 1 , 2 .
high liver cancer by cell lung cancer is a serious complication of the hepatitis B infection virus with the hepatitis B virus .
studies have shown that the relationship between chronic hepatitis B virus and arterial cancer and of the liver cancer population are resulting by infection of the hepatitis B virus .
hepatitis B vaccine has been used as the first vaccine as it prevents the formation of tumour cancer .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Histidine Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a pre-filled syringe ( glass of Type I glass ) , with a non-latex needle .
pack of 1 , 10 , 1 , 10 ,
pack of 1 , 10 , 1 , 10 ,
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
keep the syringe down and set it until it locks back to the syringe .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
27 / 05 / 2001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
12.4 / ml
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
micrograms produced as NRTI ( 0.50 - 9.2 )
on a recombinant printing ink Shellac ( strain ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection Clear .
clinical PARTICULARS
therapeutic indications
this vaccine is indicated for anthracycline use
it can be expected that the vaccination with homologous features has also been shown to develop hepatitis B virus since hepatitis B virus ( may have the anti-HBV agent ) cannot be discarded .
posology and method of administration
adult peritoneal dialysis patients or instructed to dialysis :
1 ml ( 40 g ) in each injection should be used .
influenza sugar level
the usual
2 , 6 had a similar dose interval of 1 , 6 months , followed by a third month dose after the first dose .
remember :
a booster dose should be recommended for these subjects if
as medical practice with standard medical practice for vaccines , periodic monitoring must be biopsied in haemodialysed patients .
a booster dose should be given when the antibody count is &gt; 10 IU / l .
52 Take special care with Actos :
- administration of radioactive hepatitis B infection as soon as possible after
) .
- The first dose of vaccine should be given in the seven days following the first dose .
it may be given at the same time as the immunoglobulins injection site , but in an injection site .
- Bleeding surgery is also recommended , with subsequent injections of the vaccine , if
the amount of the patient &apos;s own ) for short-term protection and long-term use .
if or you are currently vaccinated , the additional injections should be given
take the recommended vaccination schedule .
method of administration This vaccine should be injected under the skin .
in adults , the use of the injection should be preferably within the deltoid muscle .
do not administer intravascularly .
exceptionally , in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe family
special warnings and precautions for use
as a result of the long risk of hepatitis B , the infection may not potentiate , or the
in such cases , it may not cause infection of the hepatitis B virus .
the vaccine will not prevent infection caused by hepatitis A virus , hepatitis E or other known agents known to infect the liver .
as with all vaccines , appropriate medical treatment should be used immediately , as rare reactions after the administration of the vaccine .
this vaccine may contain traces of phenylalanine , which is used in the vaccination of the vaccine .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
this vaccine may be given :
- with hepatitis B carriers , required to use a separate injection site .
- to derive a certain primary illness or can be used in patients who have received to
choose a separate vaccine against hepatitis B vaccine .
- with other vaccines using the maximum injection sites and injection syringes administered together with the injection sites
pregnancy and lactation
for the surface of hepatitis B virus ( PTs ) there are no data on the use of alli in pregnant women .
however , as for all vaccines sympathomimetic medicines , it should not be expected to be taken for adverse reactions .
this is not recommended whether the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine when breast-feeding has not been studied ; no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , abnormal side effects or rare side effects which may impair the ability to drive or use machines .
undesirable effects
the following adverse reactions have been reported after widespread use of the vaccine .
as with other vaccines against hepatitis B vaccines , in some cases , the causal relationship with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) thrombocytopenia , lymphadenopathy
immune system disorders Very rare ( &lt; 1 / 10,000 ) , central nervous system excitation .
vascular disorders Very rare ( &lt; 1 / 10,000 ) pruritus .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) related to bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 )
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) of alopecia , alopecia , hives , itching , hives , erythema .
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 )
very rare ( &lt; 1 / 10,000 ) Fluid disorder , fever , malaise , symptoms .
common ( &lt; 1 / 10,000 ) Acute liver enzymes
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics for ATC code :
this vaccine leads to a gene surface antigen against the hepatitis B surface virus ( RTA ) .
as medical practice with standard medical practice for vaccines , periodic monitoring must be biopsied in haemodialysed patients .
a booster dose should be given when the antibody count is &gt; 10 IU / l .
in subjects with HIV infection , the use of other hepatitis B vaccines should be considered .
high liver cancer by cell lung cancer is a serious complication of the hepatitis B infection virus with the hepatitis B virus .
studies have shown that the relationship between chronic hepatitis B virus and arterial cancer and of the liver cancer population are resulting by infection of the hepatitis B virus .
hepatitis B vaccine has been used as the first vaccine as it prevents the formation of tumour cancer .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Histidine Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a vial ( Type I glass ) .
special precautions for disposal
shake well before use .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Sanofi SYNTHELABO LIMITED Influenza 8 , rue de Henares France
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
27 / 05 / 2001 Date of last renewal :
date OF REVISION OF THE TEXT
manufacturer ( S ) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer ( S ) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer ( s ) of the biological active substance
name and address of the manufacturer ( s ) responsible for batch release
box 581 dated S√†rl , Dr. PC Haarlem The Netherlands
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
the Marketing Authorisation Holder will continue to submit yearly Safety Update Report ( PSUR ) .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 5 micrograms / 0.5 -ml laminate
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
micrograms produced by esterases ( 0.25 K30 )
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
vials of 0.5 ml
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
5 micrograms / 0.5 ml
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
micrograms produced by esterases ( 0.25 K30 )
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
1 pre-filled syringe for injection with needle .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / 0.5 ml suspension for injection Hepatitis B ( rDNA )
consecutive days
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
oxaliplatin on 5 micrograms / 0.5 -ml marking without needles Note needle , 10 , 50 , 50
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
micrograms produced by esterases ( 0.25 K30 )
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
pre-filled syringes of 0.5 ml not needles .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
shake the vial before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 5 micrograms / 0.5 -ml dispenser with 1 injection needle
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
micrograms produced by esterases ( 0.25 K30 )
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
10 Pre-filled syringes of 0.5 ml with 1 injection needle
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 5 micrograms / 0.5 -ml marking with 2 needles Note down 1 , 10
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
micrograms produced by esterases ( 0.25 K30 )
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
10 Pre-filled syringes of 0.5 ml with 2 pre-filled syringes ( for each syringe ) .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / 0.5 ml suspension for injection Hepatitis B ( rDNA )
consecutive days
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 10 micrograms / Dr. PACK
name OF THE MEDICINAL PRODUCT
AUC0- 10 micrograms / ml suspension for injection Hepatitis B ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
B surface antigen
88 PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING
produced from a recombinant printing ink
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 vial Component of 1 ml .
1 ml clear vials .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 10 g / ml suspension for injection Hepatitis B ( rDNA )
consecutive days
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 10 micrograms / Dr. 0.375 ml
name OF THE MEDICINAL PRODUCT
AUC0- 10 micrograms / ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
6 .
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 pre-filled syringe with 1 ml needles of 1 ml Pre-filled syringes without needles of 1 ml
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 10 micrograms / newborns / syringe with 1 injection Exenatide
name OF THE MEDICINAL PRODUCT
AUC0- 10 micrograms / ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
6 .
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 pre-filled syringe with 1 injection needle
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
w.1 10 micrograms / newborns / syringe with 2 pre-filled syringes
name OF THE MEDICINAL PRODUCT
AUC0- 10 micrograms / ml suspension for injection in a pre-filled syringe .
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
6 .
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 pre-filled syringe with 2 ml
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 10 g / ml suspension for injection Hepatitis B ( rDNA )
consecutive days
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
J n / Trimethoprim
name OF THE MEDICINAL PRODUCT
AUC0- ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
6 .
of a recombinant printing ink is essential ( strain polymer ) .
list OF EXCIPIENTS
sodium chloride , myelitis and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 vial Component of 1 ml .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use Read the package leaflet before use .
intramuscular use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
12.4 / ml ( rDNA )
consecutive days
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
package LEAFLET
package LEAFLET :
information FOR THE USER
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is 5 micrograms / 0.5 ml and in addition for 2 .
before you use tools or machines 5 micrograms / 0.5 ml 3 .
how to use 5 micrograms / 0.5 ml 4 .
possible side effects 5 .
how to store 5 micrograms / 0.5 ml 6 .
further information
what AMBIRIX 5 micrograms / 0.5 ml AND WHAT IT IS USED FOR
the vaccination can be expected to have against hepatitis B virus since hepatitis B virus ( s ) do not appear against the absence of hepatitis B virus .
hepatitis E or other pathogens known to infect the hepatitis A virus , hepatitis E or other known agents known to infect the liver .
before YOU USE ALTARGO 5 micrograms / 0.5 ml
do not use Bleeding 5 micrograms / 0.5 ml :
- if your child is allergic ( hypersensitive ) to the hepatitis B surface or any of the
( see section 6 ) .
- if your child has a severe infection severe
using other vaccines :
this vaccine may be administered voluntarily with immunoglobulins B with food B , required an injection site .
this vaccine may get a primary illness or be used in patients who have received a hepatitis B vaccine in the past .
this vaccine may be administered in combination with certain other vaccines , using the injection sites and syringes different .
please tell your doctor or pharmacist if your child is pregnant or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ALTARGO 5 micrograms / 0.5 ml
dosage :
the recommended dose for each injection ( 0.5 ml ) is 5 micrograms for children and adolescents ( up to 12 years of age ) .
the vaccination course should include at least three injections .
two vaccination regimens may be recommended :
6 months )
- 3 injections of the three dose and one fourth dose
3 - 10 .
if hepatitis is administered to a recent hepatitis B virus , the first dose of Twinrix simplex and a dose of immunoglobulin with the immunoglobulins .
in some superficial vaccination strengths , it is recommended to administer a dose of booster .
your doctor or pharmacist will inform you if a dose of these is need .
method of Administration :
shake well before use , a slightly opaque , opaque , white suspension .
once the vial has been tried , the vaccine should be used rapidly and the vial should be withdrawn .
the doctor will give the vaccine in muscle .
injection will be injected in the peri- and infants of the thigh .
in children and adolescents , the injection may be injected into the affected muscle .
this vaccine should never be injected into a vein .
exceptionally , this vaccine may be administered subcutaneously in patients with thrombocytopenia ( a decrease in blood platelets ) or in heterologous patients .
if you miss a dose of 850 5 micrograms / 0.5 ml :
if a dose is missed , your doctor will decide when you should inject the correct dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B vaccines , in many cases , a causal relationship between adverse and the vaccine has been established .
thirteen percent is generally maintained .
the most common side effect are local reactions at the injection site : pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ATRIPLA 5 micrograms / 0.5 ml
keep out of the reach and sight of children .
do not use after the expiry date stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
y 5 micrograms / 0.5 ml
the active substance is a 0.5 ml dose of 0.5 ml : recombinant hepatitis B surface antigen ( acetazolamide ) haemagglutinin .
of a recombinant printing ink is essential ( strain polymer ) .
the other ingredients are : sodium chloride , contusugene and water for injections .
what documentation 5 micrograms / 0.5 ml and contents of the pack
each dose contains 0.5 ml suspension for injection in a vial .
packs of 1 and 10 vials without needle
packs of 1 vial with syringe and needle .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi SYNTHELABO LIMITED Insomnia , 8 rue de Henares Madrid , F-67640 .
manufacturer responsible for batch release :
Merck Sharp Dohme BV , hypromellose 39 , Waarderweg 39 , Braat Hoofddorp , Greece .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Belgi√´ / Belgique / Belgien :
Merck Sharp Dohme IDEA , Inc .
Sanofi IDEC GmbH , Tel :
59 .
Sverige Sanofi Final S. A. ,
0.0493 Merck Sharp Dohme , IDEA , .
Polska Sp. z. o. o .
titanium Sharp Dohme Romania S. R. L.
Merck Sharp Dohme , inovativna zdravila d. o. o .
Merck Sharp Dohme IDEA , Inc . , Suomi .
manufacturer Sanofi IDEC LIMITED , Insomnia
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe .
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is 5 micrograms / 0.5 ml and in addition for 2 .
before you use tools or machines 5 micrograms / 0.5 ml 3 .
how to use 5 micrograms / 0.5 ml 4 .
possible side effects 5 .
how to store 5 micrograms / 0.5 ml 6 .
further information
what AMBIRIX 5 micrograms / 0.5 ml AND WHAT IT IS USED FOR
the vaccination can be expected to have against hepatitis B virus since hepatitis B virus ( s ) do not appear against the absence of hepatitis B virus .
hepatitis E or other pathogens known to infect the hepatitis A virus , hepatitis E or other known agents known to infect the liver .
before YOU USE ALTARGO 5 micrograms / 0.5 ml
do not use Bleeding 5 micrograms / 0.5 ml :
- if your child is allergic ( hypersensitive ) to the hepatitis B surface or any of the
( see section 6 ) .
- if your child has a severe infection severe
using other vaccines :
this vaccine may be administered voluntarily with immunoglobulins B with food B , required an injection site .
this vaccine may get a primary illness or be used in patients who have received a hepatitis B vaccine in the past .
this vaccine may be administered in combination with certain other vaccines , using the injection sites and syringes different .
please tell your doctor or pharmacist if your child is pregnant or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ALTARGO 5 micrograms / 0.5 ml
dosage :
the recommended dose for each injection ( 0.5 ml ) is 5 micrograms for children and adolescents ( up to 12 years of age ) .
the vaccination course should include at least three injections .
two vaccination regimens may be recommended :
6 months )
- 3 injections of the three dose and one fourth dose
3 - 10 .
if hepatitis is administered to a recent hepatitis B virus , the first dose of Twinrix simplex and a dose of immunoglobulin with the immunoglobulins .
in some superficial vaccination strengths , it is recommended to administer a dose of booster .
your doctor or pharmacist will inform you if a dose of these is need .
method of Administration :
shake well before use , a slightly opaque , opaque , white suspension .
the needle is inserted ready for use until it locks into place .
the doctor will give the vaccine in muscle .
injection will be injected in the peri- and infants of the thigh .
in children and adolescents , the injection may be injected into the affected muscle .
this vaccine should never be injected into a vein .
exceptionally , this vaccine may be administered subcutaneously in patients with thrombocytopenia ( a decrease in blood platelets ) or in heterologous patients .
if you miss a dose of 850 5 micrograms / 0.5 ml :
if a dose is missed , your doctor will decide when you should inject the correct dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B vaccines , in many cases , a causal relationship between adverse and the vaccine has been established .
thirteen percent is generally maintained .
the most common side effect are local reactions at the injection site : pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ATRIPLA 5 micrograms / 0.5 ml
keep out of the reach and sight of children .
do not use after the expiry date stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
y 5 micrograms / 0.5 ml
the active substance is a 0.5 ml dose of 0.5 ml : recombinant hepatitis B surface antigen ( acetazolamide ) haemagglutinin .
of a recombinant printing ink is essential ( strain polymer ) .
the other ingredients are : sodium chloride , contusugene and water for injections .
what documentation 5 micrograms / 0.5 ml and contents of the pack
each dose contains 0.5 ml of suspension for injection in a pre-filled syringe .
pack sizes of 1 , 10 , 20 and 50 pre-filled syringes without needles and 10 pre-filled syringes with 1 or 2 pre-filled syringes with 1 or 2 needles .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi SYNTHELABO LIMITED Insomnia , 8 rue de Henares Madrid , F-67640 .
manufacturer responsible for batch release :
Merck Sharp Dohme BV , hypromellose 39 , Waarderweg 39 , Braat Hoofddorp , Greece .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Belgi√´ / Belgique / Belgien :
Merck Sharp Dohme IDEA , Inc .
Sanofi IDEC GmbH , Tel :
59 .
Sverige Sanofi Final S. A. ,
0.0493 Merck Sharp Dohme , IDEA , .
Polska Sp. z. o. o .
titanium Sharp Dohme Romania S. R. L.
Merck Sharp Dohme , inovativna zdravila d. o. o .
Merck Sharp Dohme IDEA , Inc . , Suomi .
manufacturer Sanofi IDEC LIMITED , Insomnia
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
10 micrograms / ml suspension for injection Hepatitis B ( rDNA )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is 10 micrograms / ml and what it is used for 2 .
before you use sunlamps 10 micrograms / ml 3 .
how to use raised 10 micrograms / ml 4 .
possible side effects 5 .
how to store 10 micrograms / ml 6 .
further information
what AMBIRIX 10 micrograms / ml AND WHAT IT IS USED FOR
this vaccine is
the vaccination can be expected to have against hepatitis B virus since hepatitis B virus ( s ) do not appear against the absence of hepatitis B virus .
hepatitis E or other pathogens known to infect the hepatitis A virus , hepatitis E or other known agents known to infect the liver .
before YOU USE ALTARGO 10 micrograms / ml
do not use sunlamps 10 micrograms / ml :
- if you are allergic ( hypersensitive ) to a hepatitis B surface or any of the other ingredients of
( see section 6 ) .
- if you have severe febrile infection
take special care with peel-off stickers 10 micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not recommended .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
rare side effects may affect the ability to drive and use machines .
using other vaccines :
this vaccine may be rounded with specific immunoglobulins with specific hepatitis B immunoglobulin to use a separate injection site .
this vaccine may get a primary illness or be used in patients who have received a hepatitis B vaccine in the past .
this vaccine may be administered in combination with other vaccines using the injection sites and syringes different .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ABSEAMED 10 micrograms / ml
dosage :
the recommended dose for each injection ( 1 ml ) is 10 micrograms for adults and adolescents ( from age of 16 years of age ) .
the vaccination course should include at least three injections .
two vaccination regimens may be recommended :
6 months )
- 3 injections of the three dose and one fourth dose
3 - 10 .
if hepatitis is administered to a recent hepatitis B virus , the first dose of Twinrix simplex and a dose of immunoglobulin with the immunoglobulins .
in some superficial vaccination strengths , it is recommended to administer a dose of booster .
your doctor or pharmacist will inform you if a dose of these is need .
method of Administration :
shake well before use , a slightly opaque , opaque , white suspension .
the doctor will give the vaccine in muscle .
the injection site papules in adults and adolescents is the muscle arms .
this vaccine should never be injected into a vein .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia ( a decrease in blood platelets ) or in bleeding subjects .
if you miss a dose of 850 10 micrograms / ml :
if a dose is missed , your doctor will decide when you should inject the correct dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B vaccines , in many cases , a causal relationship between adverse and the vaccine has been established .
thirteen percent is generally maintained .
the most common side effect are local reactions at the injection site : pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED 10 micrograms / ml
keep out of the reach and sight of children .
do not use after the expiry date stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
10 micrograms / ml
the active substance is a
produced from a recombinant printing ink
the other ingredients are : sodium chloride , contusugene and water for injections .
what documentation 5 micrograms / 0.5 ml and contents of the pack
each dose contains 1 ml suspension for injection in a vial .
packs of 1 and 10 vials .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi SYNTHELABO LIMITED Insomnia , 8 rue de Henares Madrid , F-67640 .
manufacturer responsible for batch release :
Merck Sharp Dohme BV , hypromellose 39 , Waarderweg 39 , Braat Hoofddorp , Greece .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Belgi√´ / Belgique / Belgien :
Merck Sharp Dohme IDEA , Inc .
Sanofi IDEC GmbH , Tel :
59 .
Sverige Sanofi Final S. A. ,
0.0493 Merck Sharp Dohme , IDEA , .
Polska Sp. z. o. o .
titanium Sharp Dohme Romania S. R. L.
Merck Sharp Dohme , inovativna zdravila d. o. o .
Merck Sharp Dohme IDEA , Inc . , Suomi .
manufacturer Sanofi IDEC LIMITED , Insomnia
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
AUC0- 10 micrograms / ml , suspension for injection in a pre-filled syringe .
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is 10 micrograms / ml and what it is used for 2 .
before you use sunlamps 10 micrograms / ml 3 .
how to use raised 10 micrograms / ml 4 .
possible side effects 5 .
how to store 10 micrograms / ml 6 .
further information
what AMBIRIX 10 micrograms / ml AND WHAT IT IS USED FOR
this vaccine is
the vaccination can be expected to have against hepatitis B virus since hepatitis B virus ( s ) do not appear against the absence of hepatitis B virus .
hepatitis E or other pathogens known to infect the hepatitis A virus , hepatitis E or other known agents known to infect the liver .
before YOU USE ALTARGO 10 micrograms / ml
do not use sunlamps 10 micrograms / ml :
- if you are allergic ( hypersensitive ) to a hepatitis B surface or any of the other ingredients of
( see section 6 ) .
- if you have severe febrile infection
take special care with peel-off stickers 10 micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not recommended .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
rare side effects may affect the ability to drive and use machines .
using other vaccines :
this vaccine may be rounded with specific immunoglobulins with specific hepatitis B immunoglobulin to use a separate injection site .
this vaccine may get a primary illness or be used in patients who have received a hepatitis B vaccine in the past .
this vaccine may be administered in combination with other vaccines using the injection sites and syringes different .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ABSEAMED 10 micrograms / ml
dosage :
the recommended dose for each injection ( 1 ml ) is 10 micrograms for adults and adolescents ( from age of 16 years of age ) .
the vaccination course should include at least three injections .
two vaccination regimens may be recommended :
6 months )
- 3 injections of the three dose and one fourth dose
3 - 10 .
if hepatitis is administered to a recent hepatitis B virus , the first dose of Twinrix simplex and a dose of immunoglobulin with the immunoglobulins .
in some superficial vaccination strengths , it is recommended to administer a dose of booster .
your doctor or pharmacist will inform you if a dose of these is need .
method of Administration :
shake well before use , a slightly opaque , opaque , white suspension .
the needle is inserted ready for use until it locks into place .
the doctor will give the vaccine in muscle .
the injection site papules in adults and adolescents is the muscle arms .
this vaccine should never be injected into a vein .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia ( a decrease in blood platelets ) or in bleeding subjects .
if you miss a dose of 850 10 micrograms / ml :
if a dose is missed , your doctor will decide when you should inject the correct dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B vaccines , in many cases , a causal relationship between adverse and the vaccine has been established .
thirteen percent is generally maintained .
the most common side effect are local reactions at the injection site : pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED 10 micrograms / ml
keep out of the reach and sight of children .
do not use after the expiry date stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
10 micrograms / ml
the active substance is a
produced from a recombinant printing ink
the other ingredients are : sodium chloride , contusugene and water for injections .
what AMBIRIX 10 micrograms / ml looks like and contents of the pack
each dose contains 1 ml suspension for injection in a pre-filled syringe .
pack sizes of 1 and 10 pre-filled syringes without needles and 1 or 2 needles .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi SYNTHELABO LIMITED Insomnia , 8 rue de Henares Madrid , F-67640 .
manufacturer responsible for batch release :
Merck Sharp Dohme BV , hypromellose 39 , Waarderweg 39 , Braat Hoofddorp , Greece .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Belgi√´ / Belgique / Belgien :
Merck Sharp Dohme IDEA , Inc .
Sanofi IDEC GmbH , Tel :
59 .
Sverige Sanofi Final S. A. ,
Sanofi IDEC Reyes , Fawdon 116 K Duero :
0.0493 Merck Sharp Dohme , IDEA , .
Polska Sp. z. o. o .
titanium Sharp Dohme Romania S. R. L.
Merck Sharp Dohme , inovativna zdravila d. o. o .
Merck Sharp Dohme IDEA , Inc . , Suomi .
manufacturer Sanofi IDEC LIMITED , Insomnia
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
AUC0- ( rDNA )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use sunlamps water / ml 3 .
how to use 40 micrograms / ml 4 .
possible side effects 5 .
how to store 40 micrograms / ml 6 .
further information
what AMBIRIX 40 micrograms / ml AND WHAT IT IS USED FOR
this vaccine is indicated for vaccination against both virus and all CCR5 cells to the hepatitis B virus in adults , or prolonging dialysis .
the vaccination can be expected to have against hepatitis B virus since hepatitis B virus ( s ) do not appear against the absence of hepatitis B virus .
hepatitis E or other pathogens known to infect the hepatitis A virus , hepatitis E or other known agents known to infect the liver .
before YOU USE ALTARGO 40 micrograms / ml
do not use sunlamps micrograms / ml :
- if you are allergic ( hypersensitive ) to any hepatitis B surface or any of the other ingredients of
in 839 ( see Strategies ) .
- if you have severe febrile infection
take special care with homologous micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not recommended .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
rare side effects may affect the ability to drive and use machines .
using other vaccines :
this vaccine may be rounded with specific immunoglobulins with specific hepatitis B immunoglobulin to use a separate injection site .
80 This vaccine may be a primary illness or be used in patients who have received a total of hepatitis B vaccine .
this vaccine may be administered in combination with other vaccines using the injection sites and syringes different .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE Final 40 micrograms / ml
dosage :
the recommended dose for each injection ( 1 ml ) is 40 micrograms for adults or prolonging dialysis .
the vaccination course should include three injections .
the most common side effect used is 2 months of age , followed by a third dose 6 month after the first injection ( 0 , 6 month ) .
3 A booster dose should be recommended for these subjects if the Instructions of hepatitis B surface antigen is less than 10 IU / l .
method of Administration :
shake well before use , a slightly opaque , opaque , white suspension .
the doctor will give the vaccine in muscle .
the injection site papules in adults is the muscle of the upper arms .
this vaccine should never be injected into a vein .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia ( a decrease in blood platelets ) or in bleeding subjects .
if you miss a dose of 850 micrograms / ml :
if a dose is missed , your doctor will decide when you should inject the correct dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B vaccines , in many cases , a causal relationship between adverse and the vaccine has been established .
thirteen percent is generally maintained .
the most common side effect are local reactions at the injection site : pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ATRIPLA 40 micrograms / ml
keep out of the reach and sight of children .
do not use after the expiry date stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
U / ml
the active substance is a
produced from a recombinant printing ink
the other ingredients are : sodium chloride , contusugene and water for injections .
what AMBIRIX 40 micrograms / ml looks like and contents of the pack
each dose contains 1 ml suspension for injection in a vial .
1 vial .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi SYNTHELABO LIMITED Insomnia , 8 rue de Henares Madrid , F-67640 .
manufacturer responsible for batch release :
Merck Sharp Dohme BV , hypromellose 39 , Waarderweg 39 , Braat Hoofddorp , Greece .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
Belgi√´ / Belgique / Belgien :
Merck Sharp Dohme IDEA , Inc .
Sanofi IDEC GmbH , Tel :
59 .
Sverige Sanofi Final S. A. ,
0.0493 Merck Sharp Dohme , IDEA , .
Polska Sp. z. o. o .
titanium Sharp Dohme Romania S. R. L.
Merck Sharp Dohme , inovativna zdravila d. o. o .
Merck Sharp Dohme IDEA , Inc . , Suomi .
manufacturer Sanofi IDEC LIMITED , Insomnia
this leaflet was last approved in
methacrylic IS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION HOLDER
thirteen percent is a mock-up &apos;vaccine at
the active substance in cyclodextrins , vaccine ( recombinant ) hepatitis B vaccine is the antigen of virus hepatitis B virus ( RTA ) hepatitis and recombinant .
30.4 is a vaccine that leads to a immune response and cell cell lines against holes , leading to further active tubular infection caused by the hepatitis B infection .
the effects of barbiturates are the protection against hepatitis B across all subgroups at the absence of reperfusion in the absence product .
the immunogenicity of the component of the component of the component component with the recombinant hepatitis B vaccine ( 40-110 ) in the future containing
there is a
the CHMP will collect as a fine review of antibody response to hepatitis B after shipment .
this variability should be corrected in non-clinical species from the recombinant components of the recombinant components .
the concerns in the immunogenicity of the immunogenicity components of the annual components of the autoimmune components , the predominant implications for protection against hepatitis B and booster vaccination after this vaccine .
in the BuCy2 visit of January 2006 , the CHMP granted a benefit of the
the CHMP decided that a long-term measure of multiple sclerosis has been completed on clinical significance of multiple clinical significance and in general immunological conditions to be taken prior to administration .
the Committee also decided that the last study of less than one year of age was done in total blisters .
therefore , only the data obtained to date should be made with caution as they are a paediatric dose ( 5 g ) of the monovalent hepatitis B vaccine .
this will assure the mock-up vaccine , so no
the immunogenicity of immunogenicity for more than 22 years did not yet been identified .
it has been decided that a decision to be taken in the responses to exert the safety and in clinical trials .
the February 2006 , the European Commission granted a marketing authorisation valid throughout the European Union ( as ) Don &apos;t meet the European Public Assessment of -L-iduronidase .
contusion
to store in a package , there are no evidence of genetic deletion , genetic or animal-derived packaging in humans .
CONCLUSIONS showing , as criteria are to be used as planned , but not as planned for safety and efficacy ( immunogenicity ) .
it
while the first
caregivers was a consequence of painful erythema test to increase immunogenicity of the immunogenicity .
during the marketing data suggest that the MAH will submit 7 studies of seven and RESIST-2 , it is still as well as during therapy .
these trials were performed in various risk analyses for embryotoxicity and 1-year studies , including children of child-bearing potential , infants , young adults and healthy subjects aged 16 to 35 years .
in the sub studies at this visit and 212 , prognostic companies were obtained in the large majority of the vaccinated clinical studies .
no investigations on protection or long-term protection were identified .
in addition , a clinical study of against the disease against the disease got worse , taken that the anti-hepatitis B vaccines have been effective for reducing hepatitis B infection and its neurologic impairment .
due to the relatively high risk of pre-existing infections , the subgroup of newborn infants are the most effective population as well as possible .
as there is no evidence for an increase in the number of cases of hepatitis B after eight courses , because of the EU of the EU / litre safety problems , no clear problems are available by the CHMP .
the results of these three studies of the compound that makes no local performance and re-polarisation on these travoprost is also converted to the exception of other patient population .
no sequelae have been observed with a fatal outcome in performance and young adult patients .
therefore , the results of this pilot drug study that the predominant product found in all patient populations is advised .
the CHMP differs with tadalafil in all countries to all the product for all countries , to find the advice and building up during the procedure .
the European Commission granted that applied information on the best product is available , on the basis of clinical observations .
these changes , in turn , do not carry it , and how likely that it stops .
the 2-year results lasted by looking at all the sections 4.2 , avoid ( when otherwise ) and
the CHMP studied in all data and clinical relevance to boost data .
the CHMP concluded that the use of this vaccine has not been completed no special risk , but at the same time to achieve the vaccine is indicated .
the potential risk to the suckling infant will be reduced to a CXCR4- by cis-atracurium .
treatment will be covered to healthcare professional and safely of the vaccine in different Member States groups and
the CHMP looked in new information .

take special care with ACOMPLIA
the Committee decided that the information is available in the Summary of Product Characteristics should be modified to ensure that the SmPC of the following reasons is to be modified and the effectiveness of clinical use for the following reasons :
based on the low immunogenicity data with respect to date , the CHMP concluded that it is necessary to ensure that it is necessary for you to have a complete liver , to protection against hepatitis B with the mock-up vaccine ;
the use of this vaccine is not recommended , but at the same time as the vaccine is indicated .
potential for the second risk will be postponed to a glucocorticoid induced by the investigator .
the CHMP decided that the benefit-risk balance of glutamate against protection against infection caused by any cross-resistance known to stimulate hepatitis B infection , in all time-points at risk of hepatitis B infection .
the CHMP recommended that the marketing authorisation holder is also recommended , with dolasetron 5 , in Section 2 , approval ( as part ) .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is the IOP-lowering value ?
Fifty-nine Calculation is a diagnosis .
it is provided in an amber containing a powder to be reconstituted as a powder to be reconstituted .
the powder consists of the active substance -L-iduronidase ( 45 mg for children or 75 mg for adult patients ) .
what is contraindications WED ?
thirteen EBV-PCR is used .
Sixty-four infections ( including indigestion , flatulence , stomach and nausea ) , gastritis ( inflammation of the stomach or intestine ) , gastritis ( inflammation of the stomach or intestine ) .
thirteen Training ( Sandoz ) can be used to inhibit adults , adolescents with stenosing ulcer and children aged 3 to 11 years .
it cannot be used in children when comparing either comparator tests ( for an interruption of stomach support ) , or to check that it is withdrawn or to test that it is able to t or to test that it is withdrawn or to test that it is able to t or to test that it is withdrawn or to test that it is able to t or to test that it is able to t or to test that it is able to t or to test that it is able to t or to test that it
J Following specific treatment to ochre infection .
how is ANSWERS WED ?
Sixty-four 80-100 is a test : air bubbles were collected and enter the population for a vaccine .
for the test , the patient should pull all the following three times samples and two prior to receipt .
the patient should encourage for at least six hours before the entire day .
the patient spent two air samples , using the patient &apos; s structures or vitamins and vitamins shoes .
the patient is a meal ( either 200 ml of fruit juice , fruit juice , or 1 g diluted citric acid diluted ) , and the powder will progress 2 plasters
however , 30 minutes after taking your child had two remaining air samples .
in children 3 to 11 years of age , the meal should include 100 ml of WFI .
for further instructions on how to give yourself this test , see the Package Leaflet .
Sixty-nine ink with also contains prednisone .
this is a complete type of pandemic can be measured by varying health care with BeneFIX .
there is no
how has the agreed been studied ?
thirteen Calculation MediNet 80-100 has been tested in four out of four patients and a study in 809 paediatric patients and adolescents .
all of the patients received 75 mg of elemental blood sugars , except children aged below 11 years of age who received 45 mg .
in adults studies have been performed in patients who have received antibiotics to treat their infection .
what benefit has Ammonaps shown during the studies ?
in all studies , results to performing the results of annual cytogenetic examinations in the peri- and 7400 analysis of cases .
what is the risk associated with sBCC ?
there is no known adverse events with this test .
however , if the patient experiences during the test , she should be tapped but not prior to the day .
why has Meda Assay has been approved ?
the Committee recommended that setting be given marketing authorisation .
other information about ARAVA :
the marketing authorisation holder is SP Europe .
the marketing authorisation was renewed on 14 August 2002 and on 14 August 2007 .
the full EPAR for Ammonaps can be found here .
this summary was last updated in 09-2007 .
EU Number
Invented name
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
package size
1 Clean
powder
haematemesis Ileus
gynaecomastia
seizures :
EU / 1 Antibody , myelitis in a EU number including EU / 1 / 97 / 344 / 002 Note up
powder
30.4 )
mg
1 Clean , Lynce in a
powder for solution for injection
oral contraceptives
seizures :
mg
M05B , 13V in a
haematemesis Assay 75 mg 1301
powder
30.4 )
gynaecomastia
including alcohol for respiratory samples , including alcohol for respiratory samples .
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
63kg Assay , 75 mg powder for oral solution
qualitative AND QUANTITATIVE COMPOSITION
75 mg Macrogolglycerol Ricinoleate , as a powder
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder for oral solution .
clear , colourless solution .
clinical PARTICULARS
therapeutic indications
24.9 Laboratories may be used for the diagnosis of wild infection with Homologous in :
- adults
- adolescents may be at risk of peptic ulcer .
this medicine is for use only .
posology and method of administration
this medicinal product must be administered by a medical professional under the supervision of a qualified medical professional .
eighteen Sandoz Assay is a single respiratory test .
for adults and adolescents from 12 years of age , the dose should be terminated 75 mg .
the patient should be overnight for more than 6 hours , preferably for the day .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
if the test is unavoidable , it must not be repeated until the next day .
Overhydration of radioactive adenomatous erythematosus may result in the results .
therefore , it should only be performed after finishing of 4 weeks without antibacterial therapy and that of 2 weeks after the last dose of two amino acids .
both therapies may interfere to the presence of mitochondrial infiltrates .
this is especially important when anaesthesia .
it is important to adhere to the instructions for use Store in section 6.6 ( Instructions for instructions for use and handling , and disposal ) , without arising for the evening &apos;s attack .
Contraindications
posology and method of administration ) .
special warnings and precautions for use
a positive test has not been shown .
190 with regulate contraceptive measures may be required when assessing the treatment of other medicinal products that have been associated with sedation , autoimmune malignancies and malignancies .
there are no adequate data on the assumption of the hydrophilic network to recommend its use in patients who have inadvertently undergone and patients under 12 years of age .
for children in more than 3 years of age , the definitive matrix for ALPHEON 3 to 11 years is available .
in Special field ( reversible ) tests , respiratory test may result in positive bone-imaging results , therefore , alternative forms may be required to confirm the presence of panel .
in patients with SUI ( see section 4.2 ) during the course of life , this latter cycle should be performed but it is not originally balanced ( CLcr and method of administration ) .
interaction with other medicinal products and other forms of interaction
J Tests will be modified by all treatments with Homologous or IFN enzymatic activity .
pregnancy and lactation
no
the product should be taken into consideration by patients on a medicinal product for their administration or lactation .
effects on ability to drive and use machines
24.9 Laboratories .
undesirable effects
no known effects .
overdose
no overdose is required for administration that would be predicted to be administered mg .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : all other forms of ATC code :
no pharmacological activity were observed for the amount of 75 mg IOP-lowering activity .
an oral
false Lung syndrome is metabolised by CYP1A1 of radioactive tracers due to the
345
0.043b
gynaecomastia
titanium dioxide toward the blood vessels .
and it is carried out by bending up to the in colour and eliminated as Truvada .
in the presence of bacterial bacterial , coupled / T balance is altered .
the quantity of ice in respiratory samples is determined by examining gains in the absolute mass ( 4-MUI ) and the absolute difference in the absolute endpoint ( baseline ) from baseline to 30 minutes .
Overhydration is produced in the stomach , only by examining visit .
other classes of bad processes are rarely present in the belly diet .
at the time of antibody-positive infection , decreased respiratory test resistance , in clinical studies investigating adult patients , 7400 successfully labelled ( 95 normalized :
w.1 w.2 w.3 Inhibitors ( 95 iliac :
0.33
in rare :
35.3 ) .
in the absence of bacterial bacterial , total displacement of urea , total , hydroxylation , after the gastrointestinal tract , be metabolised such as urea .
ammonia , which is described above , by the hydrolysis of detection is incorporated in the metabolism as pre-specified .
pharmacokinetic properties
Lansoprazol given orally , is metabolised by titanium dioxide and ammonia or believe in the endogenous cycle of urea .
the incidence of 1.069 will be measured by histomorphometric analysis .
the absorption and distribution of ethinyl-oestradiol are shorter than the catabolism of L-dopa .
therefore , the cleavage of 13 April infiltrates is the responsibility of the complete process of the complete process .
there is no significant antidote for patients with homozygous and administration of 75 mg of a significant tracer state in the first 30 minutes minutes .
preclinical safety data
there is no theoretical difference at the clinical use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
do not store above 25 C.
nature and contents of container
frequency
30.4 ( 10 ml , 7.9 with a
rubber stopper
frequency
75 mg powder for oral solution for oral solution .
you Irritability bending the plastic spike and
urine :
Sixty-nine lupus erythematosus in corneal spaces to samples
carton
special precautions for disposal and other handling
tests should be considered in the presence of a hole .
each patient should be re-assessed using the information on the outer carton .
it is recommended that the patient be able to perform the patient in position .
the second commonly ( label : &quot; confidence interval &quot; ) of the same as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way .
then drink without the same amount of orange ml ( 100 dilute ) or 1 g diluted citric acid for 200 ml diluted water for ml .
measure the contents of the content in a glass vial to hydrolyse accurate dispensing of water from tubulin parahydroxybenzoate and tap the contents of the vial .
( the total volume of water should be approximately 30 ml ) .
possible side effects 5 .
the prepared solution will be drawn immediately by the patient and the hour of the absorption has to be bioequivalent .
14 Transparent the sticker , based on the individual patient &apos; s height and aims to die .
ROS fluids containing the aid should be made in the outer carton in order to assess a family member .
failure of the
respiratory samples in the glass bags or plastic materials are analysed by CYP1A1 the mitochondrial mass per square metre ( 4-MUI ) .
the analysis of 434 / indometacin / indometacin ratio in the sub group to optimise annual reassessment .
Patient-time is N-deaminated related to the respiratory analysis .
mutants of urate fat redistribution such as ecchymoses , the stability ( peroxisome of the reference ) and consequent consequences are retained for diaries .
it is necessary to ensure that the analysis of a qualified oncologist be carried out .
the re-administration for this use is the next as follows :
preparation of treatments for Primary preparation
to determine the robustness of the recipient / indometacin inhibition of descending respiration , RT should be induced as respiratory failure and granulocytes in the sub circuit .
the
water has been extracted from baseline to unblock water or the silicone preparation that sends into a spine .
pyridoxine in the spine , all types of fibroblasts are detected .
the fraction of neuromuscular blockade , timolol caused by its intra-abdominal fluid retention , is introduced in the sub-group of mass .
severities of snacks
to convert CYP Failure of the docetaxel that occurs , its molecule should be replaced , bent , Hispanics , and retained permeability .
five main steps in the sub diary that is isolated in three main practice : vaccination , the tube , cornea and norepinephrine .
Overhydration , the formation of IFN and propafenone is available in the disposal .
introduction of sleep :
there is a little to predict CYP 1A2 in extubation , several cases of timolol .
for the analysis of respiratory biopsy analysis the glucocorticoid should be terminated for the glucocorticoid that is essential .
this leads to a wide variation in this patient group , when dividing the contents of the ribosomal inhibition of enterohepatic CYP3A is as compared to a protein-free .
norgestimate
alkalisation of respiratory test is based on the administration of halofantrine and lumefantrine specifically metabolism of midazolam with anti-epileptics and is monitored by hyperlipidaemia .
6 collaboration with the fourth dose body weight should be able to :
multiple blood tests :
even several different reductions in the same day for the operation .
a safety test :
3 Summary of Product naive and results with a small manual effects of needles .
a thrombolytic / indometacin ratio in comparison with drug-induced lipogenesis ( ABC polymer ) .
lamivudine-refractory :
patients with chronic
the healthcare professional are summarised , stability ( degeneration of the reference ) and consequent consequences .
all crystals bubbles exist for the modification of dosing should outweigh the following convention :
effects of splenic rupture in the spaces :
thirteen D between 1 and 7 users in 10 cm2 ( approx .
however , if the difference between the recipient clearance rate and a 30 minute was greater than 4 .
other forms of treatment will be used by specialists qualified .
MARKETING AUTHORISATION HOLDER
Danmark Bohumil dated w.3 polyposis Germany
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
63kg Assay , 75 mg powder for oral solution
qualitative AND QUANTITATIVE COMPOSITION
anencephaly contains :
75 mg Macrogolglycerol Ricinoleate , as a powder
pharmaceutical FORM
powder for oral solution .
clear , colourless solution .
clinical PARTICULARS
therapeutic indications
24.9 Laboratories may be used for the diagnosis of wild infection with Homologous in :
- adults
- adolescents may be at risk of peptic ulcer .
this medicine is for use only .
posology and method of administration
this medicinal product must be administered by a medical professional under the supervision of a qualified medical professional .
eighteen Sandoz Assay is a single respiratory test .
the dosage recommendations for patients with age is a 75 mg degree of 75 mg .
the patient should be overnight for more than 6 hours , preferably for the day .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
if the test is unavoidable , it must not be repeated until the next day .
Overhydration of radioactive adenomatous erythematosus may result in the results .
therefore , it should only be performed after finishing of 4 weeks without antibacterial therapy and that of 2 weeks after the last dose of two amino acids .
both therapies may interfere to the presence of mitochondrial infiltrates .
this is especially important when anaesthesia .
it is important to adhere to the instructions for use Store in section 6.6 ( Instructions for instructions for use and handling , and disposal ) , without arising for the evening &apos;s attack .
Contraindications
posology and method of administration ) .
special warnings and special precautions for use
a positive test has not been shown .
190 with regulate contraceptive measures may be required when assessing the treatment of other medicinal products that have been associated with sedation , autoimmune malignancies and malignancies .
there are no adequate data on the assumption of the hydrophilic network to recommend its use in patients who have inadvertently undergone and patients under 12 years of age .
for children in more than 3 years of age , the definitive matrix for ALPHEON 3 to 11 years is available .
in Special field ( reversible ) tests , respiratory test may result in positive bone-imaging results , therefore , alternative forms may be required to confirm the presence of panel .
in patients with SUI ( see section 4.2 ) during the course of life , this latter cycle should be performed but it is not originally balanced ( CLcr and method of administration ) .
interaction with other medicinal products and other forms of interaction
J Tests will be modified by all treatments with Homologous or IFN enzymatic activity .
pregnancy and lactation
no
the product should be taken into consideration by patients on a medicinal product for their administration or lactation .
effects on ability to drive and use machines
24.9 Laboratories .
undesirable effects
no known effects .
overdose
no
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : all other forms of ATC code :
no pharmacological activity were observed for the amount of 75 mg IOP-lowering activity .
345
0.043b
gynaecomastia
titanium dioxide toward the blood vessels .
and it is carried out by bending up to the in colour and eliminated as Truvada .
in the presence of bacterial bacterial , coupled / T balance is altered .
the quantity of specialized DEHP-free samples in the muscle is determined by curves that statistical significance ( GCP ) and the absolute difference in the absolute endpoint ( baseline ) was reached .
Overhydration is produced in the stomach , only by examining visit .
other classes of bad processes are rarely present in the belly diet .
3 .
diagnosis of panel Bleeding therapy , susceptibility to respiratory failure , in clinical studies investigating serial D PI-na√Øve patients , transfected to 0.30 ( DOI Congestive :
w.1 w.2 w.3 Inhibitors ( 95 iliac :
in the absence of bacterial bacterial , total displacement of urea , total , hydroxylation , after the gastrointestinal tract , be metabolised such as urea .
ammonia , which is described above , by the hydrolysis of detection is incorporated in the metabolism as pre-specified .
pharmacokinetic properties
Lansoprazol given orally , is metabolised by titanium dioxide and ammonia or believe in the endogenous cycle of urea .
the incidence of 1.069 will be measured by histomorphometric analysis .
the absorption and distribution of ethinyl-oestradiol are shorter than the catabolism of L-dopa .
therefore , the cleavage of 13 April infiltrates is the responsibility of the complete process of the complete process .
there is no significant antidote for patients with homozygous and administration of 75 mg of a significant tracer state in the first 30 minutes minutes .
preclinical safety data
there is no theoretical difference at the clinical use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
do not store above 25 C.
nature and contents of container
w.1 ( 10 ml , a polyethylene cap with a polyethylene cap ) containing 75 mg of 240 mg powder for oral solution .
film samples
urine
Sixty-nine lupus erythematosus in the ciliary vitamins to samples
screw
an increase of 50 :
patients
component ( 10 ml , a rigid with a polyethylene cap ) containing 75 mg of 240 mg powder for oral solution .
quantity of Atripla
film samples
urine
Sixty-nine lupus erythematosus in the ciliary vitamins to samples
screw
instructions for use and handling and disposal
tests should be considered in the presence of a hole .
each patient should be re-assessed using the information on the outer carton .
it is recommended that the patient be able to perform the patient in position .
very common failure to support the baseline supply ( baseline ) .
take down and the tables for respiratory congestion including the &quot; : &quot; time &quot; ( value 0.010-0.059 ) &quot; and back the package from the quality of life .
the
and wait 5 .
while continued , remove the accurate effects , remove the assembly and a immediately immediately with its stopper .
( if the epistaxis remains above 30 seconds , the outcome of the blood may be drawn ) .
hold the epistaxis in a vertical and 28.4 the Bio-Set band facing 15 st on the tube .
( the total volume of water should be approximately 30 ml ) .
the prepared solution will be drawn immediately by the patient and the hour of the absorption will be held .
Seven-point minutes after taking the solution ( injection 6 ) provides the morning double blind ( 6 ) Reconstituting the appearance of the upper respiratory tract SMPR (
use this multivitamin that breaks down .
14 Transparent the sticker , based on the individual patient &apos; s height and aims to die .
the vitamins that taken for respiratory failure should be inspected in the original pack only .
failure of the
respiratory samples , azapropazon in the minority of 100 ml are analysed by examining unlabelled &apos; ( MUGA ) .
the analysis of 2,192 / indometacin / indometacin ratio in the intestinal macrophages is characterized by part of the Safety Specification .
Patient-time is sequestered by the respiratory quality .
interpretation profiles of the respiratory analysis such as linearity , GP ( peroxisome of the reference ) and venlafaxine are retained for diaries .
a day-by-day analysis should be carried out by qualified qualified practice .
it is recommended that , whenever possible , after 4 weeks afterwards , and after 4 weeks .
the re-administration for this use is the next as follows :
preparation of the glucocorticoid emerged ( -0.24 )
the / indometacin / indometacin ratio in RT is determined directly into chronically accepted .
respiratory Rhinitis in the spaces of AML is slow in the conjunctival sac of using a pump timer .
the body &apos;s own intake is maintained at about 4,800 water .
air bubbles ( ACE fluids ) required at the reappearance of Glarea lozoyensis and is produced in a diary of Glarea lozoyensis .
haematemesis Ileus
to convert CYP furoate in respiratory macrophages , a hole fully integrated with homologous units is defective in order to minimize the understanding of and transmission of mono- to the foetus .
this is 260 to a thin layer and preservation prior to and preservation back
in the sub-group of this , the IOP-lowering component is feasible by the intrinsic components to measure , leading to increased intracellular ara-GTP and mitotic replicate .
a temperature of temperature occurs and provides no evidence of blood pressure prior to launch .
the connection connection to investigate and exposed to a
a loco-regional ophthalmic system is administered alone by inducing into the processing of the hydrophilic circuit .
this helps the residence time to measure the IOP-lowering effects of irinotecan / V at 1 .
norgestimate
Patient-time in respiratory test is based on oral administration of a fluoropyrimidine mOsm / epidural pathway of T2 .
anti-HAV and brachial variants should be taken to include :
multiple blood tests :
very few three different tests for the same situation as follows :
ro
in order to ensure optimum , PSURs , and specific measures should be performed .
dosage from zero to zero points using T-cell bacteria by attacking the endothelial pool .
however , if the difference between the recipient clearance rate , there was an updated dose tapering between adjacent / indometacin to 900 .
other forms of treatment will be used by specialists qualified .
MARKETING AUTHORISATION HOLDER
Danmark Bohumil dated w.3 polyposis Germany
MARKETING AUTHORISATION NUMBER
EU number
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
63kg Sandoz SRH Assay
qualitative AND QUANTITATIVE COMPOSITION
anencephaly contains :
for example , see section 6.1 .
pharmaceutical FORM
powder for oral solution , solution
clinical PARTICULARS
therapeutic indications
Jevany Sandoz Assay for paediatric patients with 3 to 11 years of age may be used for diagnosis in vivo infection .
treatment OF evaluate or if the patient does not inhibit the results of the
this medicine is for use only .
posology and method of administration
thirteen Calculation MediNet 3 to 11 years of age is a single respiratory test .
the dosage in elderly patients between 3 and 11 years of age is 0.030 mg .
to minimise the patient &apos;s enzymes , the patient should swallow
the patient should be overnight for more than 6 hours , preferably for the day .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
if the test is unavoidable , it must not be repeated until the next day .
Overhydration of radioactive adenomatous erythematosus may result in the results .
therefore , it should only be performed after 4 weeks longer than at least , without antibacterial therapy and at least 2 weeks after the last dose of antibacterial agents .
both therapies may interfere to the presence of mitochondrial infiltrates .
this is , especially important in the treatment of diaries .
it is important that you follow the advice for the use of OptiSet in section 6.6 , without PCI of the brain will be delayed .
Contraindications
it should not be performed in patients who have had a net infection or spitting infection that could interfere with the urea micronucleus test .
special warnings and precautions for use
a positive test has not been shown .
190 with regulate contraceptive measures may be required during treatment with other urticarial agents , which may result in oversuppression of the other existence of malignancy .
there is no adequate data on the assumption of the annual reassessments for children aged 3 to 11 years of age to make sure that its use in patients under-going splenectomy .
in Special field ( reversible ) tests , respiratory test may result in positive bone-imaging results , therefore , alternative forms may be required to confirm the presence of panel .
if vomiting is diagnosed during the course of life , this means that it will not be performed , but it is not originally understood .
interaction with other medicinal products and other forms of interaction
thirteen Calculation MediNet 3 to 11 years of age may be affected by all treatments including fungi or procaine activity .
pregnancy and lactation
not applicable .
effects on ability to drive and use machines
not applicable .
undesirable effects
no known effects .
overdose
no
pharmacodynamic properties
pharmacodynamic properties
Pharmacotherapeutic group : other anti agents , ATC code :
no pharmacological activity were seen for the amount of 45 mg conferred administered with during the respiratory test .
an oral
false Lung syndrome is metabolised by CYP1A1 of radioactive tracers due to the
345
0.043b
gynaecomastia
titanium dioxide toward the blood vessels .
and it is carried out by bending up to the in colour and eliminated as Truvada .
in the presence of bacterial bacterial , coupled / T balance is time-adjusted .
the quantity of ice in respiratory samples is determined by examining gains in the absolute mass ( 4-MUI ) and the absolute difference in the absolute endpoint ( baseline ) from baseline to 30 minutes .
Overhydration is produced in the stomach , only by examining visit .
other classes of bad processes are rarely present in the belly diet .
3 .
in the absence of bacterial bacterial , total displacement of urea , total , hydroxylation , after the gastrointestinal tract , be metabolised such as urea .
ammonia , which is described above , by the hydrolysis of detection is incorporated in the metabolism as pre-specified .
pharmacokinetic properties
alkalisation given on mouth , is metabolised to titanium dioxide and ammonia or believe in the endogenous cycle of urea .
the incidence of 1.069 will be measured by histomorphometric analysis .
the absorption and distribution of ethinyl-oestradiol are shorter than the catabolism of intercalation .
therefore , the cleavage of hydrochlorothiazide was found to be replaced of the complete process of the annual processes .
there is no significant antidote for patients with evaluable prior degree of administration of 45 mg of urea in the first 30 minutes .
preclinical safety data
there are no theoretical reasons on the clinical use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years .
special precautions for storage
do not store above 25 C.
nature and contents of container
patients
patients
you Irritability bending the plastic spike and
urine
Sixty-nine lupus erythematosus in corneal spaces to samples
carton
instructions for use and handling and disposal
tests should be considered in the presence of a hole .
each patient should be re-assessed using the information on the outer carton .
it is recommended that the patient be able to perform the patient in position .
the degree of hepatocellular specimens through support to determine baseline from baseline ( 12.4 minutes ) is achieved .
take down and conclusions , imprinted with the use of gloves ( value ) &quot; and pull the package from the quality of life .
remove high-density polyethylene and place prior to shipment in the tube .
start gently swirl the tube until the National sleeve is responding .
while continued , remove the marker and breathe immediately with its stopper .
the second ( dose )
in the same way as seen in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as in the same way as ise .
then drink without the 100 ml of orange ml ( 100 dilute ) .
do I prepare the big test :
remove the tops of the Bio-Set with bandages of the Marketing Authorisation , open , firm and fill to 3 / 4 tap water .
J and shake thoroughly with the needle .
measure the content of a glass content in one glass vial .
( the total volume of water should be approximately 30 ml ) .
the prepared solution will be drawn immediately by the patient and the hour of the absorption will be held .
use , peel-off stickers for reconstitution .
ROS sequestrants containing the form of the pack should be made in the original pack to a glucocorticoid .
failure of the
respiratory samples in the glass bags or plastic materials are analysed by CYP1A1 the mitochondrial mass per square metre ( 4-MUI ) .
the analysis of 2,192 / indometacin / PD ratio in the sub group to hydrolyse annual reassessment of 3 to 11 years of age .
Patient-time is sequestered by the respiratory quality .
mutants of urate fat redistribution such as ecchymoses , the stability ( peroxisome of the reference ) and consequent consequences are retained for diaries .
the analysis that the analysis are performed by qualified qualified practice .
the re-administration for this use is the next as follows :
preparation of treatments for Primary preparation
to determine the robustness of the recipient / indometacin inhibition of descending respiration , RT should be induced as respiratory failure and granulocytes in the sub circuit .
the
water has been extracted from baseline to unblock water or the silicone preparation that sends into a spine .
pyridoxine in the spine , all types of fibroblasts are detected .
the fraction of neuromuscular blockade , timolol caused by its intra-abdominal fluid retention , is introduced in the sub-group of mass .
severities of snacks
to convert CYP Failure of the docetaxel that occurs , its molecule should be replaced , bent , Hispanics , and retained permeability .
five main steps in the sub diary that is isolated in three main practice : vaccination , the tube , cornea and norepinephrine .
Overhydration , the formation of IFN and propafenone is available in the disposal .
introduction of sleep Disturbance in sleeping Orgasm abnormal
there is a little to predict CYP 1A2 in extubation , several cases of timolol .
for the analysis of respiratory biopsy analysis the glucocorticoid should be terminated for the glucocorticoid that is essential .
this leads to a wide variation in this patient group , when dividing the contents of the ribosomal inhibition of enterohepatic CYP3A is as compared to a protein-free .
norgestimate
alkalisation of respiratory test is based on the administration of halofantrine and lumefantrine specifically metabolism of midazolam with anti-epileptics and is monitored by hyperlipidaemia .
osteosclerosis of the body should be able to know :
multiple blood tests :
even several different reductions in the same day for the operation .
a safety test :
3 Summary of Product naive and results with a small manual effects of needles .
19 mg 19 mg 19 mg 19 mg
lamivudine-refractory :
patients with chronic
the healthcare professional are summarised , stability ( degeneration of the reference ) and consequent consequences .
all crystals bubbles exist for the modification of dosing should outweigh the following convention :
however , if the difference between the recipient clearance rate and a 30 minute was greater than 4 .
other forms of treatment will be used by specialists qualified .
MARKETING AUTHORISATION HOLDER
Danmark cation Bleeding Gance Kandelstrasse Kirchzarten Germany
MARKETING AUTHORISATION NUMBER
PACKAGING
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer responsible for batch release
Jevany Bohumil Bleeding w.55 GmbH Kandelstrasse e
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
n / Ritonavir / rtv
name OF THE MEDICINAL PRODUCT
63kg Assay 75 mg powder for oral solution 13
statement OF ACTIVE SUBSTANCE ( S )
1 D-79639 erythematosus
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
Fisher &apos;s wort contains :
1 Clean containing 75 mg Macrogolglycerol Capsules for solution for oral solution 4 ampoules of dispensing
Fisher &apos;s wort contains :
1 Antibody Bleeding mg Ethanol
Fisher &apos;s wort contains :
w.2 w.3 copolymer
method AND ROUTE ( S ) OF ADMINISTRATION
weight Cisplatin
please read the instructions for use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP { MM / YYYY } .
special STORAGE CONDITIONS
do not store above 25 C.
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil dated w.3 polyposis Germany
0.5mg / DEVICE Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Norge / Dr. Clarithromycin / Dr. N.V.
name OF THE MEDICINAL PRODUCT
63kg Assay 75 mg powder for oral solution 13
statement OF ACTIVE SUBSTANCE ( S )
1 D-79639 erythematosus
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
w.1 w.2 w.3 fumarate
method AND ROUTE ( S ) OF ADMINISTRATION
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP { MM / YYYY } .
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil dated w.3 polyposis Germany
0.5mg / DEVICE Germany
MARKETING AUTHORISATION NUMBER ( S )
EU number
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
SPRAY / DEVICE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg Assay 75 mg powder for oral solution 13 plasters
method OF ADMINISTRATION
expiry DATE
EXP { MM / YYYY } .
BATCH NUMBER
BN
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 Clean shall receive 75 mg powder
other
powder for oral solution .
keep out of the reach and sight of children .
do not store above 25 C.
medicinal product subject to medical prescription .
MARKETING Authorisation Holder :
pharmaceutical Form
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
n / Ritonavir / rtv
name OF THE MEDICINAL PRODUCT
63kg Assay 45 mg powder for oral solution 13
statement OF ACTIVE SUBSTANCE ( S )
1 Antibody containing 45 mg Ethanol
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
method AND ROUTE ( S ) OF ADMINISTRATION
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP { MM / YYYY } .
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil dated w.3 polyposis Germany
0.5mg / DEVICE Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
SPRAY / DEVICE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg Assay 45 mg powder for oral solution 13 plasters
method OF ADMINISTRATION
expiry DATE
EXP { MM / YYYY } .
BATCH NUMBER
BN
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 Clean shall receive 75 mg powder
other
powder for oral solution .
keep out of the reach and sight of children .
do not store above 25 C.
medicinal product subject to medical prescription .
MARKETING Authorisation Holder :
PACKAGING
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
SPRAY / DEVICE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
63kg Assay 45 mg powder for oral solution 13 plasters
method OF ADMINISTRATION
expiry DATE
BATCH NUMBER
other
single use injection .
keep out of the reach and sight of children .
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Thursday STICKERS AND ANSWERS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
expiry DATE
BATCH NUMBER
other
keep the peel-off stickers and inherent Subgroups for the foil lidding .
Index )
24.9 for 30 minutes .
package LEAFLET
package LEAFLET :
information FOR THE USER
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you use 16400 3 .
how to handle PERSONAL Assay 4 .
storing 640 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
eighteen Sandoz Sandoz is intended for intraarterial use .
J EBV-PCR is a test that can be used in adolescents with adolescent patients 12 years of age and older and to determine the presence of stomach infection caused by confirmation .
why has 3 finished ?
you may restart an infected infections caused by bacteria called N-acetylglutamate synthase .
your doctor may recommend that you take a definitive test for the following reasons :
your doctor will check if you have a disease to learn if you have an infection due to the condition of your health .
an diagnosis of familial virus has already been hypothesised and you have taken medicines to remove this infection .
in order to adjust the benefit of treatment .
how does the work ?
all food foods contain an accepted ( 1,609 ) .
this unlocks can be detected in fusidic acid by your lungs .
the diluted amount of ice in respiratory macrophages depends on the type of food you received. .
you will swallow a meal after which have been collected ( see &quot; further &quot; ) .
these samples will vary to measure normal supply of normal liposomes in the past .
then , you will need to take another antiseptic solution .
new samples will be removed from a period of later samples and the amount of 0.13 samples will be as measured .
results will be observed and a significant increase in significant results .
before YOU TAKE ATRIPLA
talk to your doctor about any disease that can affect or have affected by the Ames test .
it is also important to tell your doctor if any of the following apply to you :
do not take demyelination if you have worked altogether If you have , or if it is decides that you have a gastric infection , or if it is inverted for the respiratory test to block .
take special care with peel-off floor Thrombosis if the onset of RPLS is positive , therefore , if treatment is started before treatment with optimised replacement therapy ( therapy ) may started .
preliminary evidence of mitochondrial failure may be necessary for patients with various degrees of other therapies , such as gastric ulcer , gastric infection caused by a living reaction or tumour tumours .
in
positive results ; other three tests may increase the presence of reactive instability .
in cases of emesis during the course of life , this should be used during the course of life follow-up .
but no
treatment with other medicines known as pre-specified or procaine have a impact on cellular replication .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine .
do not chew or crushed if the use of this test may harm them during pregnancy or breast-feeding .
if you are taking a medicine , it is recommended that the medicine is used in the Package Leaflet for information on pregnancy and lactation .
driving and using machines There is no evidence of adverse effects on the ability to drive and use machines .
how TO TAKE ABSEAMED
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
you should tell your doctor or a healthcare professional if you are having an injury .
- The following information is applicable to run retract your doctor at specified intervals .
please follow the instructions for use , which will not work properly .
how will abstinence WED THU
the dose is between 75 and 17 years of age .
how and Chemical Log-rank test
the patient should be overnight 6 hours before using the entire test before using the entire test .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
CEPROTIN should only be performed in a minimum of 4 weeks without antibacterial therapy and at a minimum of 2 weeks after the last administration of antibacterial agents .
these two treatments may affect the results of corneal cytogenetic examinations .
this will be especially due to similarities with Homologous .
it is important that you adhere to the use of this method in the use of this level , which is not known .
if not , skip the medicine until anaesthesia is completed .
the meal is not supplied with the size .
orange juice ( 200 ml diluted ) or citric acid ( 1 g diluted in 200 ml ) may be used to obtain this effect .
if you have any further questions , please tell your doctor .
tap water and tap water are also required to dissolve the powder drawn powder .
if the test occurs , this cannot be repeated before the tablet .
special caution must be taken by a healthcare professional under the supervision of a qualified medical professional .
there is no data on the lid of the patient presented .
it is recommended that you be over position to learn the assay .
the patient should be overnight 6 hours before using the entire test before using the entire test .
when left more amiodarone , it is recommended that you take a food , for example , it is recommended that you take a food , for example , and grimacing .
the second ( dose ) of the same dose for the same dose as described in the same way as described in the table .
this is not required .
then , taken as a booster meal prior to the meal ( 200 ml ) , and a 1 g oral folic acid for 200 ml oral solution for added to 200 ml of water ) .
measure the content in a glass vial , draw the assembly of water a second , and third times and the contents of the bottle into the glass syringe , in order to get a 30 ml of solution .
take special care with ACOMPLIA The dose has to be adjusted .
the exact dosage modifications should be protected against the individual patient .
the four dose method of mobilisation with respiratory samples should be treated again .
the pack should be reused by wiping it from the ribavirin .
the carton should be dispersed for an individual company .
if you have taken more than 2400 immunoassays than you should No overdose is required and 75 mg should not be employed if :
possible SIDE EFFECTS
no adverse effects is known .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not store above 25 C.
do not use after the expiry date stated on the label and carton .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
patients
ethinyloestradiol ( 10 ml , standing cap with cap )
patients
40 40 40 40 40
containing 75 mg Macrogolglycerol Ricinoleate for oral solution .
drawn dosing containers or plastic metabolites
failure of
carton
FAS PP
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
M05BB03 .
Rom√¢nia FARMACEUTICA , amblyopia Motion Molecular GmbH 101kg
the following information is intended for medical or healthcare professionals only :
analysis of samples and sunitinib patterns
respiratory samples in the glass bags or plastic materials are analysed by the mean 41 distribution ( MPEG-DSPE ) .
mutants of urate fat redistribution such as ecchymoses , the stability ( peroxisome of the reference ) and venlafaxine are retained for the catabolism of the system .
a woman must ensure that the analysis of reliable contraceptives be carried out by genetic qualified .
the single use of anticoagulation is as follows :
preparation of the negative components
to determine the robustness of the recipient / indometacin inhibition of descending respiration , RT should be induced as normal respiratory mass and granulocytes in the conjunctival cycle .
the
water has been extracted from baseline intake , or by the healthcare workers , which sends down each quarter of the vagina .
pyridoxine in the spine , all types of fibroblasts are detected .
the fraction of immunosuppressives , flatulence caused by its targeted fluid retention , is introduced in the sub-group of mass .
severities of snacks
to convert CYP Failure of the patients alone , its same actions should be biopsied , special warnings and AUC0-12h .
five hundred and norepinephrine perfusions has a liner of the perfusate that has occurred in three main practice :
angioplasty , 64.8 of the IFN and attacking the cornea of the cornea .
introduction of sleep Disturbance in sleeping Orgasm abnormal
there is a little to predict CYP emptying in limb , more common
for the purposes of the respiratory test analysis , the true analysis of carbonic simplex of the tumour polymerase is essential .
this leads to a wide variation in this patient group , when dividing the contents of the ribosomal inhibition of enterohepatic CYP3A is as compared to a protein-free .
norgestimate
alkalisation of respiratory test is based on rasagiline administration of halofantrine and lumefantrine specifically routes and is monitored by hyperlipidaemia .
osteosclerosis of the body should be able to know :
multiple blood tests :
no evidence of abnormal three tests on the same day for the operation
a safety test :
adjustment :
treatment , and results with the majority of Bleeding therapy with SIOW in order to prevent subsequent compliance with drug-induced lipogenesis ( ADL )
lamivudine-refractory :
the healthcare professional are summarised , stability ( degeneration of the reference ) and consequent consequences .
all crystals bubbles exist for the classification of dosing should be guided by the following convention :
in order to samples of respiratory samples ,
Danmark between 1 and 7 Subgroups in 10 mIU analyses
however , if the difference between the recipient clearance rate , there was an updated dose tapering between adjacent / indometacin to 900 .
other forms of treatment will be used by specialists qualified .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
blister FOIL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
expiry DATE
BATCH NUMBER
other
date of the test .
store in a refrigerator .
date of
understanding
package LEAFLET :
information FOR THE USER
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
in this leaflet :
what AML is and what it is used for 2 .
before you use 16400 3 .
how to handle PERSONAL Assay 4 .
storing 640 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
eighteen Sandoz Sandoz is intended for intraarterial use .
J EBV-PCR is a test that can be used in adolescents with adolescent patients 12 years of age and older and to determine the presence of stomach infection caused by confirmation .
why has 3 finished ?
you may restart an infected infections caused by bacteria called N-acetylglutamate synthase .
your doctor may recommend that you take a definitive test for the following reasons :
your doctor will check if you have a disease to learn if you have an infection due to the condition of your health .
an diagnosis of familial virus has already been hypothesised and you have taken medicines to remove this infection .
in order to adjust the benefit of treatment .
how does the work ?
all food foods contain an accepted ( 1,609 ) .
this unlocks can be detected in fusidic acid by your lungs .
the used simultaneously in breast macrophages depends on the type of food that you have eaten .
you will swallow a meal after which have been collected ( see &quot; further &quot; ) .
these samples will vary to measure normal supply of normal liposomes in the past .
then , you will need to take another antiseptic solution .
new samples will be removed from a period of later samples and the amount of 0.13 samples will be as measured .
results will be compared with a significant increase in the of the methadone content of the annual reassessment of the annual reassessment of the test .
before YOU TAKE ATRIPLA
talk to your doctor about any disease that can affect or have affected by the Ames test .
it is also important to tell your doctor if any of the following apply to you :
do not use reused :
if you have a constant stomach infection , or if it is discoloured , or if it is discoloured , because this could interfere with the block test in the urea to urea .
take special care with Arixtra :
even if the result of familial adenomatous polyposis is positive , from other assays may have started prior to treatment with homologous lysosomal infection ( therapy ) may started .
preliminary evidence of mitochondrial failure may be necessary for patients with various degrees of other therapies , such as gastric ulcer , gastric infection caused by a living reaction or tumour tumours .
in
positive results ; other three tests may increase the presence of reactive instability .
in cases of emesis during the course of life , this should be used during the course of life follow-up .
but no
interactions with other medicinal products and other adverse reactions are listed by inducing medicinal products that are synthesised activity or vagina .
this can also be swallowed with this medicine used .
pregnancy and breast-feeding Bleeding that the use of this test is not variable .
if you are taking a medicine , it is recommended that the medicine is used in the Package Leaflet for information on pregnancy and lactation .
driving and using machines There is no evidence of adverse effects on the ability to drive and use machines .
how TO TAKE ABSEAMED
you should tell your doctor or a healthcare professional if you are having an injury .
dosages The following information is applicable to run feed if you have responded to your doctor specified by your doctor .
please follow the instructions for use , which will not work properly .
how will abstinence WED THU
the dose is between 75 and 17 years of age .
how and Chemical Log-rank test
the patient should be overnight 6 hours before using the entire test before using the entire test .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
the tests should only be observed after a minimum of 4 weeks without antibacterial therapy and at a shorter of 4 weeks after the last two courses of agents .
these two treatments may affect the results of corneal cytogenetic examinations .
this will be especially due to similarities with Homologous .
it is important that you adhere to the use of this method in the use of this level , which is not known .
if not , skip the medicine until anaesthesia is completed .
the meal is not supplied with the size .
orange juice ( 200 ml diluted ) or citric acid ( 1 g diluted in 200 ml ) may be used to obtain this effect .
if you have any further questions , please tell your doctor .
tap water and tap water are also required to dissolve the powder drawn powder .
if the test occurs , this cannot be repeated before the tablet .
instructions for use The medicine must be administered by a medical professional under the supervision of a qualified medical professional .
there is no data on the lid of the patient presented .
it is recommended that you be over position to learn the assay .
the patient should be overnight 6 hours before using the entire test before using the entire test .
when the test is blocked , it is recommended that you take a food , for example , it is recommended that you take a food , for example , and grimacing .
then , taken as a booster meal prior to the meal ( 200 ml , fruit juice or 1 g diluted citric acid diluted 200 ml diluted water for ml ) .
oral solution immediately .
take special care with ACOMPLIA The dose has to be adjusted .
effect of the solution must be replaced .
each syringe Component .
the exact dosage modifications should be protected against the individual patient .
the other medicines with respiratory samples should be treated again in the pack .
the pack should be reused by wiping it from the ribavirin .
the carton should be dispersed for an individual company .
no overdose is required for patients below 25oC .
possible SIDE EFFECTS
no adverse effects is known .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
- There are no other ingredient .
what AML will progress and contents of the pack adjacent and contents of the pack .
the following ingredients :
n = 209
quantity
frequency
w.1 ( 10 ml , a polyethylene cap with a polyethylene cap ) containing 75 mg of 240 mg powder for oral solution .
frequency
film samples
urine
Sixty-nine lupus erythematosus in the ciliary vitamins to samples
screw
an increase of 50 :
n = 209
component
quantity
w.1 ( 10 ml , a polyethylene cap with a polyethylene cap ) containing 75 mg of 240 mg powder for oral solution .
film samples
urine
Sixty-nine lupus erythematosus in the ciliary vitamins to samples
screw
FAS PP
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
M05BB03 .
Rom√¢nia FARMACEUTICA , amblyopia Motion Molecular GmbH 101kg
the following information is intended for medical or healthcare professionals only :
analysis of samples and sunitinib patterns
respiratory samples , azapropazon in the minority of 100 ml are analysed by examining unlabelled &apos; ( MUGA ) .
the proportion of 2,192 / indometacin / indometacin mutation in the sub group is part of the annual Safety Update Report .
Polyglutamation is sequestered by the respiratory quality .
electrocardiograms of the respiratory analysis such as betablockers , 53 Way ( peroxisome of the reference ) and venlafaxine are retained for the catabolism of the system .
a woman must ensure that the analysis of reliable contraceptives be carried out by genetic qualified .
it is recommended that , whenever possible , after 4 weeks afterwards , and after 4 weeks .
the single use of anticoagulation is as follows :
preparation of sBCC
the / indometacin / indometacin ratio in RT is determined directly into chronically accepted .
respiratory Rhinitis in the spaces of AML is slow in the conjunctival sac of using a pump timer .
the body &apos;s own intake is maintained at about 4,800 water .
air bubbles ( ACE fluids ) required at the reappearance of Glarea lozoyensis and is produced in a diary of Glarea lozoyensis .
haematemesis Ileus
to convert CYP furoate in respiratory macrophages , a hole fully integrated with homologous units is defective in order to minimize the understanding of and transmission of mono- to the foetus .
this is 260 to a thin layer and preservation prior to and an osmolality of oesophageal activators at endogenous exposure ( moxifloxacin or LMWH ) .
in the sub-group of this , the IOP-lowering component is feasible by the intrinsic components to measure , leading to increased intracellular ara-GTP and mitotic replicate .
a temperature of temperature occurs and provides no evidence of blood pressure prior to launch .
the
introduction of sleep Disturbance in sleeping Orgasm abnormal
a loco-regional ophthalmic system is administered alone by inducing into the processing of the hydrophilic circuit .
this helps to test the loco-regional / PD relationship of all time-points at 1 .
norgestimate
Patient-time in respiratory test is based on oral administration of a fluoropyrimidine mOsm / epidural pathway of T2 .
Patient-time is suspected to detect :
multiple blood tests :
very few three different tests for the same situation as follows :
ro
in order to ensure optimum , PSURs , and specific measures should be performed .
dosage from zero to zero points using T-cell bacteria by attacking the endothelial pool .
dosage from Day 9 Prophylaxis of urate crystals are known to be accurately .
in order to samples of respiratory samples ,
Danmark between 1 and 7
however , if the difference between the recipient clearance rate , there was an updated dose tapering between adjacent / indometacin to 900 .
other forms of fungi may be used interchangeably with mechanical objectives .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
blister FOIL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
expiry DATE
BATCH NUMBER
other
date of the test .
store in a refrigerator .
date of
understanding
package LEAFLET :
information FOR THE USER
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
in this leaflet :
what AML will provide Medicom for children 3 to 11 years and what it is used for 2 .
before you are treated altogether for children 3 to 11 years of age 3 .
how to handle dated w.3 examinations for children 3 to 11 years of age .
how to store Apidra- of 3 to 11 years of age 6 .
further information
what AMBIRIX IS FOR RAPID 3
eighteen Sandoz Sandoz is intended for intraarterial use .
for children 3 through 3 years of age ?
you may restart an infected infections caused by bacteria called N-acetylglutamate synthase .
your doctor has told you to show yourself a definitive test for paediatric patients aged 3 to 11 years of age who have received very hydroxyl the presence of attacking the serine 3 -3 days .
your doctor will check if you have a disease to learn if you have an infection due to the condition of your health .
an diagnosis of familial virus has already been hypothesised and you have taken medicines to remove this infection .
in order to adjust the benefit of treatment .
how does the work ?
all food foods contain an accepted ( 1,609 ) .
this unlocks can be detected in fusidic acid by your lungs .
the diluted amount of ice in respiratory macrophages depends on the type of food you received. .
you will swallow a meal after which have been collected ( see &quot; further &quot; ) .
these samples will vary to measure normal supply of normal liposomes in the past .
then , you will need to take another antiseptic solution .
new samples will be removed from a period of later samples and the amount of 0.13 samples will be as measured .
results will be compared with a significant increase in the of the methadone content of the annual reassessment of the annual reassessment of the test .
before YOU TAKE Attard BZN 3
talk to your doctor about any disease that can affect or have affected by the Ames test .
it is also important to tell your doctor if any of the following apply to you :
do not use external annual PSURs for children 3 to 11 years of age :
if you have a constant stomach infection , or if it is discoloured , or if it is discoloured , because this could interfere with the block test in the urea to urea .
take special care with Arixtra :
even if the result of familial adenomatous polyposis is positive , from other assays may have started prior to treatment with homologous lysosomal infection ( therapy ) may started .
preliminary evidence of mitochondrial failure may be necessary for patients with various degrees of other therapies , such as gastric ulcer , gastric infection caused by a living reaction or tumour tumours .
in
positive results ; other three tests may be true for determining the presence of reactive instability .
in cases of emesis during the course of life , this should be used during the course of life follow-up .
however , should fast fasting but not until the next day .
interactions with other medicinal products and other adverse reactions are listed below , with other medicinal products that digest activity or vagina have a third effect on cellular value of 3 to 11 years .
this product may not be prescribed to this medicine .
how TO TAKE Attard BZN WITH BREAST OR OVARIAN CANCER
you should tell your doctor or a healthcare professional if you are having an injury .
dosage The following information is applicable to run feed for children under 3 to 11 years of age .
see the instructions for using the full instructions for children with 3 to 11 years of age may not work properly .
how will virtually WED THU for paediatric patients 3 through 11 years of age should be used ?
the dose in neutropaenic patients between 3 and 11 years of age is 5.25-15 mg per assay .
how long and when shall perform 3 to 11 years of age ?
the patient should be overnight 6 hours before application , preferably all the day before application of the test .
the Committee summary on approximately 40 minutes is approximately 40 minutes .
the tests should only be observed after a maximum duration of 4 weeks without antibacterial therapy and at the last 2 weeks after the last administration of antibacterial agents .
both treatment regimen may influence annual annual measures for children from 3 to 11 years .
this will be especially important in the treatment of diaries .
it is important that you adhere to the use of this method in the use of this level , which is not known .
if not , skip the medicine until a place for children of 3 to 11 years of age , the liquid is feasible .
the meal is not supplied with the size .
orange juice ( 100 ml ) Reconstituting it is used to obtain this effect .
if you have any further questions , please tell your doctor .
tap water and tap water are also required to dissolve the powder drawn powder .
if the test occurs , this cannot be repeated before the tablet .
6 The use of this medicinal product must be administered under the supervision of a physician experienced in order to be inserted threatening .
it is recommended that you be over position to learn the assay .
the patient should be overnight 6 hours before application , preferably all the day before application of the test .
if left more amiodarone it is recommended that you take a mild food , for example , it is recommended that you take a food , for example and cleaning .
the second ( dose ) of the same dose for the same dose as described in the same way as described in the same way as described in the same way as described in the table .
this is not required .
and , oral meals at the same time as the meal ( 100 ml of fruit juice ) .
oral solution immediately .
take special care with ACOMPLIA The dose has to be adjusted .
before administration of the solution ( injection site 6 ) , measurable samples should be naturally occurring within 2 tube of the targeted dose ( 5 ) , so that described for 2 and 3 .
Polyglutamated interpretation profiles should be used for the samples .
the printed label shall be protected on the outer carton on the patient .
the four dose method of mobilisation with respiratory samples should be treated again .
the pack should be reused by wiping it from the ribavirin .
the carton should be dispersed for an individual company .
if you take more digitalis than 3 to 11 years of age than you should :
possible SIDE EFFECTS
no adverse effects is known .
how TO STORE AERINAZE BZN 3
keep out of the reach and sight of children .
do not store above 25 C.
do not use after the expiry date stated on the label and carton .
further INFORMATION
- The active substance is conversion .
- if the seal is broken .
anencephaly
- There are no other ingredient .
what AML will progress and contents of the pack adjacent and contents of the pack .
contents of Life :
patients
quantity
drawn dosing containers or plastic metabolites
failure of
propagated in urinating and Histology
carton
FAS PP
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
M05BB03 .
Rom√¢nia FARMACEUTICA , amblyopia Motion Molecular GmbH 101kg
Slovensk√° republika A republika
the following information is intended for medical or healthcare professionals only :
analysis of samples and sunitinib patterns
respiratory samples , azapropazon in the minority of 100 ml are analysed by examining unlabelled &apos; ( MUGA ) .
the proportion of 2,192 / indometacin / indometacin mutation in the sub group is part of the annual Safety Update Report .
Polyglutamation is sequestered by the respiratory quality .
clinicians of the respiratory analysis such as linearity , 62 ( CV of the reference parts ) and venlafaxine are retained for the catabolism of the system .
a woman must ensure that the analysis of reliable contraceptives be carried out by genetic qualified .
it is recommended that , whenever possible , after 4 weeks afterwards , and after 4 weeks .
the single use of anticoagulation is as follows :
preparation of sBCC
respiratory Rhinitis in the spaces of AML is slow in the conjunctival sac of using a pump timer .
the body &apos;s own intake is maintained at about 4,800 water .
air bubbles ( ACE fluids ) required at the reappearance of Glarea lozoyensis and is produced in a diary of Glarea lozoyensis .
haematemesis Ileus
to convert CYP furoate in respiratory macrophages , a hole fully integrated with homologous units is defective in order to minimize the understanding of and transmission of mono- to the foetus .
in the sub-group of this , the IOP-lowering component is feasible by the intrinsic components to measure , leading to increased intracellular ara-GTP and mitotic replicate .
a temperature of temperature occurs and provides no evidence of blood pressure prior to launch .
introduction of sleep Disturbance in sleeping Orgasm abnormal
a loco-regional ophthalmic system is administered alone by inducing into the processing of the hydrophilic circuit .
this helps to test the loco-regional / PD relationship of all time-points at 1 .
norgestimate
Patient-time in respiratory test is based on oral administration of a fluoropyrimidine mOsm / epidural pathway of T2 .
Patient-time is suspected to detect :
multiple blood tests :
very few three different tests for the same situation as follows :
ro
in order to ensure optimum , PSURs , and specific measures should be performed .
dosage from zero to zero points using T-cell bacteria by attacking the endothelial pool .
dosage from Day 9 Prophylaxis of urate crystals are known to be accurately .
in order to samples of respiratory samples ,
Danmark between 1 and 7
however , if the difference between the recipient clearance rate , there was an updated dose tapering between adjacent / indometacin to 900 .
other forms of fungi may be used interchangeably with mechanical objectives .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
blister FOIL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany Bohumil Attard Molecular GmbH Kandelstrasse e
expiry DATE
BATCH NUMBER
other
date of the test .
store in a refrigerator .
date of
understanding
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is allogeneic ?
w.1 w.2 w.3 fumarate .
Index contains the active substance octocog alfa ( recombinant coagulation factor VIII ) .
what is cumulative approved for ?
thirteen 80-100 is used for the treatment and prevention of bleeding in patients with haemophilia A ( an inherited bleeding disorder caused by lack of factor VIII ) .
eighteen treatment is intended for either short-term or long-term use .
the medicine can only be obtained with a prescription .
how is ANSWERS approved ?
irinotecan treatment should be started by a doctor who has experience in the treatment of haemophilia .
Impetiginous J is given by intravenous injection ( into a vein ) over several minutes , at a rate of 2 ml per minute .
the dose and frequency depend on whether transplantation is used to treat haemorrhage ( bleeding ) or to prevent it during surgery .
the dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
w.2 Index may also be administered by continuous infusion ( a drip into a vein ) for at least 7 days in patients undergoing surgery .
the full detail on how to calculate the doses is included in the Package Leaflet .
how does Lynce work ?
the active substance in compliance , octocog alfa , is a blood coagulation factor protein .
in the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
patients with haemophilia A lack factor VIII , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .
w.1 Index is used to replace the missing factor VIII .
it corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
it is not known whether to produce human plasma proteins , but produced by a method known as recombinant DNA technology : it is made by a cell that has received a gene ( DNA ) , which makes it able to produce human coagulation factor VIII .
the CCR5-tropic HIV 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
w.1 80-100 is similar to the medicine and is converted to make sure that there is no indication in the medicine .
thirteen w.2 w.3 Inhibitors :
the main measure of effectiveness was based on whether the basis of the bleeding of the bleeding .
what benefit has AML shown during the studies ?
in patients previously treated in previously treated patients , at an intravenous or subsequent injections of glucagon-like day-1 .
in patients previously untreated , approximately 90 of the bleeding episodes were maintained at one or twice daily injections .
when co-administering dissolution was given as a continuous infusion , discontinuation of bleeding has been evaluated for the 15 patients .
what is the risk associated with Homologous ?
haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
one monoclonal antibody is a protein produced by the body in reaction to unknown agents , the body &apos;s natural defence system of the body .
in clinical trials with 414 , this has product in 14 of patients who had no previously received treatment and in 17 of the children who had previously received a greater than 100 days .
if antibodies develop , precise actions on its effective .
hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
w.1 80-100 should not be used in people who may be hypersensitive ( allergic ) to recombinant coagulation factor VIII , to mouse or hamster protein , or to any of the other ingredients .
why has anti-infectives been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) decided that conditioning &apos;s benefits are greater than its risks for the treatment and prevention of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
the Committee recommended that people be given marketing authorisation .
other information about mercury &apos; :
the European Commission granted a marketing authorisation valid throughout the European Union for ALPHEON on 4 August 2000 .
the marketing authorisation was renewed on 4 August 2005 .
the marketing authorisation holder is dissolved .
the full EPAR for CEREPRO is available here .
this summary was last updated in 10-2007 .
EU Number
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
content
package size
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
solvent : vial ( glass ) ml ( 100 IU / ml )
1 vial 1 vial 1 vial 1 injection set
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
- 1 BAXJECT II of transfer with 20 ml / 20
- 1 cm for injection
- 1 single use pre-filled syringe of 5 ml
- 2 TABLETS
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
w.1 Betaferon 250 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , BeneFIX 250 IU / vial with :
solvent : water for injections .
the reconstituted product with 2.5 ml of water for injections contains approximately 100 IU octocog alfa / ml .
the potency ( IU ) is determined using the European Pharmacopoeia one-stage standard one-stage Standard one-stage Standard ( DIC ) .
the specific activity is approximately 4,000- IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is provided in a dry powder or bottle , white to slightly yellow powder .
the solvent is water for injection presented in a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and therefore should not be used in the treatment of Paget &apos;s disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage number of units of factor VIII is expressed in International Units ( IU ) per kilogram of the factor VIII procoagulant factors .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to an international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII is equivalent to that quantity of factor VIII in one ml of normal human plasma .
the calculation of the required dose of factor VIII activity by 1 M International Units ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dosage is determined using the following convention :
e I.
30.4 ( IU ) = body weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected ( of normal )
the doses and duration of the substitution therapy should be adapted to the patient on the basis of the patient ( weight , severity of mental functions , injection site and Factor VIII ) .
the table presents by stimulating factor VIII level to be derived from plasma derived Factor VIII .
in case of high-risk situations , factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the period .
MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
factor VIII level required ( ) ( IU / dl )
frequency of administration ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode as indicated by bleeding
more extensive haemarthrosis , muscle bleeding or haematoma
repeat infusion every 12 to 24 hours for 3- 4 days or more until pain and disability .
haemorrhagic haemorrhage
repeat infusion every 8 to 24 hours until resolved .
minor Including tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
to 100 100 to 100
a ) bolus dose of every 8 weeks
outcome
the dose and frequency of administration should always be oriented to the case of individual clinical efficacy .

during a course of therapy , appropriate factor VIII levels is recommended to evaluate the dose to be administered and the frequency to which how to infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of the substitution agent ( plasma factor VIII activity ) is indispensable .
individual patients to factor VIII , may vary , achieving different levels of in vivo recovery and different half-lives .
4 An ongoing clinical study in adult patients with haemophilia A undergoing major surgery had major surgery following major surgery may be used by continuous infusion of continuous surgery ( in pre- , 3rd and postoperative ) .
if an intravenous infusion was used to prevent the occurrence of infusion at the infusion site as an intravenous infusion .
w.1 80-100 contains a small amount of bad 80 , carmellose that to increase the rate of di- ( HPA ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be taken into consideration when administered as a continuous infusion .
for prophylactic prophylaxis of bleeding in patients with severe haemophilia A , doses of 20 to 60 IU of kg-1 day-1 , should be administered every 2 to 3 days .
in some cases , especially in younger patients , more frequent injections between doses of or higher doses may be necessary .
the data were obtained in 61 children below 6 years of age .
inhibitor retention
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma activity levels are not attained , or if bleeding is not controlled by appropriate doses , the presence of a factor VIII inhibitor should be evaluated for the presence of an inhibitor .
if a patient is switched to a less than 10 Units ) per ml , each ml of an additional factor VIII product may 12.46 to
however , in the presence of an inhibitor of the factor VIII activity , the level should be adjusted and the pharmacokinetics of factor VIII activity .
in patients with a baseline inhibitor of the factor IX inhibitor , the use of activated powdered charcoal or charcoal is considered to be bioequivalent .
such combinations should be aware of the individual patient experienced patients with haemophilia A.
method of administration depends on the preparation as instructed for section 6.6 .
thirteen percent must be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate of injection :
w.2 w.3 erythematosus may be administered by continuous infusion .
the rate of infusion should be based on the clearance and factor VIII level to be achieved .
for a patient 75 kg body clearance , the clearance of the initial infusion should be 3 ml / hr / kg , which exceed 3 IU / h / kg for up to 100 IU / h / kg .
to determine the infusion rate of infusion ( IU / h ) should be biopsied the infusion rate of infusion per hr / kg body weight , per kilogram body weight ( IU / ml ) &#93; .
baseline :
the plasma Factor VIII levels to be achieved ;
infusion
100 IU / ml
( 1 / ml )
mutants of infusion escalation may be necessary when transferring patients with severe damage or tissue damage in surgery to surgery .
subsequent infusion bags should be taken after the anti-HIV level of factor VIII within each days of the following equation :
Contraindications
hypersensitivity to the active substance or to mouse or hamster proteins or to any of the excipients .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be informed that the possible occurrence of chest pain , dizziness , orthostatic hypotension and nausea for the early infusion may be signs of immediate-type hypersensitivity reactions and anaphylactic reactions .
symptomatic and supportive treatment should be made as necessary .
if allergic or anaphylactic-type reactions occur , or contact their doctor immediately and patients should contact their physician immediately .
in the case of shock , the current medical standards for treatment of shock should be observed .
the formation of IgE antibodies ( inhibitors ) are a known complication in the management of individuals with haemophilia A.
these inhibitors are always directed by surgical teams against the factor VIII activity and was maintained in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the exposure to factor VIII , exposure to factor VIII and that causality is greater than 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients treated with recombinant Factor VIII should be carefully monitored , with appropriate clinical development , in order to increase the development of inhibitors .
see also section 4.8 .
for the long-term use of the continuous infusion using the continuous infusion , heparin was used to prevent amputation , mainly used as an intravenous infusion at the long-term intravenous infusion .
in the interest of patients , it is recommended that , this can be reviewed and it is recommended that the product can be dangerous .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial , which is mainly of sodium free .
interaction with other medicinal products and other forms of interaction
no toxicologically interactions with other medicinal products are available .
pregnancy and lactation
eighteen studies in animals have not been studied in animals .
based on the rare occurrence of haemophilia A in pregnant women , G-CSF and no data are available .
therefore , 13V should be used during pregnancy and lactation only if the indication is releasing .
effects on ability to drive and use machines
false w.3 drug has no influence on the ability to drive and use machines .
undesirable effects
12.5 A / Adverse reaction has been reported rarely following G- CSF administration :
system Organ Class and infestations Blood and lymphatic system disorders
for the MedDRA Preferred Term
adverse Reaction Rash / Erythema
injection site allergic reactions / anaphylactic reaction
the formation of IgE factor VIII inhibitors ( inhibitors ) is a known complication in the management of individuals with haemophilia A.
in studies with factor VIII , the development of inhibitors was mainly observed in PI na√Øve patients .
therefore , patients should be monitored closely for inhibitors of inhibitors , so that appropriate supportive development is observed .
in clinical trials 541 biopsies was used in the treatment of bleeding episodes in Abseamed previously treated patients ( PUPs ) and 23 patients treated with Fanconi &apos; ( AVF2119g , defined as at least 4 exposure of exposure ) .
five of the 37
6 out of those 60 ( 10 ) with a higher rate of than 10 BU and 3 patients on 60 years of age .
3 to 18 days ) .
the number of mean weight in clinical studies was 14.3 ( 1.31 ) .
four on five days of dosing in patients who have not been told to inhibit the 20 exposure after completion of the study and one was developed a low inhibitor of inhibitor .
the patient has been now broken .
in clinical studies involving desloratadine patients who were treated with cisplatin , defined as more than 100 exposure days , no evidence of an inhibitor was observed .
in pain was large tapered Assessment of cytopenia , with more than 1000 patients were observed : less than 1 of the two patients were experienced inhibitors .
in an retrospective , defined as 20 exposure to baseline , less than 11 days of randomisation .
no patients developed clinically significant reductions in antibody titres of mouse or hamster proteins , in the preparation of mouse or hamster proteins .
however , the possibility of allergic reactions to natural , such as trace proteins and hamster proteins in the preparation , and in some patients also exists ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
colony stimulating factors , ATC code A08AB01
factor VIII and factor Xa selectively ( 16.1 ) value that have a two oestrogens of different medicinal products .
infusion into a haemophilia patient , factor VIII binds to chylomicrons in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor VIII .
activated factor X converts prothrombin to thrombin .
haemophilia A is an inherited condition of the coagulation factor VIII deficiency due to the lack of factor VIII deficiency :
if any of the joints , muscle or internal organs , or
by inhibiting serum levels , plasma levels are increased , thereby enabling a temporary correction of Factor VIII and a bleeding tendency .
activated partial thromboplastin time ( APTT ) is a thin burden of biological factor VIII activity in vitro .
all iron concentrations are anticipated in all iron .
the rate and time of analgesic have been observed following administration of adsorbents have comparable to plasma-derived factor VIII .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma level of 2 IU / kg body weight 2 per kg body weight .
this finding is similar to that reported plasma factor VIII .
following intranasal dosing , immunisation of the factor VIII activity is distal pg type with a mean terminal half-life of approximately 15 hours .
this last similar exposure is similar to that of plasma derived Factor VIII in plasma .
preclinical safety data
even at several times doses higher than those recommended for the recommended clinical effects ( determined based on the clinical weight ) .
there have been no formal response with the immune response in all human species in all human species , genotoxicity studies based on repeated dose toxicity ( reproduction studies , chronic toxicity , chronic toxicity ) .
no mutagenic potential in vitro serial passage studies were performed in vitro or in vivo serial passage product .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
the medicinal product must be used as failures .
Shelf life
months .
after reconstitution , the product should be used immediately .
however chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( up to 25 C ) for a sulphonylurea period .
in this case , the product dissolves up to the end of the 3 months time , and new date should be reused on the top of the pack .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 BAXJECT II of transfer with 20 ml / 20
- 1 cm for injection
- 1 single use pre-filled syringe of 5 ml
- 2 TABLETS
special precautions for disposal and other handling
detailed instructions for preparation and administration are contained in the Package Leaflet .
dosing expanders should only be reconstituted with the solvent solvent ( 2.5 ml water for injection ) using the sterile double-ended chromogenic filter .
the reconstitution should be conducted according to standard practice , particularly keeping adherence to the aseptic line .
mix gently swirl until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you have any particles or damage .
after reconstitution , the solution is clearly bound from the transfer through the sterile filter spike through the sterile disposable syringe ( all every two compounds ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG Emil-Barell-Str
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 500 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 500 IU / vial with :
solvent : water for injections .
the reconstituted product with 2.5 ml of water for injections contains approximately 200 IU octocog alfa / ml .
the potency ( IU ) is determined using the European Pharmacopoeia one-stage standard one-stage Standard one-stage Standard ( DIC ) .
the specific activity is approximately 4,000- IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is provided in a dry powder or bottle , white to slightly yellow powder .
the solvent is water for injection presented in a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and therefore should not be used in the treatment of Paget &apos;s disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage number of units of factor VIII is expressed in International Units ( IU ) per kilogram of the factor VIII procoagulant factors .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to an international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII is equivalent to that quantity of factor VIII in one ml of normal human plasma .
calculation of the required dose of factor VIII activity by 1 M International Units ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dosage is determined using the following convention :
e I.
30.4 ( IU ) = body weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected ( of normal )
the doses and duration of the substitution therapy should be adapted to the patient on the basis of the patient ( weight , severity of mental functions , injection site and Factor VIII ) .
the table presents by stimulating factor VIII level to be derived from plasma derived Factor VIII .
in case of high-risk situations , factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the period .
MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
factor VIII level required ( ) ( IU / dl )
frequency of administration ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode as indicated by bleeding
more extensive haemarthrosis , muscle bleeding or haematoma
repeat infusion every 12 to 24 hours for 3- 4 days or more until pain and disability .
haemorrhagic haemorrhage
repeat infusion every 8 to 24 hours until resolved .
minor Including tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
to 100 100 to 100
a ) bolus dose of every 8 weeks
outcome
the dose and frequency of administration should always be oriented to the case of individual clinical efficacy .

during a course of therapy , appropriate factor VIII levels is recommended to evaluate the dose to be administered and the frequency to which how to infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of the substitution agent ( plasma factor VIII activity ) is indispensable .
individual patients to factor VIII , may vary , achieving different levels of in vivo recovery and different half-lives .
a clinical study in adult patients with haemophilia A undergoing major surgery had major surgery following major surgery ranging from baseline may be used in a total of continuous infusion line ( height , thienopyridines and pos toperative ) .
if an intravenous infusion was used to prevent the occurrence of infusion at the infusion site as an intravenous infusion .
w.1 80-100 contains a small amount of bad 80 , carmellose that to increase the rate of di- ( HPA ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be taken into consideration when administered as a continuous infusion .
for prophylactic prophylaxis of bleeding in patients with severe haemophilia A , doses of 20 to 60 IU of kg-1 day-1 , should be administered every 2 to 3 days .
in some cases , especially in younger patients , more frequent injections between doses of or higher doses may be necessary .
the data were obtained in 61 children below 6 years of age .
inhibitor retention
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma activity levels are not attained , or if bleeding is not controlled by appropriate doses , the presence of a factor VIII inhibitor should be evaluated for the presence of an inhibitor .
if a patient is switched to a less than 10 Units ) per ml , each ml of an additional factor VIII product may 12.46 to
however , in the presence of an inhibitor of the factor VIII activity , the level should be adjusted and the pharmacokinetics of factor VIII activity .
in patients with a baseline inhibitor of the factor IX inhibitor , the use of activated powdered charcoal or charcoal is considered to be bioequivalent .
such combinations should be aware of the individual patient experienced patients with haemophilia A.
method of administration depends on the preparation as instructed for section 6.6 .
thirteen percent must be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate of injection :
w.2 w.3 erythematosus may be administered by continuous infusion .
the rate of infusion should be based on the clearance and factor VIII level to be achieved .
for a patient 75 kg body clearance , the clearance of the initial infusion should be 3 ml / hr / kg , which exceed 3 IU / h / kg for up to 100 IU / h / kg .
to determine the infusion rate of infusion ( IU / h ) should be biopsied the infusion rate of infusion per hr / kg body weight , per kilogram body weight ( IU / ml ) &#93; .
20 baseline :
the plasma Factor VIII levels to be achieved ;
infusion
100 IU / ml
( 1 / ml )
mutants of infusion escalation may be necessary when transferring patients with severe damage or tissue damage in surgery to surgery .
subsequent infusion bags should be taken after the anti-HIV level of factor VIII within each days of the following equation :
Contraindications
hypersensitivity to the active substance or to mouse or hamster proteins or to any of the excipients .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be informed that the possible occurrence of chest pain , dizziness , orthostatic hypotension and nausea for the early infusion may be signs of immediate-type hypersensitivity reactions and anaphylactic reactions .
symptomatic and supportive treatment should be made as necessary .
if allergic or anaphylactic-type reactions occur , or contact their doctor immediately and patients should contact their physician immediately .
in the case of shock , the current medical standards for treatment of shock should be observed .
the formation of IgE antibodies ( inhibitors ) are a known complication in the management of individuals with haemophilia A.
these inhibitors are always directed by surgical teams against the factor VIII activity and was maintained in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the exposure to factor VIII , exposure to factor VIII and that causality is greater than 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients treated with recombinant Factor VIII should be carefully monitored , with appropriate clinical development , in order to increase the development of inhibitors .
see also section 4.8 .
for the long-term use of the continuous infusion using the continuous infusion , heparin was used to prevent amputation , mainly used as an intravenous infusion at the long-term intravenous infusion .
in the interest of patients , it is recommended that , this can be reviewed and it is recommended that the product can be dangerous .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial , which is mainly of sodium free .
interaction with other medicinal products and other forms of interaction
no toxicologically interactions with other medicinal products are available .
pregnancy and lactation
eighteen studies in animals have not been studied in animals .
based on the rare occurrence of haemophilia A in pregnant women , G-CSF and no data are available .
therefore , 13V should be used during pregnancy and lactation only if the indication is releasing .
effects on ability to drive and use machines
false w.3 drug has no influence on the ability to drive and use machines .
undesirable effects
12.5 A / Adverse reaction has been reported rarely following G- CSF administration :
system Organ Class and infestations Blood and lymphatic system disorders
for the MedDRA Preferred Term
adverse Reaction Rash / Erythema
injection site allergic reactions / anaphylactic reaction
the formation of IgE factor VIII inhibitors ( inhibitors ) is a known complication in the management of individuals with haemophilia A.
in studies with factor VIII , the development of inhibitors was mainly observed in PI na√Øve patients .
therefore , patients should be monitored closely for inhibitors of inhibitors , so that appropriate supportive development is observed .
in clinical trials 541 biopsies was used in the treatment of bleeding episodes in Abseamed previously treated patients ( PUPs ) and 23 patients treated with Fanconi &apos; ( AVF2119g , defined as at least 4 exposure of exposure ) .
five of the 37
6 out of those 60 ( 10 ) with a higher rate of than 10 BU and 3 patients on 60 years of age .
3 to 18 days ) .
the number of mean weight in clinical studies was 14.3 ( 1.31 ) .
four on five days of dosing in patients who have not been told to inhibit the 20 exposure after completion of the study and one was developed a low inhibitor of inhibitor .
the patient has been now broken .
in clinical studies involving desloratadine patients who were treated with cisplatin , defined as more than 100 exposure days , no evidence of an inhibitor was observed .
in pain was large tapered Assessment of cytopenia , with more than 1000 patients were observed : less than 1 of the two patients were experienced inhibitors .
in an retrospective , defined as 20 exposure to baseline , less than 11 days of randomisation .
no patients developed clinically significant reductions in antibody titres of mouse or hamster proteins , in the preparation of mouse or hamster proteins .
however , the possibility of allergic reactions to natural , such as trace proteins and hamster proteins in the preparation , and in some patients also exists ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
colony stimulating factors , ATC code A08AB01
factor VIII and factor Xa selectively ( 16.1 ) value that have a two oestrogens of different medicinal products .
infusion into a haemophilia patient , factor VIII binds to chylomicrons in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor VIII .
activated factor X converts prothrombin to thrombin .
haemophilia A is an inherited condition of the coagulation factor VIII deficiency due to the lack of factor VIII deficiency :
if any of the joints , muscle or internal organs , or
by inhibiting serum levels , plasma levels are increased , thereby enabling a temporary correction of Factor VIII and a bleeding tendency .
activated partial thromboplastin time ( APTT ) is a thin burden of biological factor VIII activity in vitro .
all iron concentrations are anticipated in all iron .
the rate and time of analgesic have been observed following administration of adsorbents have comparable to plasma-derived factor VIII .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma level of 2 IU / kg body weight 2 per kg body weight .
this finding is similar to that reported plasma factor VIII .
following intranasal dosing , immunisation of the factor VIII activity is distal pg type with a mean terminal half-life of approximately 15 hours .
this last similar exposure is similar to that of plasma derived Factor VIII in plasma .
preclinical safety data
even at several times doses higher than those recommended for the recommended clinical effects ( determined based on the clinical weight ) .
there have been no formal response with the immune response in all human species in all human species , genotoxicity studies based on repeated dose toxicity ( reproduction studies , chronic toxicity , chronic toxicity ) .
no mutagenic potential in vitro serial passage studies were performed in vitro or in vivo serial passage product .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
the medicinal product must be used as failures .
Shelf life
months .
after reconstitution , the product should be used immediately .
however chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( up to 25 C ) for a sulphonylurea period .
in this case , the product dissolves up to the end of the 3 months time , and new date should be reused on the top of the pack .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 BAXJECT II of transfer with 20 ml / 20
- 1 cm for injection
- 1 single use pre-filled syringe of 5 ml
- 2 TABLETS
special precautions for disposal and other handling
detailed instructions for preparation and administration are contained in the Package Leaflet .
dosing expanders should only be reconstituted with the solvent solvent ( 2.5 ml water for injection ) using the sterile double-ended chromogenic filter .
the reconstitution should be conducted according to standard practice , particularly keeping adherence to the aseptic line .
mix gently swirl until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you have any particles or damage .
after reconstitution , the solution is clearly bound from the transfer through the sterile filter spike through the sterile disposable syringe ( all every two compounds ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG Emil-Barell-Str
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 1000 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 1000 IU / vial .
solvent : water for injections .
the reconstituted product with 2.5 ml of water for injections contains approximately 400 IU octocog alfa / ml .
the potency ( IU ) is determined using the European Pharmacopoeia one-stage standard one-stage Standard one-stage Standard ( DIC ) .
the specific activity is approximately 4,000- IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is provided in a dry powder or bottle , white to slightly yellow powder .
the solvent is water for injection presented in a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and therefore should not be used in the treatment of Paget &apos;s disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage number of units of factor VIII is expressed in International Units ( IU ) per kilogram of the factor VIII procoagulant factors .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to an international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII is equivalent to that quantity of factor VIII in one ml of normal human plasma .
calculation of the required dose of factor VIII activity by 1 M International Units ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dosage is determined using the following convention :
e I.
30.4 ( IU ) = body weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected ( of normal )
the doses and duration of the substitution therapy should be adapted to the patient on the basis of the patient ( weight , severity of mental functions , injection site and Factor VIII ) .
the table presents by stimulating factor VIII level to be derived from plasma derived Factor VIII .
in case of high-risk situations , factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the period .
MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
factor VIII level required ( ) ( IU / dl )
frequency of administration ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode as indicated by bleeding
more extensive haemarthrosis , muscle bleeding or haematoma
repeat infusion every 12 to 24 hours for 3- 4 days or more until pain and disability .
haemorrhagic haemorrhage
repeat infusion every 8 to 24 hours until resolved .
minor Including tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
to 100 100 to 100
a ) bolus dose of every 8 weeks
outcome
the dose and frequency of administration should always be oriented to the case of individual clinical efficacy .

during a course of therapy , appropriate factor VIII levels is recommended to evaluate the dose to be administered and the frequency to which how to infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of the substitution agent ( plasma factor VIII activity ) is indispensable .
individual patients to factor VIII , may vary , achieving different levels of in vivo recovery and different half-lives .
a clinical study in adult patients with haemophilia A undergoing major surgery had major surgery following major surgery that may be used with continuous infusion of surgery ( see sections 4.2 , allogeneic and 5.2 ) .
if an intravenous infusion was used to prevent the occurrence of infusion at the infusion site as an intravenous infusion .
w.1 80-100 contains a small amount of bad 80 , carmellose that to increase the rate of di- ( HPA ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be taken into consideration when administered as a continuous infusion .
for prophylactic prophylaxis of bleeding in patients with severe haemophilia A , doses of 20 to 60 IU of kg-1 day-1 , should be administered every 2 to 3 days .
in some cases , especially in younger patients , more frequent injections between doses of or higher doses may be necessary .
the data were obtained in 61 children below 6 years of age .
inhibitor retention
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma activity levels are not attained , or if bleeding is not controlled by appropriate doses , the presence of a factor VIII inhibitor should be evaluated for the presence of an inhibitor .
if a patient is switched to a less than 10 Units ) per ml , each ml of an additional factor VIII product may 12.46 to
however , in the presence of an inhibitor of the factor VIII activity , the level should be adjusted and the pharmacokinetics of factor VIII activity .
in patients with a baseline inhibitor of the factor IX inhibitor , the use of activated powdered charcoal or charcoal is considered to be bioequivalent .
such combinations should be aware of the individual patient experienced patients with haemophilia A.
method of administration depends on the preparation as instructed for section 6.6 .
thirteen percent must be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate of injection :
w.2 w.3 erythematosus may be administered by continuous infusion .
the rate of infusion should be based on the clearance and factor VIII level to be achieved .
for a patient 75 kg body clearance , the clearance of the initial infusion should be 3 ml / hr / kg , which exceed 3 IU / h / kg for up to 100 IU / h / kg .
to determine the infusion rate of infusion ( IU / h ) should be biopsied the infusion rate of infusion per hr / kg body weight , per kilogram body weight ( IU / ml ) &#93; .
baseline :
the plasma Factor VIII levels to be achieved ;
infusion
100 IU / ml
( 1 / ml )
mutants of infusion escalation may be necessary when transferring patients with severe damage or tissue damage in surgery to surgery .
subsequent infusion bags should be taken after the anti-HIV level of factor VIII within each days of the following equation :
Contraindications
hypersensitivity to the active substance or to mouse or hamster proteins or to any of the excipients .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be informed that the possible occurrence of chest pain , dizziness , orthostatic hypotension and nausea for the early infusion may be signs of immediate-type hypersensitivity reactions and anaphylactic reactions .
symptomatic and supportive treatment should be made as necessary .
if allergic or anaphylactic-type reactions occur , or contact their doctor immediately and patients should contact their physician immediately .
in the case of shock , the current medical standards for treatment of shock should be observed .
the formation of IgE antibodies ( inhibitors ) are a known complication in the management of individuals with haemophilia A.
these inhibitors are always directed by surgical teams against the factor VIII activity and was maintained in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the exposure to factor VIII , exposure to factor VIII and that causality is greater than 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients treated with recombinant Factor VIII should be carefully monitored , with appropriate clinical development , in order to increase the development of inhibitors .
see also section 4.8 .
for the long-term use of the continuous infusion using the continuous infusion , heparin was used to prevent amputation , mainly used as an intravenous infusion at the long-term intravenous infusion .
in the interest of patients , it is recommended that , this can be reviewed and it is recommended that the product can be dangerous .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial , which is mainly of sodium free .
interaction with other medicinal products and other forms of interaction
no toxicologically interactions with other medicinal products are available .
pregnancy and lactation
eighteen studies in animals have not been studied in animals .
based on the rare occurrence of haemophilia A in pregnant women , G-CSF and no data are available .
therefore , 13V should be used during pregnancy and lactation only if the indication is releasing .
effects on ability to drive and use machines
false w.3 drug has no influence on the ability to drive and use machines .
undesirable effects
12.5 A / Adverse reaction has been reported rarely following G- CSF administration :
system Organ Class and infestations Blood and lymphatic system disorders
for the MedDRA Preferred Term
adverse Reaction Rash / Erythema
injection site allergic reactions / anaphylactic reaction
the formation of IgE factor VIII inhibitors ( inhibitors ) is a known complication in the management of individuals with haemophilia A.
in studies with factor VIII , the development of inhibitors was mainly observed in PI na√Øve patients .
therefore , patients should be monitored closely for inhibitors of inhibitors , so that appropriate supportive development is observed .
in clinical trials 541 biopsies was used in the treatment of bleeding episodes in Abseamed previously treated patients ( PUPs ) and 23 patients treated with Fanconi &apos; ( AVF2119g , defined as at least 4 exposure of exposure ) .
five of the 37
6 out of those 60 ( 10 ) with a higher rate of than 10 BU and 3 patients on 60 years of age .
3 to 18 days ) .
the number of mean weight in clinical studies was 14.3 ( 1.31 ) .
four on five days of dosing in patients who have not been told to inhibit the 20 exposure after completion of the study and one was developed a low inhibitor of inhibitor .
the patient has been now broken .
in clinical studies involving 73 previously treated patients ( PTPs , itching , more than 100 exposure days ) and followed for 4 years of age , was not observed .
in pain was large tapered Assessment of cytopenia , with more than 1000 patients were observed : less than 1 of the two patients were experienced inhibitors .
in an retrospective , defined as 20 exposure to baseline , less than 11 days of randomisation .
no patients developed clinically significant reductions in antibody titres of mouse or hamster proteins , in the preparation of mouse or hamster proteins .
however , the possibility of allergic reactions to natural , such as trace proteins and hamster proteins in the preparation , and in some patients also exists ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
colony stimulating factors , ATC code A08AB01
factor VIII and factor Xa selectively ( 16.1 ) value that have a two oestrogens of different medicinal products .
infusion into a haemophilia patient , factor VIII binds to chylomicrons in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor VIII .
activated factor X converts prothrombin to thrombin .
haemophilia A is an inherited condition of the coagulation factor VIII deficiency due to the lack of factor VIII deficiency :
if any of the joints , muscle or internal organs , or
by inhibiting serum levels , plasma levels are increased , thereby enabling a temporary correction of Factor VIII and a bleeding tendency .
activated partial thromboplastin time ( APTT ) is a thin burden of biological factor VIII activity in vitro .
all iron concentrations are anticipated in all iron .
the rate and time of analgesic have been observed following administration of adsorbents have comparable to plasma-derived factor VIII .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma level of 2 IU / kg body weight 2 per kg body weight .
this finding is similar to that reported plasma factor VIII .
following intranasal dosing , immunisation of the factor VIII activity is distal pg type with a mean terminal half-life of approximately 15 hours .
this last similar exposure is similar to that of plasma derived Factor VIII in plasma .
preclinical safety data
even at several times doses higher than those recommended for the recommended clinical effects ( determined based on the clinical weight ) .
there have been no formal response with the immune response in all human species in all human species , genotoxicity studies based on repeated dose toxicity ( reproduction studies , chronic toxicity , chronic toxicity ) .
no mutagenic potential in vitro serial passage studies were performed in vitro or in vivo serial passage product .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
the medicinal product must be used as failures .
Shelf life
months .
after reconstitution , the product should be used immediately .
however chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( up to 25 C ) for a sulphonylurea period .
in this case , the product dissolves up to the end of the 3 months time , and new date should be reused on the top of the pack .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 BAXJECT II of transfer with 20 ml / 20
- 1 cm for injection
- 1 single use pre-filled syringe of 5 ml
- 2 TABLETS
special precautions for disposal and other handling
detailed instructions for preparation and administration are contained in the Package Leaflet .
dosing expanders should only be reconstituted with the solvent solvent ( 2.5 ml water for injection ) using the sterile double-ended chromogenic filter .
the reconstitution should be conducted according to standard practice , particularly keeping adherence to the aseptic line .
mix gently swirl until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you have any particles or damage .
after reconstitution , the solution is clearly bound from the transfer through the sterile filter spike through the sterile disposable syringe ( all every two compounds ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG Emil-Barell-Str
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 w.2 2000 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 2000 IU / vial with :
solvent : water for injections .
the reconstituted product with 5.0 ml of water for injections contains approximately 400 IU octocog alfa / ml .
the potency ( IU ) is determined using the European Pharmacopoeia one-stage standard one-stage Standard one-stage Standard ( DIC ) .
the specific activity is approximately 4,000- IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is provided in a dry powder or bottle , white to slightly yellow powder .
the solvent is water for injection presented in a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and therefore should not be used in the treatment of Paget &apos;s disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage number of units of factor VIII is expressed in International Units ( IU ) per kilogram of the factor VIII procoagulant factors .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to an international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII is equivalent to that quantity of factor VIII in one ml of normal human plasma .
calculation of the required dose of factor VIII activity by 1 M International Units ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dosage is determined using the following convention :
e I.
30.4 ( IU ) = body weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected ( of normal )
the doses and duration of the substitution therapy should be adapted to the patient on the basis of the patient ( weight , severity of mental functions , injection site and Factor VIII ) .
the table presents by stimulating factor VIII level to be derived from plasma derived Factor VIII .
in case of high-risk situations , factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the period .
MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
factor VIII level required ( ) ( IU / dl )
frequency of administration ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode as indicated by bleeding
more extensive haemarthrosis , muscle bleeding or haematoma
repeat infusion every 12 to 24 hours for 3- 4 days or more until pain and disability .
haemorrhagic haemorrhage
repeat infusion every 8 to 24 hours until resolved .
minor Including tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
to 100 100 to 100
a ) bolus dose of every 8 weeks
outcome
the dose and frequency of administration should always be oriented to the case of individual clinical efficacy .

during a course of therapy , appropriate factor VIII levels is recommended to evaluate the dose to be administered and the frequency to which how to infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of the substitution agent ( plasma factor VIII activity ) is indispensable .
individual patients to factor VIII , may vary , achieving different levels of in vivo recovery and different half-lives .
a clinical study in adult patients with haemophilia A undergoing major surgery had major surgery following major surgery ranging from baseline may be used by continuous infusion of continuous surgery ( in pre- , 3rd and postoperative ) .
if an intravenous infusion was used to prevent the occurrence of infusion at the infusion site as an intravenous infusion .
w.1 80-100 contains a small amount of bad 80 , carmellose that to increase the rate of di- ( HPA ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be taken into consideration when administered as a continuous infusion .
for prophylactic prophylaxis of bleeding in patients with severe haemophilia A , doses of 20 to 60 IU of kg-1 day-1 , should be administered every 2 to 3 days .
in some cases , especially in younger patients , more frequent injections between doses of or higher doses may be necessary .
the data were obtained in 61 children below 6 years of age .
inhibitor retention
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma activity levels are not attained , or if bleeding is not controlled by appropriate doses , the presence of a factor VIII inhibitor should be evaluated for the presence of an inhibitor .
if a patient is switched to a less than 10 Units ) per ml , each ml of an additional factor VIII product may 12.46 to
however , in the presence of an inhibitor of the factor VIII activity , the level should be adjusted and the pharmacokinetics of factor VIII activity .
in patients with a baseline inhibitor of the factor IX inhibitor , the use of activated powdered charcoal or charcoal is considered to be bioequivalent .
such combinations should be aware of the individual patient experienced patients with haemophilia A.
method of administration depends on the preparation as instructed for section 6.6 .
thirteen percent must be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate of injection :
w.2 w.3 erythematosus may be administered by continuous infusion .
the rate of infusion should be based on the clearance and factor VIII level to be achieved .
for a patient 75 kg body clearance , the clearance of the initial infusion should be 3 ml / hr / kg , which exceed 3 IU / h / kg for up to 100 IU / h / kg .
to determine the infusion rate of infusion ( IU / h ) should be biopsied the infusion rate of infusion per hr / kg body weight , per kilogram body weight ( IU / ml ) &#93; .
baseline age :
the plasma Factor VIII levels to be achieved ;
infusion
100 IU / ml
( 1 / ml )
mutants of infusion escalation may be necessary when transferring patients with severe damage or tissue damage in surgery to surgery .
subsequent infusion bags should be taken after the anti-HIV level of factor VIII within each days of the following equation :
Contraindications
hypersensitivity to the active substance or to mouse or hamster proteins or to any of the excipients .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be informed that the possible occurrence of chest pain , dizziness , orthostatic hypotension and nausea for the early infusion may be signs of immediate-type hypersensitivity reactions and anaphylactic reactions .
symptomatic and supportive treatment should be made as necessary .
if allergic or anaphylactic-type reactions occur , or contact their doctor immediately and patients should contact their physician immediately .
in the case of shock , the current medical standards for treatment of shock should be observed .
the formation of IgE antibodies ( inhibitors ) are a known complication in the management of individuals with haemophilia A.
these inhibitors are always directed by surgical teams against the factor VIII activity and was maintained in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the exposure to factor VIII , exposure to factor VIII and that causality is greater than 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients treated with recombinant Factor VIII should be carefully monitored , with appropriate clinical development , in order to increase the development of inhibitors .
see also section 4.8 .
for the long-term use of the continuous infusion using the continuous infusion , heparin was used to prevent amputation , mainly used as an intravenous infusion at the long-term intravenous infusion .
in the interest of patients , it is recommended that , this can be reviewed and it is recommended that the product can be dangerous .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial , which is mainly of sodium free .
interaction with other medicinal products and other forms of interaction
no toxicologically interactions with other medicinal products are available .
pregnancy and lactation
eighteen studies in animals have not been studied in animals .
based on the rare occurrence of haemophilia A in pregnant women , G-CSF and no data are available .
therefore , 13V should be used during pregnancy and lactation only if the indication is releasing .
effects on ability to drive and use machines
false w.3 drug has no influence on the ability to drive and use machines .
undesirable effects
12.5 A / Adverse reaction has been reported rarely following G- CSF administration :
system Organ Class and infestations Blood and lymphatic system disorders
for the MedDRA Preferred Term
adverse Reaction Rash / Erythema
injection site allergic reactions / anaphylactic reaction
the formation of IgE factor VIII inhibitors ( inhibitors ) is a known complication in the management of individuals with haemophilia A.
in studies with factor VIII , the development of inhibitors was mainly observed in PI na√Øve patients .
therefore , patients should be monitored closely for inhibitors of inhibitors , so that appropriate supportive development is observed .
in clinical trials 541 biopsies was used in the treatment of bleeding episodes in Abseamed previously treated patients ( PUPs ) and 23 patients treated with Fanconi &apos; ( AVF2119g , defined as at least 4 exposure of exposure ) .
five of the 37
6 out of those 60 ( 10 ) with a higher rate of than 10 BU and 3 patients on 60 years of age .
3 to 18 days ) .
the number of mean weight in clinical studies was 14.3 ( 1.31 ) .
four on five days of dosing in patients who have not been told to inhibit the 20 exposure after completion of the study and one was developed a low inhibitor of inhibitor .
the patient has been now broken .
in clinical trials involving 73 previously treated patients ( PTPs , itching , more than 100 exposure days ) and followed for 4 years of age , no evidence of an inhibitor was observed .
in pain was large tapered Assessment of cytopenia , with more than 1000 patients were observed : less than 1 of the two patients were experienced inhibitors .
in an retrospective , defined as 20 exposure to baseline , less than 11 days of randomisation .
no patients developed clinically significant reductions in antibody titres of mouse or hamster proteins , in the preparation of mouse or hamster proteins .
however , the possibility of allergic reactions to natural , such as trace proteins and hamster proteins in the preparation , and in some patients also exists ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
colony stimulating factors , ATC code A08AB01
factor VIII and factor Xa selectively ( 16.1 ) value that have a two oestrogens of different medicinal products .
infusion into a haemophilia patient , factor VIII binds to chylomicrons in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor VIII .
activated factor X converts prothrombin to thrombin .
haemophilia A is an inherited condition of the coagulation factor VIII deficiency due to the lack of factor VIII deficiency :
if any of the joints , muscle or internal organs , or
by inhibiting serum levels , plasma levels are increased , thereby enabling a temporary correction of Factor VIII and a bleeding tendency .
activated partial thromboplastin time ( APTT ) is a thin burden of biological factor VIII activity in vitro .
all iron concentrations are anticipated in all iron .
the rate and time of analgesic have been observed following administration of adsorbents have comparable to plasma-derived factor VIII .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma level of 2 IU / kg body weight 2 per kg body weight .
this finding is similar to that reported plasma factor VIII .
following intranasal dosing , immunisation of the factor VIII activity is distal pg type with a mean terminal half-life of approximately 15 hours .
this last similar exposure is similar to that of plasma derived Factor VIII in plasma .
preclinical safety data
even at several times doses higher than those recommended for the recommended clinical effects ( determined based on the clinical weight ) .
there have been no formal response with the immune response in all human species in all human species , genotoxicity studies based on repeated dose toxicity ( reproduction studies , chronic toxicity , chronic toxicity ) .
no mutagenic potential in vitro serial passage studies were performed in vitro or in vivo serial passage product .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
the medicinal product must be used as failures .
Shelf life
months .
after reconstitution , the product should be used immediately .
however chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( up to 25 C ) for a sulphonylurea period .
in this case , the product dissolves up to the end of the 3 months time , and new date should be reused on the top of the pack .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 BAXJECT II of transfer with 20 ml / 20
- 1 cm for injection
- 1 single use pre-filled syringe of 5 ml
- 2 TABLETS
special precautions for disposal and other handling
detailed instructions for preparation and administration are contained in the Package Leaflet .
dosing expanders should only be reconstituted with the solvent solvent ( 5.0 ml ) using the sterile device with in-line filter .
the reconstitution should be conducted according to standard practice , particularly keeping adherence to the aseptic line .
mix gently swirl until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you have any particles or damage .
after reconstitution , the solution is clearly bound from the transfer through the sterile filter spike through the sterile disposable syringe ( all every two compounds ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG Emil-Barell-Str
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
name and address of the manufacturer responsible for batch release
30.4 , 35 8.6 ( 1.1 ) Italy
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to restricted medical prescription ( See Annex I :
summary of Product Characteristics , section 4.2 ) .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
pharmacovigilance system
risk Management Plan
as per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
Danmark 250 IU Powder and solvent for solution for injection
factor VIII recombinant Factor VIII ( octocog alfa )
statement OF ACTIVE SUBSTANCE ( S )
1 vial :
IU octocog alfa ( 100 IU / ml ) .
list OF EXCIPIENTS
glycine , sodium chloride , calcium chloride , histidine , polysorbate 80 , sucrose .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial of 2.5 ml water for injections .
method AND ROUTE ( S ) OF ADMINISTRATION
single use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE

special STORAGE CONDITIONS
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( &lt; 25 C ) for a single period not exceeding 3 months and what to do at a new date .
use the reconstituted solution immediately .
do not refrigerate after reconstitution .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG , Immermannstra Motion , Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
gynaecomastia
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
contents BY WEIGHT , BY VOLUME OR BY UNIT
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
Danmark 250 IU Powder for solution for injection
factor VIII recombinant Factor VIII ( octocog alfa )
method OF ADMINISTRATION
intravenous use .
expiry DATE
BATCH NUMBER
gynaecomastia
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 vial :
IU octocog alfa ( 100 IU / ml ) .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
16 ml OUTER WRAPPER LABEL ON MULTIPACKS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION

use the entire contents .
expiry DATE
BATCH NUMBER
gynaecomastia
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
w.1 500 IU Powder and solvent for solution for injection
factor VIII recombinant Factor VIII ( octocog alfa )
statement OF ACTIVE SUBSTANCE ( S )
1 vial :
IU octocog alfa ( 200 IU / ml ) .
list OF EXCIPIENTS
glycine , sodium chloride , calcium chloride , histidine , polysorbate 80 , sucrose .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial of 2.5 ml water for injections .
method AND ROUTE ( S ) OF ADMINISTRATION
single use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE

special STORAGE CONDITIONS
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before opening can be stored at room temperature ( &lt; 25 C ) for a single period not exceeding 3 months and what to do at a new date .
use the reconstituted solution immediately .
do not refrigerate after reconstitution .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Bayer Schering Pharma AG , Immermannstra Motion , Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
gynaecomastia
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
contents BY WEIGHT , BY VOLUME OR BY UNIT
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
w.1 500 IU Powder for solution for injection
factor VIII recombinant Factor VIII ( octocog alfa )
method OF ADMINISTRATION
intravenous use .
expiry DATE
BATCH NUMBER
gynaecomastia
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 vial :
IU octocog alfa ( 200 IU / ml ) .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
16 ml OUTER WRAPPER LABEL ON MULTIPACKS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION

use the entire contents .
expiry DATE
BATCH NUMBER
gynaecomastia
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
